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ABSTRACT 
Alzheimer’s disease (AD) is the leading cause of dementia, accounting for 50 to 80 
percent of dementia cases, and the prevalence of the disease is projected to increase 
significantly with time.  AD is characterized by severe cognitive decline with age, 
ultimately requiring continued caregiving and eventually death.  The pathology of AD is 
characterized by the presence of extracellular amyloid plaques, intracellular 
neurofibrillary tangles (NFT) composed of hyperphosphorylated tau protein, neuron 
loss, and evidence of inflammation indicated by the presence of reactive microglia and 
astrocytes. Frontotemporal Lobe Dementia (FTLD) is a rare form of dementia that is 
related to AD, most notably in the pathology of hyperphosphorylated tau and 
macroscopic brain shrinkage.  It has been defined as one of a host of tauopathies, and 
has a more rapid onset than AD.  Symptoms that resemble personality changes, 
moreso than memory loss, are characteristic of these other tauopathies (FTLD is a 
representative of a whole class of neurological disorders).  Like AD, there are no known 
treatments or cures for FTLD.  AD and FTLD are two manifestations of a class of 
diseases known as tauopathies, due to the presence of toxic forms of tau. 
Tau is a protein normally found in neurons.  It functions as a stabilizer for 
microtubules, and has a role in the trafficking of materials from the cell body to the 
presynaptic terminal.  In AD and FTLD, tau can become hyperphosphorylated, which 
causes it to form twisted fibrils called NFTs.  An emerging area of research is to identify 
antibodies that target tau as a way to clear tau pathology and hopefully reduce synaptic 
and neuron loss (Boutajangout et al., 2011b).  While these diseases have no known 
cure or treatment at present, immunotherapy is emerging as a very promising approach 
	 vii	
for treatment.  The studies presented here investigated a variety of antibodies directed 
against tau, and incorporated different timeframes and administration routes to identify 
the best candidate for future clinical investigation of tau immunotherapy.   
The mouse model rTg4510, known for expressing cognitive-related tauopathy, was 
primarily used to evaluate tau antibody effectiveness prior to clinical consideration.  Our 
investigations began by utilizing a more familiar mouse model which was also reported 
to express tau pathology. 
Our studies first examined intracranial injection of a variety of antibodies using an 
mouse model previously reported to demonstrate tau pathology, to identify short-term 
clearance of tau pathology and NFTs.  Next, we examined a more robust tau-producing 
mouse line, to further identify a most effective antibody, as well as to examine the time 
course of effect, after administration.  A longer-term administration, and different route 
of administration was tested using mini-osmotic pump implantation into the mice, which 
provided for 28-day continuous infusion.  This approach was followed with 
administration of antibodies, systemically.   Behavioral analysis, in addition to 
pathological testing, was incorporated into the longer-term administration studies. 
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CHAPTER 1:  BACKGROUND AND SIGNIFICANCE 
1.1 Alzheimer’s Disease  
Alzheimer’s disease (AD) is currently the sixth leading cause of death in the 
United States (US).  An estimated 5.4 million people currently are suffering from AD and 
it is the only cause of death, of the top 10 in the US, which cannot be treated, 
prevented, or slowed acceptably yet.  It is a slowly developing and progressive disease 
that affects memory such that patients eventually lose their ability to function and 
interact with the environment.  Early clinical symptoms include difficulty remembering 
names and recent events, as well as frequent cases of apathy and depression.  Later 
symptoms include impaired judgment, disorientation, confusion, behavior changes, and 
difficulty speaking, swallowing, and walking (Alzheimer’s Association, 2011).  A 
diagnosis of AD is one of the darkest diagnoses a person, and his or her family and 
friends, can receive.  People, (friends, relatives, and caretakers), who surround and 
support an advanced AD patient, report that they no longer recognize the patient, just 
as the patient has no memory or recognition of the people in their lives. 
AD is not only debilitating and deadly, it is also very costly.  There are 
approximately 15 million unpaid caregivers in the US who incur an annual cost of about 
$200 billion.  Due to the toll on caregivers, about one-third of caretakers report 
symptoms of depression, and nearly two-thirds of them report high levels of stress.  
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These burdens significantly increase the cost of health care to the caregivers, 
themselves.    
Our population is aging due to other health care advances, however this aging 
population, and especially that of the ‘baby boomer generation’, is transitioning into a 
dramatic rise in symptoms of AD, as well as increasing familial burdens to care for these 
beloved aging people.  It is projected that the cost of care for this disease will be $1.1 
trillion by 2050 (Alzheimer’s Association, 2011).  Therefore it is of utmost importance for 
patients and caregivers that treatments for AD are identified. 
 
1.2 Alzheimer’s Disease and other Dementias - Pathology 
AD pathology can be described macroscopically and microscopically.  
Macroscopically, widespread atrophy of the brain and associated cerebral loss is 
observed, along with cerebral amyloid angiopathy (CAA). Microscopically, there are 
numerous markers of the disease: extracellular deposition of amyloid β protein (Aβ), in 
the form of amyloid plaques (dense core plaques), and extracellular soluble Aβ, which 
are formed by accumulation of the Aβ40 or Aβ42 molecule.   Intracellularly, the 
microtubule stabilizing protein tau becomes hyperphosphorylated, forming neurofibrillary 
tangles (NFTs), which lead to dystrophic neurites and synapse loss.  Evidence of 
inflammation in the affected areas is also shown as recruitment of microglia and 
astrocytes.  Ultimately there is a loss of neuronal cells in the affected areas, and an 
additional increase in inflammatory cells presents.  Development of plaques, NFTs and 
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inflammatory indications of degeneration can predict a future of AD or other 
tauopathies. 
The US Food and Drug Administration (FDA) has approved at least five drugs 
that slow the progression of the disease by 6 to 12 months, however there are no drugs 
as of yet that delay the onset, or halt progression of the disease (Alzheimer’s 
Association, 2011).  Accordingly, there is a large research effort to identify drugs that 
can significantly reduce or even stop disease progression.  Recently, immunotherapy 
has shown promise in clearing amyloid pathology or tau pathology in transgenic (Tg) 
mouse models of the disease.  Immune-based drugs, targeting different components of 
AD and tauopathy, are in clinical trials. 
 
1.3 Immunotherapy Concepts and Mechanisms 
Immunotherapy consists of administration of a substance that will provide 
treatment by way of modulating the immune system: antigens that lead to an 
endogenous immune response have been examined, also antibodies directly directed 
against the foreign or unwanted entity are used to remove and destroy the invading 
entity (plaques and/or tangles).   
The use of antigen administration has been described as the “humoral” 
response, which refers to the fact that antibody-mediated interactions occur in the 
“humors,” namely the extracellular fluids such as plasma, lymph, and the non-cellular 
portion of blood.  However, it was discovered that cells (in particular, macrophages, as 
well as T-cells, and natural killer cells, not just serum), are important for eliciting immune 
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responses.  This understanding has lead to a division in definition, between “cellular 
immunity” and “humoral immunity.” 
Lymphocytes are the cells responsible for adaptive immunity.  Two main 
categories of lymphocytes have been identified: B cells, which are derived from bone 
marrow, and T cells, which are produced in the thymus.  B cells synthesize 
immunoglobin (Ig) molecules, otherwise known as antibodies, and also inherently 
possess Igs in their plasma membrane to recognize foreign or unwanted material 
(antigens).  B cells possess Igs for one specific antigen, and only one antigen.  B cells 
act as memory cells after their first encounter with the specific antigen, and remain as 
memory cells to facilitate the immune system to act more quickly and robustly upon 
future encounters with the antigen.   
T cells, in contrast, possess receptors that recognize glycoproteins on cell 
membranes to identify ‘foreign’ agents for breakdown and removal.  Major 
histocompatibility complex (MHC) T-helper (TH) cells, also known as CD4+ T cells 
because they possess CD4 on their surface, become activated when they are 
presented with antigens posessing MHC class II antigenic components.  Once 
activated, T cells will secrete cytokines to assist in the active immune response.    
Cytotoxic T cells (TC), also known as CD8+ T cells, possess CD8 glycoprotein on their 
surface, and recognize antigen associated with MHC class I antigens leading to this 
immune response.  Upon recognition binding, they actively destroy the invading cells or 
pathogens. 
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Antibodies are specific immunoglobulin (Ig) entities that act as adapter 
molecules.  They consist of two heavy chains of amino acids and two light chains that 
are connected by disulfide bonds in a Y configuration.  The two antigen-binding regions 
are defined as the F(ab) regions.  Two such binding domains are present on an 
antibody, thereby requiring binding of either two sites from one antibody, or usually, 
binding by two antibodies.  
The contant region, located on opposite arms of the antibody, is referred to as 
the Fc region.  The Fc region binds to Fc receptors located on phagocytic cells.  Fc 
binding facilitates antigen breakdown and removal with help from the monocytes, or 
related phagocytic cells possessing proper binding recognition for the Fc portion of the 
bound antibody. 
Each F(ab) region possess two constant regions, one on the outer, antigenic 
binding region; a heavy chain peptide, with an additional, modifying component 
comprise the light chain of the F(ab) regions of an antibody.  Two, variable, light chain 
regions are similarly arranged as the heavy chains, within an antibody, however the light 
chains are only located within the antigen binding region of the antibody, thereby 
increasing recognition of multiple foreign substances.  The F(ab) variable region 
determines the antigen specificity of the Ig, whereas the Fc region determines the 
celluar response in result to antibody binding. 
  Antibodies are classified as either monoclonal (resulting from one B cell specific 
to one cell specific to antigen, which is replicated or cloned to produce numerous 
identical antibodies), or polyclonal (a composite of multiple B cells that can recognize 
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multiple antigens, possibly from one individual protein, and are hybridomas of immune 
cells with cells exhibiting rapid proliferation, such as cancer cells).  Polyclonal antibodies 
target multiple antigens, and thereby exhibit a greater spectrum of recognition.  
However, since they are not generated from a specific singular cell polyclonal 
antibodies possess the potential to simultaneously target a greater multitude of 
antigens, but also possess a greater potential for inducing “side effect” since they are 
less discriminating. 
Monoclonal antibodies are advantageous for immunotherapy, due to their 
specificity as a result from cloning of one cell.  This minimizes potential side effects, as 
they target very specific antigens.  On the other hand, this specificity can result in 
monoclonal antibodies ‘missing’ the target antigen and failing to launch an appropriate 
immune response.   
Polyclonal antibodies are produced as hybridomas; hybridomas incorporate 
immune cells into cancer cells to create multiple, quickly proliferating, copies of a 
desired antibody.  As such, polyclonal antibodies can be preferable to monoclonal 
antibodies to increase a generalized immunological response to treatment, however 
they possess lower specificity for single antigens, leading to a greater potential of 
generating undesired, or unintended, potential for inducing ‘side effects’.  
Antibodies utilize the body’s immune system by binding to phagocytic cells, then 
initiate a cellular response to target the antigen and prepare it for phagocytic destruction 
an removal.  Binding of antigen to antibody leads to an intracellular response.  Based on 
the binding properties, and generated responses of such binding, five classes of 
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antibodies exist. These are different Ig structures (isotypes) referred to as: IgG, IgA, 
IgM, IgD, and IdgE.  These isotypes of antibody vary, based on their Fc region and the 
cellular events that occur upon binding to their receptor.  IgG is the most abundant of 
the classes, and is the class that is emphasized herein due to the presence of microglia 
in neuronal tissue. 
Antibodies effect a response after forming an antigen-antibody complex.  
Following antigen binding to a cell with Fc receptors, opsonization of the antigen occurs, 
which is defined as the coating by adhesion molecule(s), to initiate complement 
deactivation, or to direct phagocyte engulfment of the antigen.  These two processes 
can work in concert, or independently, to lead to destruction of the bound antigens.   
Additionally, microglia respond to foreign substances, then are activated to secrete 
cytokines, which help to stimulate T-cell mediated immune responses and inflammation.   
Microglial activation, the neuronal component of the immune system, is an important 
process to evaluate so as to protect the BBB separated CNS. 
 
1.4  Mechanisms of Immunotherapy 
Immunotherapy directs the immune system to remove unwanted material from 
the body.  This can be accomplished by amplifying the body’s innate immune system to 
remove antigen.  Immunotherapy can also be implemented to remove an unfamiliar 
antigen, by activating the acquired immune system (memory immune cells and 
phagocytes), and by introducing antigen to the affected body to spur creation of new 
antibodies, which recognize this foreign substance.  Exposure to an unfamiliar pathogen 
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or antigen will lead to the immune response, which will begin to create antibodies within 
the invaded organism, to eliminate the ‘foreign invader’ and to form memory cells in 
case this foreign invader is encountered again in the future. 
Vaccination is the most common form of immunotherapy.  It is an established, 
safe process to expose humans and other organisms to antigen to induce the recipient 
to produce their own adaptive antibodies.  This is typically accomplished by injection of 
the foreign antigen, although vaccines can also be inhaled via a nasal spray, absorbed 
via a dermal patch, or ingested.  
Edward Jenner first attempted immunotherapy procedures in 1798 by using 
cowpox exposure to prevent the more severe smallpox (Sanchez-Sampedro et al., 
2015).   The cowpox virus was similar enough to the smallpox virus that he realized 
exposure to one could lead to development of resistance to the other.  Louis Pasteur is 
credited with popularizing active vaccination, and creating the term “vaccination” when 
he had chickens experiencing cholera.  He injected “old” versions of the pathogen into 
younger chickens whereby they developed immunity to the disease.  From there, he 
moved on to vaccination of sheep against anthrax, and eventually translated these 
experiences into human vaccination (rabies vaccination) such that people would 
develop immunity to a given pathogen for future exposures.  Since his time, vaccines 
have nearly eliminated diseases such as measles, mumps, tetanus, polio, and 
whooping cough.  
  Immunization can be defined as passive or active, which describes the nature of 
the substance injected as well as the anticipated physiological response to it.  Active 
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immunization is the administration of an antigen, or an inactivated (attenuated) version, 
a fragment of the full antigen or a biochemical analogue.  Active immunization triggers 
the body’s adaptive system to respond by producing antibodies against the toxin.  A 
majority of the antibodies will act to remove the toxic agent, however some will help to 
form memory cells in case of future exposure.  These memory cells help produce an 
exacerbated response with each future exposure to the antigen.   
In contrast to active immunization, passive immunization involves administration 
of already produced antibodies directed against the toxic substance.  In humans, the 
half life of an exogenous antibody is about 21 days (Stowell, 2006).   Because the 
antibodies are being introduced and not endogenously produced, they will essentially 
get used up, as they bind to antigen, leading to a decline of function.  Therefore, 
passive immunotherapy requires routine and continual inoculation, whereas active 
immunization can require very few treatments provided the patient responds to the 
immunogen and launches his or her own immune response, properly (without serious 
side effects).   
An adjuvant is frequently provided with active vaccines to boost the immune 
system’s response to the foreign substance (the immunogen, or antigen).  Adjuvants 
increase the immunogenicity of the administered compound by activating macrophages 
(such as microglia) and they increase the antigen-presenting feature of an antigen, 
thereby helping to increase endogenous production of antibody; adjuvants stimulate the 
immune system to produce a greater response than the antigen alone would produce. 
“Freund’s adjuvant,” is commonly used and is well tolerated in animal studies. Most 
adjuvants consist of aluminum-based compounds such as alum.   Alum stimulates Th2 
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responses (anti-inflammatory), while Freund’s Adjuvant stimulates Th1 responses (pro-
inflammatory).  Another common adjuvant, Quil A, is often used in veterinary practices, 
and the equivalent for human clinical studies is called QS-1 (discussed below) 
(Ghochikyan et al., 2006, Ragupathi et al., 2010). 
1.5  Role of Glial cells in Inflammation and Treatment of Neuronal Disorders   
Microglia are the primary immune cells in the CNS, and are a neuronal-based 
class of myeloid-derived monocytes, dedicated to the brain and CNS to function as the 
privileged phagocyte within the CNS and peripheral nerves.  These cells have been 
demonstrated to present in association with amyloid plaques and other sites of 
neurological damage or insult.  Microglial cells possess Fc receptors: Fcγ-R receptors 
bind to the Fc portion of the antibody to effect cellular responses.  As such, these cells 
have been closely examined when neuro-immunotherapy is investigated. 
 
1.6 Immunotherapeutic Approaches to Alzheimer’s Disease 
Immunotherapy was partially pioneered in the 1980’s (Shenk et al., 1984), and 
then was applied to AD (Simpson et al., 1987, Schenk et al., 1999b).  The initial AD 
studies focused on clearing Aβ, which forms the extracellular amyloid plaques 
characteristic of this disease.  Aβ is produced by proteolytic cleavage of the amyloid 
precursor protein (APP) by β-secretase and γ-secretase.  The Aβ peptide can be either 
40 or 42 amino acids in length, with the Aβ42 peptide being more prone to form β-
pleated sheets than Aβ40.  Aβ accumulation can lead to formation of oligomers, fibrils, 
and dense-core plaques.   
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Early treatment approaches for AD have focused on Aβ, in part due to the 
genetic correlates between AD and Aβ.  The E4 allele of apolipoprotein E (ApoE4) is 
one of the major risk factors for developing AD, and the presence of this allele is 
associated with increased amyloid burden.  Additionally, mutations in the genes for 
amyloid precursor protein (APP), presenilin 1 (PS1), and presenilin 2 (PS2), are 
involved in the production of Aβ, specifically the aggregation prone Aβ42 (Citron, 2010).   
Studies targeting Aβ, by drug or immunotherapy, have shown great promise in 
mouse models of AD.   The first reported immunotherapy study for treating AD was 
conducted by Schenk et al, of Elan Pharmaceutical (Schenk et al., 1999b).  Synthetic 
human Aβ42 or serum amyloid-P component (SAP), with Freund’s Adjuvant, were 
peripherally injected into PDAPP mice, with controls receiving phosphate buffered 
saline (PBS) plus adjuvant or no treatment.  Mice were injected at 6 weeks of age, 
before AD pathology develops, or at 11 months, when pathology is well established.  
They found that the mice developed large antibody titres; 8 of 9 of those injected with 
Aβ had titres greater than 1:10,000, and those injected with SAP ranged between 
1:1,000 and 1:10,000 with one mouse exceeding this level.  At 13 months, the animals 
were evaluated for immunohistochemical (IHC) markers of AD pathology and the Aβ42 
vaccinated mice showed almost no pathology, while the SAP vaccinated mice exhibited 
pathology similar to controls.  Older vaccinated mice were given a similar vaccination 
and evaluation schedule, and those vaccinated with Aβ42 showed markedly reduced 
pathology compared to controls (Schenk et al., 1999b). 
This study was followed by work in our own laboratory, using a different mouse 
model of AD, the APP/PS1 mouse, which has been shown to display cognitive deficits 
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resembling AD in concurrence with the development of amyloid pathology.  Mice were 
vaccinated subcutaneously starting at 5.5 months of age with either Aβ42 or keyhole 
limpet haemocyanin (KLH) adjuvant, alone, as a control.  Vaccinated mice were tested 
for behavioral/cognitive effects, using the radial arm water maze (RAWM).  At 11.5 
months, all mice were able to learn the platform location, suggesting that the immune 
response elicited by the vaccinations did not impair working memory.  The vaccinations 
were continued, and when the mice were re-tested at 15.5 months of age, the Aβ42-
vaccinated mice showed superior learning compared to the KLH-injected controls.  
Pathological testing for Aβ pathology showed that the Aβ42 –vaccinated mice exhibited 
reduced plaque-burden and less Aβ42 and Aβ40 than the respective controls (Morgan et 
al., 2000a).  This study verified the Schenk study using a different AD mouse model, 
and extended that study to demonstrate corresponding cognitive improvements in 
response to active immunotherapy.  Additionally, this study demonstrated no 
detrimental inflammation resulting from the treatment.   
Concurrent with the above studies, another group reported results of vaccinating 
TgCRND8 mice with Aβ42.  Approximately 50 percent reduction in dense core amyloid 
plaques was identified.  There was no difference in total Aβ levels and reduced 
cognitive deficit in the Morris water maze (Janus et al., 2000). 
Numerous additional studies followed, using various immunogens, adjuvants, 
and routes of administration.  The majority of these studies demonstrated that B cell 
epitopes reside within the first 15 amino acids of Aβ, while T cell epitopes exist in the Aβ 
mid-region and C-terminus. Immunogens can be designed to favor Th2 vs Th1 immune 
responses (Lemere, 2009).  This research addressed concerns of autoimmunity, in that 
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the administration of a peptide fragment of a protein can elicit both a protective protein-
clearing effect via B cells, and a cytotoxic T cell response to the endogenous Aβ.   
A consideration when immunizing with peptide fragments, rather than the entire 
protein, is the tertiary conformation of the antigen.  Variation of structures can influence 
the ability to produce effective antibodies to the immunogen.   
Antigen-Ig binding is conformation specific, so it is not surprising that injection of 
a fragment of amyloid failed to elicit immune responses in some of the animals because 
its tertiary structure was not identical to the antigenic portion of the full protein.  These 
considerations become important when translating the animal experiments to the clinic, 
as described below. 
 
1.7 Translation of Immunotherapy Using Animal Models To Human Applications 
Initial active immunotherapy studies in animals led to a series of passive 
immunization attempts.  Elan Pharmaceuticals led this endeavor by injecting one of two 
monoclonal antibodies against Aβ (10D5 or 21F12), or a polyclonal Ig fraction from their 
Aβ1-42 vaccinated mice, or PBS control.  Mice were injected intraperitoneally (i.p.) on a 
weekly basis for 6 months, then were evaluated for pathology.  They found that the 
polyclonal antibody reduced plaque burden by 93%, and the 10D5 monoclonal antibody 
reduced it by 81%.  They proceeded to examine two additional antibodies, 3D6 and 
16C11, finding similar plaque reduction with 3D6, but no effect from the 16C11 
antibody.  These studies identified no T-cell proliferation, leading to the conclusion that 
a T-cell response is not necessary for plaque clearance.  Fluorescent tagging revealed 
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that the antibodies had entered the brain and found their way to the plaques.  Further 
investigation revealed that these antibodies had cleared pre-existing plaques, and that 
microglia were involved in the clearance via Fc receptor-mediated phagocytosis (Bard 
et al., 2000). 
While the mouse data appeared to be a promising method for treating AD 
pathology and memory loss, complications in translating the mouse studies to human 
clinical trials has been established.  Several drugs that target Aβ immunologically have 
been or are currently in human trials.   
The first clinical trial, the AN1792 trial conducted by Elan and Wyeth, reported 
administration of an active vaccination by injecting full length Aβ1-42.  Three hundred 
patients were vaccinated intramuscularly with full length Aβ1-42 in a strong Th1 adjuvant, 
QS-21 (described above), while 72 participants received a placebo control. A positive 
antibody response was identified in 59 (22%) of the immunized individuals, while the 
remaining 241 patients were considered non-responders as determined by plasma 
antibody titers.  Significant reduction of CSF tau was additionally observed in the 
antibody-responders.  However no significant difference was found in a battery of 
neuropsychological tests, between the vaccinated and placebo groups.  In Phase II of 
the study, 18 of the 300 vaccinated patients (6%) developed meningoencephalitis, as 
evidenced by magnetic resonance imaging (MRI), while none of the placebo group 
developed this condition.  Thirteen of the antibody responders (22%), and five of the 
non-responders were found to have enlarged ventricles and reduced overall brain 
volume.   The incidence of meningoencephalitis was not correlated with serum Aβ 
levels.  Therefore it was unclear whether this side effect was due to the Aβ antibody 
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itself, or to T cell mediated inflammation, or to microglial responses indicative of a 
possible autoimmune reaction.   Additionally, it was thought that the chosen QS-21 
adjuvant may have caused the cytotoxic T cell response.  Follow-up of two of the 
subjects revealed elevation of soluble Aβ, which can contain toxic oligomers (Orgogozo 
et al., 2003, Bayer et al., 2005, Gilman et al., 2005, Patton et al., 2006).  A 5-year follow 
up showed no difference in the rate of overall decline of the patients, and despite plaque 
reduction, there was no significant difference in survival or the time to development of 
severe dementia (Holmes et al., 2008).  The clinical trials for AN1792 were ultimately 
terminated due to the negative side effects and the lack of psychological improvement 
in the patients. 
Despite the early termination of the AN1792 study, investigation into anti-amyloid 
immunotherapy has continued.   Currently three passive immunization drugs are in 
human Phase III trials to clear Aβ: Bapineuzumab–a humanized monoclonal antibody, 
3D6, which binds to an N-terminal epitope of Aβ deposits and reduces amyloid load 
primarily by microglial clearance, and was studied by Elan and Wyeth; Solanezumab–a 
humanized monoclonal antibody, 266, that binds to the mid-region of soluble Aβ and 
reduces amyloid load via the peripheral sink method, was evaluated by Eli Lilly and 
Company; additionally Baxter examined intravenous IgG (IVIG)–a human immunoglobin 
preparation that contains endogenous polyclonal antibodies to Aβ and that binds soluble 
Aβ and reduces amyloid load through the peripheral sink method (Citron, 2010, Joly-
Amado et al., 2014).  
The extensive body of work to date on Aβ immunotherapy has shown that both 
active and passive vaccination can result in clearance of dense core plaques and other 
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Aβ-associated pathology of AD, in mouse models and in human trials.  Antibodies to Aβ 
can cross the blood-brain barrier (BBB) and solubilize plaques, reverse or prevent 
plaque pathology and even prevent or reverse some associated cognitive loss.   
Four potential mechanisms, which may work independently or together, have 
been proposed to explain the method of Aβ clearance by antibodies (Lemere, 2009, 
Citron, 2010, Morgan, 2011a): 
• Microglia Mediated Clearance:  This model suggests that circulating antibodies 
reach parenchymal amyloid deposits and bind to Aβ, then the Fc portion of the 
antibody binds to the Fc receptor on microglia to facilitate phagocytosis and 
removal of the plaques and/or Aβ.  This hypothesis is supported by the early 
work reported by Bard et al (Bard et al., 2000) and by the presence of microglia 
around plaques (Bacskai et al., 2002). 
• Antibody-Antigen Direct Resolution: This model suggests that the binding of 
antibody to antigen may prevent aggregation and/or dissolve pre-formed 
aggregates.  It is as if the antibody breaks down the toxic aggregates of Aβ42 as if 
the antibody were an enzyme.  This proposed mechanism is supported by work 
by Solomon et al (1997) who showed in vitro that some site-directed monoclonal 
antibodies disturb the assembly of fibrillar amyloid, observed in Aβ aggregation 
and plaque formation. 
• Peripheral Sink: Antibodies may not be required to cross the blood-brain barrier 
(BBB) in order to clear amyloid from the brain.  This model suggests that 
antibodies in the bloodstream act on amyloid in the blood, altering the equilibrium 
between the brain and the vasculature, causing an efflux of amyloid out of the 
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brain, into circulation for removal.  This notion is supported by studies that have 
shown effective plaque removal in the brain accompanied by high circulating 
concentrations of Aβ. 
• Alteration of toxic species: This model suggests that interaction with antibodies 
modifies the secondary structure of amyloid by breaking down plaques or 
oligomers into less toxic entities.  This process would resemble a catalytic 
breakdown of amyloid, and is supported by the small ratio of antibody to antigen 
that is needed.  Unlike the ‘direct resolution’ mechanism, this hypothesis just 
addresses the aggregation or dis-aggregation of the unwanted protein.  Support 
for this hypothesis comes from work conducted by Morgan et al (2011), which 
revealed antibody to Aβ stoichiometry levels of a magnitude of 1:1000 (antibody 
to Aβ).  If demonstrated, this would be a preferable mechanism because it could 
produce robust clearance of Aβ and plaques without the involvement of microglia 
or other immune-system entities. 
Some questions remain as to which of these potential mechanisms are the 
pathways at work in immunotherapy studies.  It is possible that multiple pathways are 
involved, and that the pathways might be antibody-specific. 
A potential limitation to Aβ immunotherapy is that amyloid pathology develops 
well before cognitive and behavioral symptoms appear, so strategies focused on Aβ 
clearance may prove too late in the pathological process to fully ameliorate the disease 
(Krishnamurthy and Sigurdsson, 2011, Morgan, 2011a).  In addition, Aβ plaque load, 
unlike NFTs, doesn’t correlate linearly with severity of dementia (Bierer et al., 1995).  
This became evident when patients from the AN1792 trial were brought to autopsy and 
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showed post-mortem evidence of significant, if not complete, removal of amyloid 
pathology, however little or no cognitive benefit from drug administration had been 
observed (Holmes et al., 2008).  Another follow-up study identified the distinction 
between antibody responders and non-responders in human patients: when the 
antibody responders were compared to patients that received placebo, a significant 
reduction in functional decline was observed using the Disability Assessment for 
Dementia scale and the Dependence Scale (Vellas et al., 2009).  Additionally, no further 
cases of encephalopathy were observed in this follow-up study. 
Amyloid deposits and plaques can also be found within the vasculature of the 
brain, a condition that is referred to as cerebral amyloid angiopathy (CAA) (Beckmann 
et al., 2016, Diem et al., 2016, Merlini et al., 2016).  Amyloid deposits can exist 
throughout the vasculature, in addition to being observed in the brain.  Early treatment 
approaches for AD focused, in part, on removing Aβ (amyloid) plaques, due to the 
genetic correlates between AD and CAA.  The E4 allele of apolipoprotein E (ApoE4) is 
one of the major risk factors for developing AD, and the presence of this allele is also 
associated with increased amyloid burden, as plaques, in both the brain and peripheral 
vasculature (Miller-Thomas et al., 2016, van Veluw et al., 2016).  
CAA may result in the development of microhemorrhages.  Therefore clearance 
of parenchymal amyloid plaques has proven to be a confounder when investigating Aβ 
immunotherapy.  While reports of Aβ immunotherapy have shown significant reductions 
of soluble amyloid in the parenchyma, concurrent increases of cerebral 
microhemorrhages associated with amyloid-laden vessels have been observed.  
Perhaps such vascular components may be due to a weakening of the vessel walls 
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caused by a local inflammatory response (Pfeifer et al., 2002).  This might suggest that 
the Aβ vaccines clear amyloid, and specifically plaques, in the parenchyma quickly, 
resulting in a transfer of amyloid from parenchyma to the blood stream, such that 
amyloid clearance may compromise the integrity of blood vessel walls, which may 
present as greater degrees of CAA. 
 
1.8 Introduction to Tauopathies 
Recent work for treating dementias (including AD) has turned towards treatments 
that can target pathological tau.  Tau becomes pathologic in AD and other tauopathies, 
such as frontotemporal lobar degeneration (FTLD), frontotemporal dementia with 
associated Parkinsonism linked to chromosome 17 (FTDP-17), Pick’s Disease (PiD), 
corticobasal degeneration (CBD), and agryophilic grain disease (AGD). 
Tau is a microtubule-associated protein that is normally soluble and present in 
the cytoplasm of neurons.  It is a cytoskeletal protein that acts to stabilize microtubules 
and to facilitate intracellular axonal transport.  It interacts with kinesin, thereby affecting 
cellular transport mechanisms, and has multiple binding sites for microtubules, providing 
structure and function to cells, particularly neurons.  It can also regulate signaling 
pathways and activate or inhibit several enzymes (Morris et al., 2011).  It can be 
associated with the plasma membrane, where it is phosphorylated at tyrosine residues 
and might play a role in intracellular signal transduction (Wang and Liu, 2008).  
Normal tau is usually found in axons, but in tauopathies tau is redistributed to cell 
bodies and dendrites.  Then, it localizes to dendritic spines and impairs trafficking of 
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NMDA and AMPA receptors to the presynaptic membrane.  This impedes signaling and 
eventually leads to synapse loss (Hoover et al., 2010).  During development, tau can 
undergo several post-translational modifications, including phosphorylation, 
glycosylation, ubiquitination, truncation, and nitration (Wang and Liu, 2008).  The 
primary post-translational modification, especially as is relevant to AD and other 
tauopathies, is phosphorylation.  Hyperphosphorylated tau leads to conformational 
changes and aggregation into oligomers and NFTs (Polydoro et al., 2009). The NFTs 
seen in AD are hyperphosphorylated, aggregated, insoluble complexes of tau 
molecules.  Hyperphosphorylation leads to the formation of paired helical filaments 
(PHFs), which become the trademark intracellular “tangles” identified in AD. 
Tau protein can be subdivided into 4 regions: an N-terminal projection region, a 
proline rich domain, a microtubule binding domain (MBD), and a C-terminal region.  Six 
isoforms of tau exist in the human nervous system, which result from variations in the 
splicing of a single gene located on chromosome 17.  The protein ranges in size from 
352 to 441 amino acids, based on the presence or absence of exon 2 and/or exon 3, 
which results in a 29- or 58-amino-acid insert in the N-terminal region.   
The MBD can consist of repeats of 31 to 32 amino acids encoded by exon 10.  
Tau variants are named by based on which N-terminal exons are included (N) and the 
number of MBD-repeats (R) they comprise: eg. 0N has no N-terminal exons, 1N has 
exon 2, and 2N has exons 2 and 3, while 3R tau has 3 MBD repeats, and 4R tau has a 
fourth due to the inclusion of exon 10; (Lee et al., 2001, Morris et al., 2011).  The 
number of repeats affects the ability of tau to bind to microtubules, with 4R tau having a 
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different affinity for microtubule binding (Espinoza et al., 2008, Wisniewski and 
Sigurdsson, 2010).   
The normal brain has similar levels of 3R and 4R tau.  Tauopathies are 
somewhat characterized by the number of MBD repeats they express; for example PiD 
only has 3R tau, while AD has a combination of 3R and 4R tau.  The amino terminal, 
which is comprised by a large number of acidic amino acids, projects from the 
microtubules and may play a role in spacing between microtubules.  It may also be 
involved in connecting microtubules to other cytoskeleton proteins (Wang and Liu, 
2008). 
Tau mutations have been identified In AD, and in other tauopathies, with 32 
mutations having been described in more than 100 families with FTDP-17 (Goedert and 
Jakes, 2005).  Two primary types of mutation can occur: alternative splicing of exon 10, 
which results in different ratios of MBD repeats (3 repeats vs. 4 repeats), and mutations 
that alter tau’s interactions with microtubules (Krishnamurthy and Sigurdsson, 2011).   
Two mutations, some in exon 12 (V337M), and one in exon 13, R406W—lead to 
the formation of PHFs that can alter all six isoforms of tau, similar to the filaments found 
in AD.  The P301L mutation in exon 10, which only effects 20 to 25 percent of tau 
molecules, leads to the formation of twisted ribbons containing the 4R isoform (Goedert 
and Jakes, 2005).  It has been suggested that a correct ratio of 3R to 4R tau may be 
necessary for its normal function, or that an overproduction of 4R tau could lead to an 
excess of binding to microtubules, leading to cytosolic accumulation and aggregation of 
tau (Goedert and Jakes, 2005). 
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Mutation can cause tau to become hyperphosphorylated, leading to misfolding 
and disruption of function.  Tau has more than 30 serine and/or threonine sites that are 
subject to phosphorylation. Antibodies directed at these sites enable examination of 
these phosphorylation sites to assess relative tau pathology.  For example, the AT8 
antibody recognizes phosphorylation at Ser199/202, an early stage of 
hyperphosphorylation.  Phosphorylation at Ser262 is identified using the 12E8 antibody.  
AT270 recognizes phosphorylation at Thr181.  AT180 identifies phosphorylation at 
Thr231, and PHF-1 recognizes paired helical filaments phosphorylated at Ser396 & 
Ser404, a late-stage hyperphosphorylation marker.  Ser422 is another AD-relevant 
phosphorylation site (Wisniewski and Sigurdsson, 2010, Xia et al., 2015).   
Phosphorylation at most targets leads to a moderate reduction in microtubule binding.  
However, Ser262 has been identified as a unique phosphorylation site in that its 
phosphorylation seems to prove instrumental in leading to microtubule detachment and 
possible PHF aggregation, as is seen in AD; phosphorylation of this amino acid reduces 
binding affinity by about 300 percent (Mandelkow et al., 1995). 
Several kinases lead to tau hyperphosphorylation, including proline-directed 
mitogen-activated protein kinases (MAPK), glycogen synthase kinase 3 (GSK 3β) and 
cyclin dependent kinase (cdk5) (Mandelkow et al., 1995).  In general, the greater the 
phosphorylation of tau, the lower its ability becomes to bind to microtubules.  
Microtubule affinity-regulating kinase (MARK) phosphorylates Ser262 as well as other 
serine residues, causing tau to become detached from microtubules, leading to a 
reduction in length of tau, which results in it becoming unstable, and the resulting 
function can present as if no tau is present (Mandelkow et al., 1996). 
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Tau can also undergo post-translational modifications such as truncation, 
nitration, and more.  Caspases and other proteases truncate tau at Glu391 or Asp421 of 
the C-terminal, producing fragments that can form NFTs or lead to apoptosis (Wang and 
Liu, 2008).  Tau can be nitrated at various Tyr residues, and nitrated tau has been found 
to be co-localized with NFTs, which may represent oxidative damage. 
 
1.9 Early Studies Investigating Tau-Directed Immunotherapy 
Tau is an intracellular protein, which suggests that antibodies may not be able to 
reach and exert an effect on tau pathology.  Early studies have demonstrated that both 
active and passive forms of immunization clear some of the pathological forms of tau.  
Rosenmann et al  (2006) injected full-length recombinant human tau protein with 
complete Freund’s Adjuvant (CFA) and pertussis toxin (PT) into wild type C57BL/6 mice 
to see if this might cause an autoimmune response such as encephalomyelitis, which 
was observed in clinical trials with Aβ vaccination.  The CFA+PT adjuvant was chosen 
for its proinflammatory effect to enable the researchers to focus on immunotherapy 
safety issues.  Using this approach, they detected encephalomyelitis along with NFT 
formation 1.5 to 5 months post-injection (Orgogozo et al., 2003).  
 A follow-up study involved injecting a combination of 3 phospho-tau peptides, 
along with CFA and PT, peripherally into two NFT mouse models, hypothesizing a 
reduction of pathology.  This peptide combination covered 5 pathogenic phospho tau 
residues.  Encephalopathic symptoms were not seen up to 8 months post-injection, 
however significant reductions were seen in NFTs and phospho-tau by staining for 
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Gallyas, AT 8 and AT 180, as well as an increase in microglia population in response to 
the phospho-tau injections. In this study, these effects were still seen 8 months after a 
single injection followed by one booster (Boimel et al., 2010). 
Initial work by Sigurdsson et al (2008) examined the effects of active 
immunization with 4E6G7, a computer-designed immunogen peptide of tau amino acids 
379 to 408, which includes the PHF-1 phosphorylation sites of Ser396 and Ser404 (a 
late-stage phosphoepitope in NFTs).  This immunogen, or alum adjuvant as control, 
were injected subcutaneously for 2 to 5 months into JNPL3 P301L mice, which express 
4R/0N tau via a FTDP-17-associated tau mutation, P301L (Denk and Wade-Martins, 
2009), and develop pathology primarily in motor regions of the brain: the motor cortex, 
brainstem, and spinal cord.  Alum was chosen as an adjuvant because it is well 
tolerated and leads to a Th2-type immune response.   
The vaccinated mice were found to have reductions of insoluble tau and 
increases in soluble tau.  The mice also exhibited improved performance on rotarod and 
balance beam tests.  Additionally, a gender difference was observed, with female mice 
expressing greater levels of tau pathology.  These differences were observed both 
before and after treatment, compared to male mice.  It has been suggested pathological 
tau was cleared at higher rates in females, compared to males (Bayer et al., 2005, 
Sigurdsson, 2008).   
A series of investigations have been conducted to investigate the physiologic 
location(s), and access of tau antibodies to such locations, within the brain.   
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Intracellular and extracellular presence (or absence of) antibodies the passage of 
antibodies from the blood and CSF, into into neurons and other parenchymal tissue.  
Sigurdsson’s group collected and purified antibodies generated against the tau 
P301L immunogen, then FITC-labeled them, and injected the antibodies into the carotid 
arteries of the JNPL3 P301L mice.  Subsequent histochemistry was examined, and 
identified labeled antibodies to be primarily located in the brain, within neurons, and co-
localized with markers for pathologic tau.  The labeled antibodies also were injected into 
non-transgenic animals and no uptake into the brain was observed, suggesting that the 
BBB likely is compromised in the transgenic animals.  These results may extrapolate 
into humans with tauopathies, thereby facilitating antibody transport from the periphery, 
into the brain (Sigurdsson, 2009). 
The mouse model used by Sigurdsson et al. in these studies does not 
necessarily represent AD pathology; it is primarily a model of motor pathology that 
progresses so quickly that cognitive maze testing is not practical.  However, this was an 
early, published study indicating that immunization against tau could be a successful 
therapeutic approach for treating tauopathies and perhaps could function to treat AD.  
They followed this with work using a different mouse model that mimics AD more 
closely and exhibits development of tangles in addition to displaying cognitive deficits 
associated with AD.  Their newer mouse model was created by crossing htau mice with 
M146L-mutation PS1 mice maintained on a mouse-tau knock-out background.  These 
mice displayed early (before 2 months of age), rapidly progressing tau pathology in 
cortical and hippocampal areas.  The same immunogen 4E6G7 was administered i.p. 
with alum adjuvant, controls received adjuvant alone.  Antibody titers were measured by 
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ELISA, and were notable, throughout the experiment.  Behavioral testing included the 
same motor tests as described above, and also included the radial arm maze, the 
closed field symmetrical maze and object recognition testing.  Immunization resulted in 
significant performance improvement in all three cognitive tests compared to controls.  
IHC for PHF1 revealed significant decreases in the immunized mice vs. controls.  
Soluble PHF1 tau was also reduced as measured by Western blotting.  Most notable is 
that the behavioral improvements correlated well with the reductions of PHF1-detected 
pathology. (Boutajangout et al., 2010).   
 In 2001, Lim et al created a mouse model, VLW, that expresses human 4-repeat 
tau with 2 N-terminal inserts from exons 2 and 3 along with three mutations, G272V, 
P301L and R406W, that have been found in FTDP-17 patients.  Ultrastructural tissue 
analysis revealed an increase in the number of lysosomal complexes in neurons of VLW 
mice compared to age-matched wild types. Lysosomal bodies were also found in tau-
positive neurons, which the authors speculated were residual bodies derived from 
lysosomes (Lim et al., 2001).   
	
1.10 Potential Intracellular Metabolism of Tau 
Two primary pathways for protein degradation exist within cells, the proteosome 
pathway and the lysosome pathway, which includes autophagy.  The proteosomal 
pathway requires ubiquitination —a post-translational modification process in which 
activated ubiquitin binds to lysine (Lys) residues of a modified protein. Lysine can 
become acetylated in AD, impeding this route of degradation (Otvos et al., 1994).  
However, tau can be present as an unfolded protein with three lysines available for 
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ubiquitination: Lys-6, Lys-11 and Lys-48, with the added Lys-48 being the primary site 
for polyubiquitination and degradation by the ubiquitin-proteosome-system (UPS).  Lys-
6 functions as an inhibitory site for the UPS (Wang and Liu, 2008).  The UPS is a 
quality-control system for proteins and helps to eliminate small, misfolded soluble 
proteins.  When misfolded tau is deposited as NFTs there is a potential problem with the 
UPS. 
The lysosomal pathway, or autophagy, is the pathway for degradation of larger 
aggregates of misfolded proteins, mutant proteins that are known for conformational 
instability, and proteins that possess the propensity to form oligomers and aggregates.  
These misfolded proteins reside in the cytoplasm, where they can be easily 
sequestered into autophagosomes and then enzymatically degraded (Ding and Yin, 
2008).  This macroautophagy pathway can be overwhelmed in pathologic conditions, 
leading to accumulation of aggregates in the cytosol which, over time, can form paired 
helical filaments, as in AD (Sigurdsson, 2009). 
In addition, enzyme-activity staining for acid phosphatase, which is a marker for 
lysosomes, showed an increase in staining, particularly in the cortex and hippocampus 
of VLW mice compared to wild type, which resembles staining for tau.  Further analysis 
revealed that mutated tau, as opposed to wild type tau, showed greater lysosomal 
activity (Lim et al., 2001). (Bi et al., 2000).  
 
	 28	
1.11 Application of Immunotherapy to Potential Treatments for Dementias 
Aβ immunotherapy studies began by focusing on investigations on active 
immunization.  These studies utilized various forms of Aβ, first in mice, and then 
translated into human clinical trials.  A similar course of investigation has evolved in tau 
immunotherapy.  Active immunization was examined first, utilizing various mouse 
models and immunogens (antigens), as described above.   Other studies evaluated 
passive immunization using various antibodies and multiple mouse models, to identify if 
exogenous antibodies could prove more effective for treatment use.   
Sigurdsson et al (2011) led this endeavor by administering PHF1 to JNPL3 mice.  
Mice that were 2- to 3 months old were given weekly injections of PHF1 or pooled 
mouse IgG.  Blood was collected at various points and was assayed for the tau epitope 
4E6G7 (described above) by enzyme-linked immunosorbent assay (ELISA).  At 5 to 6 
months of age, the mice were administered behavioral testing (traverse or balance 
beam, rotarod, and open field).  The dentate gyrus, motor cortex, and brainstem were 
evaluated using IHC for PHF1 to compare pathological forms of tau to total tau levels.  
A significant reduction of PHF1 was identified in the dentate gyrus, along with a strong 
trend of reduction in the motor cortex, but no difference was noted in the brain stem. 
Western blotting for PHF1 and CP13/B19 revealed significant decreases of insoluble 
pathological tau, but no differences in soluble or sarkosyl soluble tau.  Behavioral 
analysis demonstrated fewer footslips on the traverse beam in the treated group, while 
the other motor testing did not appear to be affected.   
Because this mouse model primarily exhibits motor deficits, cognitive 
performance was not evaluated.  The results do, however, show great promise for 
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passive immunotherapy directed against tau, although the authors noted that this 
passive-immunotherapy approach seemed to be less efficacious than the prior active-
immunization studies, which targeted essentially the same region of phosphorylated tau.  
This conclusion was based on the absence of an effect in the brainstem, despite 
effectiveness in the dentate gyrus.  They also noted, however, that passive 
immunization is likely to be safer, by avoiding a possible negative T cell response such 
as that found in the clinical AN1792 study (Boutajangout et al., 2011a). 
Their work was followed by a passive immunization study in the laboratory of 
Martin Citron at Eli Lilly using two different tau-overexpressing mouse lines, the JNPL3 
mouse and P301S mutated mice.  The JNPL mice have been discussed above.  The 
P301S mouse strain is a more rapidly progressing line of Tg mice, with pathology 
becoming evident at younger ages, compared to older mice.  It has also proven useful 
for studying tau pathologies and potential treatments.  Chai et al (2011) tested two 
different types of anti-tau antibodies on these mice, initially with investigating PHF1 
antibody administration.  In addition, they examined MC-1, which is specific for 
conformation alterations of tau.  The JNPL3 mice were given systemic injections of 
either antibody or an IgG1 control from 2 months of age until 6 months.  Western 
blotting revealed similar results between the different treatment groups, so this team 
developed an ELISA assay using the AT8 antibody, which revealed a significant and 
substantial reduction of phosphorylated tau in response to both administered antibodies.   
A subsequent study involved administering the same antibodies to the P301S 
mice from age 2 to 5 months that were then subjected to motor testing.  Treated mice 
showed a significant improvement on the rotarod for both antibody groups compared to 
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controls.  The rate and progression of pathology and motor deficits was greater for the 
P301S mice than for the JNPL3 mice.  ELISA analysis revealed 45 percent reduction in 
pathology with PHF1 antibody administration, and a 33 percent reduction in pathology 
after MC-1 administration.  IHC testing also revealed reduced tau pathology after 
administration of either antibody compared to control, and no significant difference in 
microglia or astrocyte activation (Chai et al., 2011a). 
Immunotherapy directed against tau is likely to encounter some limitations as 
additional studies are conducted and the field grows.  The first potential issue relates to 
tau being a normal protein with specific cellular functions (unlike Aβ, which currently is 
not known to have necessity-based biological function).  Immunotherapy against tau will 
have to be investigated with caution, to ensure that normal tau is not disrupted and that 
clearance of toxic species of tau doesn’t result in depletion of normal tau.  Studies to 
date have avoided this issue by specifically targeting hyperphosphorlyated tau species.  
Studies conducted using tau knock-out animals have shown relatively normal function 
(Denk and Wade-Martins, 2009), suggesting that the body has a way of compensating 
for lower or non-existent levels of normal tau when it is cleared inadvertently.  If tau 
immunotherapeutics advance to clinical trials, there should be little risk to control or 
non-demented individuals whose BBBs should be intact; very little antibody crosses the 
BBB the under normal circumstances.  Tau is an endogenous protein, therefore issues 
regarding overactivity of the immune system or autoimmunity may present.  Such issues 
have been minimized given the overall results from the Aβ studies. 
Immunotherapy treatments for dementias have recently become an attractive 
means for targeting tau protein, in part because of some of the issues limiting Aβ 
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efficacy in clinical studies, and in part because tau pathology is more directly linked to 
the symptoms and severity of AD.  There is a much stronger correlation between 
cognitive decline and the development of tau aggregates than Aβ deposition 
(Sigurdsson, 2008)  The best strategy for treating AD might prove to be one that targets 
both Aβ and tau in concert. 
 
1.12 Translation into Human Treatments in the Clinic 
 Minimization of side effects and other improperly directed effects can partially be 
minimized by incorporating lessons from the Aβ clinical trials into experimental and 
clinical-trial design.  Early studies of tau immunotherapy have shown encephalitis-like 
functional deficits in some of the mouse studies, however it is still thought that the 
choice of adjuvant may be the major reason for this (Sigurdsson, 2009). 
 
1.13 Future Directions for Tau-Directed Immunotherapy 
Early immunotherapy strategies for treating AD, tauopathies, and other 
neurodegenerative disorders suggested that this could be a fruitful avenue for future 
treatment strategies.  Oligomers of Aβ and/or tau are likely to be the subject of 
increasing focus, as is further described, below.  Many groups have been investigating 
oligomeric forms of amyloid and tau and view these to be the most toxic forms of the 
proteins.  As the groundwork is laid in tau passive immunotherapy studies, it is likely 
that the next generation of immunotherapies will be directed at oligomers.  Additionally, 
a number of experts have suggested the future of immunotherapeutic treatments for AD 
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and related dementias will likely address Aβ and tau, in concert.  It is our hope that the 
studies presented herein will yield results that could make their way into the clinic in the 
very near future. 
 
1.14 rTg4510 Mice and Their Role in Studying Tauopathies, Including AD 
Transgenic mice have been established, using many techniques, to facilitate 
scientific understanding of basic biological processes, disease mechanisms, and 
treatment approaches for the advance of medical science and care.  Aβ approaches for 
AD and related dementias are addressed above.  In more recent times, however, tau 
pathology shows much stronger correlation to the behavioral symptoms of dementias.   
One of the most robust tau-producing mouse lines relevant to dementias is the 
rTg4510 mouse.  This mouse line combines a specific tau mutation, P301L, which leads 
to pathologic tau mutation, with a second genetic line, TTA, a tetracycline-controlled 
activator that can either turn on, or off, the expression of the mutant P301L gene.  As 
such, the mutant tau can be regulated by a normal “on” state (mutant P301L 
expression), or can be “turned off” by administration of doxyclicine.  The TTA 
transactivator is further described as a CaM++ kinase transactivator (CaMK++) due to 
regulation by doxycycline, as shown in Figure 1.1. 
Our lab has established a population of rTg4510 mice for the following studies.  
These mice have both a TTA/CaMK++ transactivator, and the p301L mutation.  This dual 
mutation, combined, enables tau pathology to be turned on and off.  Additionally, it 
directs tau pathology to upper/cognitive regions of the brain (whereas the p301L 
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mutation, alone, tends to express in lower, motor regions without the TTA transactivator, 
further referred to as Tet). The studies described herein focused on the differential 
location of the pathology, which occurs in upper cognitive brain regions.  Figure 1.1 
provides an illustration of the genetic design for how this combination-transgene strain 
of mice was created. 
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Figure 1.1:  Tet‐Off expression system. The expression of tauP301L gene is suppressed 
in the presence of Dox in bigenic mice derived by crossing parental strains carrying 
either responder or activator transgenes (a). In Tet‐Off expression system, a 
tetracycline‐controlled tTA protein regulates the expression of a target gene, in this case 
tau gene which is under the transcriptional control of a TRE. The TRE is composed of 
tetO fused to a promoter [human cytomegalovirus (CMV) immediate‐early promoter]. In 
the absence of CMV, or Dox, tTA binds to tetO of TRE and activates transcription of tau 
transgene (b). Doxycycline, which is usually delivered in food or drinking water, has 
higher binding affinity to tTA and thus, when present, prevents tTA from binding to TRE 
and consequently suppresses the expression of tau gene (c).  
Republished with permission of John Wiley and Sons, from Genes, Brain and Behavior, 
C. Jannus, Volume 7:s1, 2008; permission conveyed through Copyright Clearance 
Center, Inc. 
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CHAPTER 2: PRELIMINARY STUDIES 
	
2.1 Introduction 
Our laboratory has conducted a number of studies using animal models to 
establish the feasibility of treating tau pathology, and to identify pharmacologic effects 
and behavioral impacts of various tau treatment strategies.  This series of studies 
initially examined treatment effects using anti-tau antibodies in APP mice with the added 
transgenes for presenilin1 (PS1) and inducible nitric oxide negative (iNOS), NOS2-/-
/APP/PS1 mice.  Such mice have been reported to express tau pathology, in addition to 
Aβ pathology.  
Identifying the relatively minor (or “lack of”) toxicity and behavior effects from anti 
tau treatment to APP/NOS2-/-mice (with and without the added PS1 transgene) led to 
further examination of the effects of tau treatment in more robust tau-producing mice.  
The transgenic mouse model rTg4510 is specifically designed and bred to overproduce 
tau pathology.  The combination of the P301L mutation, with the Tet transactivator, 
specifically leads to tau pathology in higher brain regions (cognitive regions such as 
cortex and hippocampus), and provides a useful model for identifying tau-based 
treatments when investigating AD-related tauopathy treatment strategies. 
These studies sought to identify the most effective and specific antibody 
treatment, the best route of administration, and optimal time frames for treating tau 
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pathology in rTg4510 mice.  The goal was to develop a greater perspective of tau 
antibody treatment.  Behavior was also examined, and was compared to observed 
alterations of brain pathology before and after treatment with tau antibodies.   
Initial studies utilized a commercially available antibody, Tau 5. Four tau 
antibodies that exhibit distinctly different mechanisms of action also were explored: two 
with demonstrated affinity for pathological tau but not normal tau, one pan-tau antibody 
that has yet to demonstrate any specificity for pathological tau, and one directed 
specifically to tau oligomers: 
Tau 5 is specific to tau and binds to the mid-region, amino acids 218 – 225, and 
as such is able to bind all forms of tau because this region is conserved among all post-
translationally modified forms of tau. 
PHF1 is a phosphorylation-dependent monoclonal antibody that recognizes 
phosphorylated serine (pSer) 396 and pSer404, two phosphorylation sites in 
pathological tau, which is hyperphosphorylated at the paired helical filaments (PHFs) in 
what is generally considered to be “late stage” for AD.  This antibody is often used in 
IHC or Western blotting to visually localize and quantify hyperphosphorylated tau.   It 
can recognize either of the pSer epitopes, alone, or both together.  It exhibits greater 
than 10-fold sensitivity when both are present (Otvos et al., 1994). 
MC1 is a conformation-dependent monoclonal antibody that recognizes early-
stage pathology conformation changes of PHFs across all 6 isoforms of tau.  It has dual 
epitopes at the N-terminal and between amino acids 312 and 342 in the third 
microtubule-binding domain (MBD) (Jicha et al., 1997, Oddo et al., 2004) and will only 
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bind tau that is conformationally modified such that MC1 simultaneously connects the 
N-terminal epitope with the mid-domain epitope.  Given that conformational variation, 
especially the pathological conformations identified in AD and other neurodegenerative 
diseases, is an important factor in proteins’ overall function, it was prudent to evaluate a 
conformational-dependent antibody in these studies.  The ability to bind two linearly 
separated binding domains simultaneously reflects the existence (and possible 
clearance, via treatment) of early NFTs 
DA9 is a pan-tau monoclonal sequence antibody that binds to acids 102 through 
140 and has no known specificity for pathological tau, thus only binds normal tau, which 
is necessary for normal functioning. This antibody was included to address the question 
of whether normal tau is affected or reduced.   
TOMA (tau oligomeric monoclonal antibody, also called H12) was included in 
later studies because it has been shown to reduce oligomers and improve behavior in 
JNPL3 and htau mice (Lasagna-Reeves et al., 2011b, Castillo-Carranza et al., 2014b, 
Guerrero-Munoz et al., 2014, Lasagna-Reeves et al., 2014).  It had not yet been tested 
in rTg4510 mice.   
Anti-GFP was used as a control because it is a similar isotype of IgG. IgG 
antibodies do not activate complement in the mouse, so any clearance observed from 
treatment antibodies, when compared to the GFP IgG1, would be due to other 
mechanisms such as those described above for Aβ (Bacskai et al., 2002).   
Behavioral testing before, and after, treatment was conducted to correlate 
pathology to behavioral effects of the treatments. Intracranial injection of Tau 5 or an 
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anti-GFP control antibody was first conducted using NOS-/-/APP/PS1 mice to assess 
effects of tau treatment and any inflammation that might result from antibody injections.  
Additionally, an antibody directed against tau and administered to amyloid-producing 
mice could also affect amyloid pathology, which we therefore also evaluated.  
Investigation using a more specific tau mouse model, rTg4510, was then conducted 
using additional antibodies. 
 
2.2 Tau Administration   
Several injection paradigms were investigated, using multiple Tg mouse strains 
and antibodies.  Intracranial injections, using convection-enhanced delivery (CED) 
(Carty et al., 2010) to maximize dispersion of the injected antibodies, were performed at 
a rate of 2.5 μl/min, for a total of 2 μl (2 μg) per injection site, followed by one minute 
before needle retraction.  Parenchymal injections were administered using stereotaxic 
equipment, with proper coordinates set for each brain region and adjusted for brain 
atrophy, given the age of the mouse. 
Ventricular injection was also examined, using 15 μl of antibody per animal, 
injected at a flow rate of 2.5 μl /min into the right ventricle.  Gallyas and Nissl staining 
were completed to identify changes in NFTs or neuronal population.   Infusion of 
antibodies followed, using implanted pumps to deliver longer-term exposure to the 
treatment antibodies.  Subcutaneous (sc) injections were later administered by i.p. into 
the abdominal cavity. 
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2.3 Behavioral Testing 
General mobility and activity testing: open-field testing, balance beam, rotarod, 
and Y maze, was conducted to identify potential physical or cognitive performance 
deficits. The number of arm entries in the Y maze can be used as a measure of general 
activity levels of the mice.  The percent of alternations provides an indication of working 
memory; it is expected that normal (nTg) mice will remember the most recent arms 
visited then opt for a different arm, searching for reward (food).  This represents a 
behavior akin to evolutionary foraging strategies.   
Cognitive function was examined using the radial arm water maze (RAWM), 
which tests for learning and memory abilities.  RAWM testing was followed by open pool 
testing to evaluate vision and swimming abilities, as a control, to ensure the mice were 
capable of conducting the tasks required for the RAWM.  These are swimming tests; 
RAWM consists of 6 different arms radiating from a center area, with one arm 
containing a hidden escape platform.   
On the first day, the first 4 blocks (12 trials) use a visible platform alternated with 
a hidden platform to assist the mice to use spatial cues, to learn which arm to swim to 
for safety.  The platform location remains constant for each mouse, but is alternated 
between mice within each group to rule out confounding factors such as odor trails from 
previous mice.  The last block (3 trials) on day 1, and all of the blocks on day 2, used a 
hidden platform to force the mice to rely on spatial memory cues to find the escape.  
Throughout testing, the time for the mouse to find the platform is recorded as are the 
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number of errors (defined as entries into an incorrect arm, or greater than 15 seconds 
spent in one arm or in the pool center without arm selection).  Analysis of the number of 
errors provides the best evaluation of learning and memory.  
Results were verified by open pool testing, where a visible platform is placed in 
random quadrants of the pool, and the time required for each mouse to find the escape 
platform is recorded.  Open field is a control test for RAWM, to ensure the mice can see 
the platform and that they are able to swim competently to reach it. 
Following intracranial antibody injection, the animals were given a brief recovery 
period (6 – 7 days).  Post-injection RAWM behavioral testing was conducted using 
procedures described above.  For post-injection testing, the escape platform was placed 
in a different arm than where it had been during the pre-injection testing.  Modified arm 
placement was intended as a “new” test of cognitive ability, not as a long-term retention 
test, to identify if the antibody injection resulted in any change in learning and memory 
ability over time.   
Post-injection behavioral testing further included fear conditioning (FC).  FC 
consisted of a first day of training, pairing a tone with a foot shock, then a second day of 
associative memory evaluation.  During training, the mice were placed in a chamber 
and were allowed to freely explore for 2.5 minutes, at which time an audible tone was 
played.  The tone lasted for 30 seconds and ended with the administration of a foot 
shock.  Mice were observed for freezing behavior (an indication of fear), and their 
movements were recorded digitally.  At the 4-minute time point during training, a second 
30-second tone was administered that again ended with a foot shock.  The mice were 
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observed for 7 minutes after being placed in the chamber and their movement was 
digitally recorded as amperage, recorded by a camera inside the chamber.  Freezing 
was defined if the motion of the mouse was less than threshold, which was established 
as 10 mA, for 2 msec. 
One day after training, two tests of association and memory were conducted.  
The first of these is referred to as “context” testing, which tests for hippocampal-
dependent memory.  The mouse was placed in the same chamber in which it received 
the foot shock, for 3 minutes, and similar observations of freezing were recorded.  No 
shock was administered.  This procedure tests for contextual learning and memory.  Did 
the mouse associate the context with the previous shock, and freeze, simply due to its 
environment or context? 
The second FC test was “cued” testing, which is a test of amygdala-dependent 
associative memory.  For this task, a different chamber was used, olfactory cues were 
changed, the appearance of the experimenter changed, and lighting to the room was 
turned off.  These changes were intended to remove all context-based cues from the 
previous day’s training.  Mice were placed in this novel environment and allowed to 
explore for 3 minutes, at which time the original tone was played.  The tone remained 
on for the duration of the experiment, but no foot shocks were delivered.  Again, 
freezing behavior was recorded to identify if the mice remembered the association 
between tone and shock.  This is a test for auditory association with learning.  Does 
tone, alone, result in freezing?  All FC testing results were reported as percentage of 
time freezing.   
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2.4 Tissue Collection 
Mice were euthanized after completion of the post-treatment behavioral studies.  
A 200 mg/kg-body weight injection of Somnasol was administered.  Approximately 10 
minutes, post-injection, an ear punch was collected for confirmation genotyping.  Mice 
were then intracardially perfused with a 0.9% sodium chloride solution.   
Tissue collection consisted of dissecting the anterior cortex, posterior cortex, 
hippocampus, striatum, thalamus, cerebellum and “rest of brain” (ROB) from the right 
hemisphere of the brain, freezing them on dry ice and storing at -80 degrees for 
potential biochemistry evaluation.  The left hemispheres were fixed for 24 hours using a 
freshly made 4% paraformaldehyde (PFA) solution, after which time they were 
transferred to Dulbecco’s phosphate buffered saline (DPBS) + Azide, until they were 
cryoprotected for sectioning.  Further cryoprotection consisted of a sequential 
immersion in increasing sucrose solutions, beginning with 10% for 24 hours, 20% for 24 
hours, and finally 30% for 24 hours.   
The left hemisphere was sectioned for immunohistochemical (IHC) and 
histological staining.  Sections of 25 μm were collected using a sliding microtome with a 
4-degree Celsius cooled stage to freeze the brains.  Sections were collected into 24-
well plates containing DPBS + Azide.  Four successive sections were collected, per 
well.    Free floating IHC was conducted on sections spaced 300 μm apart, in the region 
of the depth of injection.  In general, 6 sections were selected per animal.  Staining for 
CD45 was conducted using a rat monoclonal antibody to clone YW62.3 (Thermo), and 
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staining for diffuse Aβ was conducted using an antibody that was a gift from Paul 
Gottschall, University of Akansas.   
 
2.5 Western Blot  
Biochemistry was examined using Western blot.  Dissected brain regions were 
homogenized, then sonicated in RIPA buffer, with added protease and phosphatase 
inhibitors, then centrifuged at 40,000 x G for 30 min at 4° C.  Supernatant was collected 
for analysis of RIPA-soluble proteins.  The resulting pellet was digested with 70% formic 
acid, to analyze RIPA-insoluble proteins.  Samples were separated using 10% Tris-
glycine gels, then were transferred to either nitrocellulose or PVDF membranes, for 
probing and fluorescent and/or photo-luminescent detection.   
NOS-/-/APP/PS1 mice 
Antibodies were administered via intracranial parenchymal injection into reported 
tau producing mice, NOS2-/- mice crossed with either APP (tg2576) or APP/PS1 mice.  
Littermate nTg mice were used as controls.  Eight mice per group were injected, one 
group being NOS2-/-/nTg, the second being NOS2-/-/APP, and the third was NOS2-/-
/APP/PS1.  For each group, half of the mice received Tau 5 antibody, bilaterally, and 
the other half received anti-GFP bilaterally, into the hippocampus. 
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rTg4510 mice 
Intracranial injections of either Tau 5 antibody or an isotype-specific (IgG1) 
control antibody against GFP were administered bilaterally into the hippocampus, to half 
of each genotype group, using rTg4510 mice and their littermates.  
Five rTg4510 mice (9 -11 month old) were intracranially injected with either Tau 
5, or an IgG1 control, anti-GFP, into the hippocampus.  Two µg of Tau 5 antibody 
(directed against the mid domain of the tau peptide) was injected into one hippocampus, 
and 2 µg of anti-GFP control was injected into the hippocampus on the opposite side.   
Tau 5, or anti-GFP, was subsequently injected into contralateral sides of a small 
population of younger, 3.5 month old, rTg4510 mice. The hemisphere receiving Tau 5 
vs. anti-GFP was alternated between different animals to reduce hemispheric influence. 
Tissue was collected 4 days later.  Whole brain sections were collected  
Antibodies were then injected, unilaterally, into the cortex and hippocampus, of 
rTg4510 mice that were 11 - 13 months of age.  Injection was conducted similarly to the 
Tau 5 antibody injections described, above.  
Following the initial pilot studies with Tau 5, antibodies for: PHF-1, MC-1, DA-9, 
or anti-GFP as an IgG1, control were unilaterally injected into both the hippocampus 
(HPC) and the anterior cortex (ACx) of 11 – 13 month old rTg4510 mice (8 mice per 
group). Tissue collection occurred 4 days after injection.  The anterior pole of each 
whole brain was dissected, and was snap frozen for biochemistry.   
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Tau 5, MC-1, anti-GFP or TOMA were then examined using different administration 
protocols, as described below. 
2.6 Results: NOS2-/-APP/PS1 Mice and Controls 
Intracranial injection of Tau 5 or a green fluorescent protein (GFP) control 
antibody anti-GFP (both murine IgG1), into NOS2-/- mice crossed with either APP 
(tg2576) or APP/PS1 mice was first investigated.  Littermate nTg mice were used as 
controls.  Eight mice per group were injected, one group being NOS2-/-/nTg, the second 
being NOS2-/-/APP, and the third was NOS2-/-/APP/PS1.  For each group, half of the 
mice received Tau 5 antibody, bilaterally, and the other half received anti-GFP 
bilaterally, into the hippocampus. 
Behavior analysis was forefront in this study to identify if antibody injection, in 
general (control or treatment), would demonstrate effects on performance.  Additionally, 
we sought to identify any potential benefit from the Tau 5 antibody in neuronal amyloid-
producing groups of mice.  Pre-injection baseline (first round) behavior testing was 
conducted; Figures 2 through 4 show the results from the baseline activity behavioral 
testing. 
Figure 2.1 shows motor ability results.  Panel A demonstrates the latency to fall 
off of an elevated balance beam.  The NOS2-/-/APP mice had previously exhibited the 
greatest performance deficit in this task. Our results indicated that this performance 
difference was not statistically different from the other groups.  Panel B shows the time 
the mice were able to remain on the rotarod, which is a rotating treadmill that gradually 
increases in speed over time.  All mice were able to perform this task, showed 
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improvement with subsequent trials, and did not perform significantly different based on 
genotype.   NOS2-/-/APP/PS1 mice were non-significantly more active (hyperactive), in 
the Y maze as shown in Figure 2.2., with Panel A presenting the total number of arm 
entries and Panel B showing the percent of alterations between arms.  The NOS2-/-
/nTg mice displayed significantly greater percentages of alterations in the Y Maze than 
the other two genotypes, indicating that they had a better memory of which arms had 
already been visited.  These results are consistent with previous results by our 
laboratory, using this mouse line, even without the NOS2 gene deletion (Gordon et al., 
2001).   
Figure 2.3 presents the results of RAWM and open pool tests.  Panel A shows 
RAWM results as a function of time.  Each Block represents the average of 3 trials, per 
block, conducted over two days.  This figure shows that all of the mice are able to learn 
the task.  The total number of errors for the three groups (Panel B) was also compared, 
and here we note that there is significant impairment in the NOS2-/-/APP/PS1 mice 
compared to the NOS2-/- mice.  Results are consistent with those previously reported 
from our laboratory for NOS2 sufficient mice (Arendash et al., 2001).  Results in Panel 
C show that the mice were able to see the platform and were able to perform the tasks 
required to find it.  
Figure 2.4 shows post-injection results for the RAWM, by block.  A greater 
number of errors were initially observed with all mice, since many animals returned to 
the original platform location.  Over time, they learned the new location, and Tau 5 
animals appeared to learn the new location more quickly.  Statistical analysis did not 
demonstrate significance, however.  The NOS2-/-/APP/PS1 mice, in all treatment 
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conditions, demonstrated the most impaired performance, as was the case in the first, 
pre-injection RAWM test.  
Figure 2.5 divides the pre-injection RAWM testing into the resulting 6 groups, and 
provides a comparison between pre- and post- injection RAWM testing for all six 
groups.  The most notable results are the increased number of errors at the onset of 
post-injection RAWM testing.  Also notable, for both rounds of testing (pre-, vs. post- 
injection), was a genotype difference.  Tau 5 treated mice made fewer errors, across all 
genotypes.  However extra variability was introduced by comparing multiple genotypes 
and evaluation of treatment results across all three genotypes.  Therefore a treatment-
induced difference could not be identified statistically. 
Figure 2.6 shows FC training results, post injection, and illustrates NOS2-/-/nTg 
mice mice appear to exhibit more of a deficit learning the task compared to anti-GFP 
controls (Panel A).  NOS2-/-/APP mice froze similarly by treatment during the course of 
training (Panel B).  NOS2-/-/APP/PS1 mice showed an increase in freezing behavior in 
response control treatment vs Tau 5 injection (Panel C). 
Testing of contextual memory (Figure 2.7) shows no significant differences by 
either genotype or treatment. 
Figure 2.8 shows results from cued testing in NOS2-/- mice and controls.  Tau 5 
treated mice appeared to minimally increase their associative memory freezing 
response in nTg mice (Panel A).  No other differences were noted between either 
genotype or treatment with FC. 
	 48	
Figure 2.9 shows the results of CD 45 IHC staining.  We focused our attention to 
the area of injection (essentially CA1) to best visualize relative microglial activation in 
response to intracranial injection of the 2 antibodies.  Specifically, we were trying to 
identify if the Tau 5 antibody resulted in more, less, or similar levels of inflammation 
compared to the control.  Most notably was greater CD 45 staining, reflective of 
inflammation, in the NOS2-/-/APP/PS1 mice compared to the other genotypes, however 
no significant difference between the treated vs. control groups was identified.  
Aβ IHC was also examined, on the chance that the tau antibody treatment might 
show an impact on amyloid pathology in these primarily amyloid-producing mice.  As 
expected, there was no Aβ staining evident in the NOS2-/-/nTg mice, and the greatest 
staining was observed in the NOS2-/-/APP/PS1 mice.  Since we have not found tau 
pathology in any of these mice, and these mice are known to be primarily amyloid 
producers, we did not evaluate IHC pathology for tau.  Additionally, we weren’t 
anticipating any significant changes in Aβ IHC in the mice that were treated with Tau 5 
vs the anti-GFP controls, since the target is different.  Surprisingly enough, Figure 2.10 
shows that an increase in Aβ staining was observed in the Tau 5 treated mice.  As with 
the behavior data (particularly the FC data), it must first be noted that the ending 
number of animals for each unique group was only 4, thereby making the determination 
of satisfactory statistical significance difficult.  It is for this reason that the observed 
statistical significance was especially surprising.  However, as with the behavioral 
results, the significance that we found is more likely to be genotype-dependent as 
opposed to being treatment-dependent.  
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No significant differences in biochemistry were observed by Western blot, as a 
result of tau treatment.  Therefore results are not included here.   
 
rTg4510 mice GFP vs Tau 5 
 Figures 2.11 and 2.12 present micrograph and statistical results for the microglial 
markers CD 45 and Iba1, respectively.  Figure 2.13 shows similar results for cell density 
using Nissl staining.  No significant differences were noted in any of these 
examinations, however the Nissl staining results did appear to reveal a greater, but non-
significant, number of cells in the treated animals compared to the control animals. 
Subsequent to antibody injection, behavioral analysis was conducted as 
described above.  Figure 2.14 provides results from Rotarod activity testing.  Figure 
2.15 presents results from Y Maze alternations. Both tests revealed no activity 
differences between the different treatment groups, for this genotype.  The open field 
test was also completed, but it similarly showed no difference between treatments, 
therefore the results are not included here. 
Post-treatment cognitive tests were also conducted to identify any treatment-
based effects.  Novel Object Recognition (NOR) testing results are reported in Figure 
2.16.  RAWM results are reported in Figure 2.17. Novel Object Recognition testing 
showed that the MC-1 treatment restored rTg4510 mice to nTg performance levels.  
Tau 5 treated mice demonstrated slight improvement in recognition of a foreign object, 
suggesting that they remembered the original object and avoided the novel object.  The 
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RAWM test revealed a high level of variability between the mice, but by the last block of 
testing, MC-1 treated mice performed significantly better than the IgG1 controls.  
 
Ventricular Injection 
No significant differences were noted as a result of ventricular injection, between 
any of the treatment groups.  This method of administration did not appear to be 
productive therefore results are not included. 
 
Discussion 
We could attempt to dissect the observed differences, or lack thereof, by 
repeating these experiments using additional mice to increase the statistical power of 
the results.  However, this experiment was just a pilot study, so we chose not to pursue 
it further.  The main goal of this pilot study was to do a thorough behavioral investigation 
of the mice, both before and after surgery, and to note any substantial differences in 
microglial activation or amyloid pathology as a result of tau antibody administration 
(post-surgery).  The significance (or lack thereof) reported here could be substantiated, 
or contradicted, by adding additional animals, or by conducting follow-up studies.  
However the fundamental goals of the pilot study had been achieved and the decision 
was made to move forward by studying the effects of anti-tau antibodies on more 
relevant tau-producing mice. 
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 Preliminary data, reflected initial attempts to utilize an antibody directed to all 
forms of tau; its epitope is specific and conserved enough to represent binding to total 
tau and all forms of tau.  However, the tau molecule, itself, may not be the most toxic 
form in the context of AD and tauopathies.  Also, as noted above, tau can be 
hyperphosphorylated at many locations; it can undergo mutation and/or conformational 
changes, it can undergo other types of post-translational modification, and it eventually 
forms filaments, which can further aggregate and lead to the formation of NFTs.  There 
are many different “types” of antibodies directed for different forms of tau. 
Characterization of the APP/NOS mice, initially, did not reveal the reported tau 
pathology or neuron loss.  They were still useful as preliminary study animals to assess 
potential inflammation, which might result from antibody injections.  An antibody 
directed against tau, administered to amyloid-producing mice, could also affect amyloid 
pathology.   
 
2.7 Pilot Test of Total Tau Antibody Using rTg4510 Mice 
Initial investigation of toxicity and behavior effects resulting from anti-tau 
treatment to AP/NOS-/-mice, (with and without the added PS1 transgene), led to further 
studies to examine the effects of tau treatment on robust tau-producing mice.  The 
transgenic mouse model rTg4510 is specifically designed, and bred, to overproduce tau 
pathology.  The combination of the P301L mutation, with the Tet transactivator, 
specifically leads to tau pathology in higher brain regions (cognitive regions), and 
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provides a very useful model for identifying tau treatments when investigating AD 
related tauopathy treatment strategies. 
Small groups of rTg4510 mice, ranging in age, were intracranially injected with a 
commercially available antibody to tau, Tau 5.  This antibody binds to the mid-region of 
tau, namely amino acids 218 – 225, and as such is able to bind all forms of tau since 
this region is conserved among all post-translationally modified forms of tau.  It also 
binds to the 6 different isoforms of tau.   
The intent was to identify if treatment using Tau 5, and binding by this antibody, 
might indicate whether or not immunotherapy could be effective in directly treating 
pathological tau, and whether it might be effective in treating pathologically generated 
tau-mice.  This antibody is effective in binding and/or labeling all forms of tau, even 
‘normal’ healthy forms of it.  Therefore we expected it to demonstrate effectiveness 
across different breeds of tau mice. 
Initially, 5 rTg4510 mice (9 -11 month old) were intracranially injected with either 
Tau 5, or an IgG1 control, anti-GFP, into the hippocampus by use of convection-
enhanced delivery (CED) (Carty et al., 2010).  Two µg of Tau 5 antibody (directed 
against the mid domain of the tau peptide) was injected into one hippocampus, and 2 µg 
of anti-GFP control (both murine IgG1) was injected into the hippocampus on the 
opposite side.  Anti-GFP is not known to have any biological activity in the mouse, and it 
has the advantage of being an IgG1 isotype, akin to Tau 5 and the other antibodies 
investigated herein.  The GFP antibody also does not stain normal mouse brain proteins 
when used in immunostaining reactions.     
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Tau 5, or anti-GFP, was subsequently injected into contralateral sides of a small 
population of younger, 3.5 month old, rTg4510 mice. The hemisphere receiving Tau 5 
vs. anti-GFP was alternated between different animals to reduce hemispheric influence. 
Tissue was collected 4 days later.  Whole brain sections were collected into two 
horizontally aligned 24-well plates.  Four adjacent sections were placed in each well, 
then the next well was filled in the first plate, and section collection continued in the first 
plate, until it continued into the second plate.  Sections from the center-most wells were 
used for IHC and other staining.  
After completion of the post-treatment behavioral studies, mice were euthanized 
using a 200 mg/kg-body weight injection of Somnasol.  Approximately 10 minutes, post-
injection, an ear punch was collected for confirmation genotyping, then mice were 
intracardially perfused with a 0.9% sodium chloride solution.  Tissue collection consisted 
of dissecting the anterior cortex, posterior cortex, hippocampus, striatum, thalamus, 
cerebellum and “rest of brain” (ROB) from the right hemisphere of the brain, freezing 
them on dry ice and storing at -80 degrees for potential biochemistry.  The left 
hemispheres were fixed for 24 hours using a freshly made 4% paraformaldehyde (PFA) 
solution, after which time they were transferred to DPBS + Azide until they were 
cryoprotected for sectioning.  Cryoprotection consisted of a sequential immersion in 
increasing sucrose solutions, beginning with 10% for 24 hours, 20% for 24 hours, and 
finally 30% for 24 hours.  Then, the left hemisphere was sectioned for 
immunohistochemical (IHC) and histological staining.  Sections of 25 μm were collected 
using a sliding microtome with a 4-degree Celsius cooled stage to freeze the brains.  
Sections were collected into 24-well plates containing DPBS + Azide, 4 successive 
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sections were collected, per well.  Free floating IHC was conducted on sections spaced 
300 μm apart, in the region of the depth of injection.  In general, 6 sections were 
selected per animal.  Staining for CD45 was conducted using a rat monoclonal antibody 
to clone YW62.3 (Thermo), and staining for diffuse Aβ was conducted using an antibody 
that was a gift from Paul Gottschall, University of Akansas.   
Additionally, we examined biochemistry using Western blot.  Dissected brain 
regions were homogenized then sonicated in RIPA buffer, with added protease and 
phosphatase inhibitors, then centrifuged at 40,000 x G for 30 min at 4° C.  Supernatant 
was collected for analysis of RIPA-soluble proteins.  The resulting pellet was digested 
with 70% formic acid, to analyze RIPA-insoluble proteins.  Samples were separated 
using 10% Tris-glycine gels, then were transferred to either nitrocellulose or PVDF 
membranes, for probing and fluorescent and/or photo-luminescent detection.   
 
 
We could attempt to dissect the observed differences, or lack thereof, by 
repeating these experiments using additional mice to increase the statistical power of 
the results.  However, this series of experiments were just pilot studies, so we chose not 
to pursue it further.  The main goal of this pilot study was to do a thorough behavioral 
investigation of these mice, both before and after surgery, and to note any substantial 
differences in microglial activation or amyloid pathology as a result of tau antibody 
administration (post-surgery).  The significance (or lack thereof) reported here could be 
substantiated, or contradicted, by adding additional animals, or by conducting follow-up 
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studies.  However the fundamental goals of the pilot study had been achieved and the 
decision was made to move forward by studying the effects of anti-tau antibodies on 
more relevant tau-producing mice. 
FC results must be qualified, based on the low number of experimental subjects 
per group at the time of testing.  Three genotypes of mice were each divided in half for 
the different treatments, resulting in only 4 animals in each genotype-treatment group.  
With that noted, there was consistency amongst the results.   
After completion of pre-injection behavioral studies, intracranial injections were 
administered bilaterally into the hippocampus.  Injections of either Tau 5 antibody or an 
isotype-specific (IgG1) control antibody against GFP were administered to half of each 
genotype group.  Anti-GFP is not known to have any biological activity in the mouse, 
and it has the advantage of being an IgG1 isotype, akin to Tau 5 and the other 
antibodies investigated here.  
 
Results: NOS2-/-APP/PS1 Mice and Controls 
Intracranial injection of Tau 5 or a green fluorescent protein (GFP) control 
antibody, anti-GFP (both murine IgG1), into NOS2-/- mice crossed with either APP 
(tg2576) or APP/PS1 mice was investigated.  Littermate nTg mice were used as 
controls.  Eight mice per group were injected, one group being NOS2-/-/nTg, the second 
being NOS2-/-/APP, and the third was NOS2-/-/APP/PS1.  For each group, half of the 
mice received Tau 5 antibody, bilaterally, and the other half received anti-GFP 
bilaterally, into the hippocampus. 
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Behavior analysis was forefront in this study to identify if antibody injection, in 
general (control or treatment), would demonstrate effects on performance.  Additionally, 
we sought to identify any potential benefit from the Tau 5 antibody in neuronal amyloid-
producing groups of mice.  NOS2-/-/APP/PS1 mice were non-significantly more active 
(hyperactive), as shown in Figure 2.1.  Panel A demonstrates the latency to fall off of an 
elevated balance beam.  The NOS2-/-/APP mice had previously exhibited the greatest 
performance deficit in this task. Our results indicated that this performance difference 
was not statistically different from the other groups.  Panel B shows the time the mice 
were able to remain on the rotarod, which is a rotating treadmill that gradually increases 
in speed over time.  All mice were able to perform this task, showed improvement with 
subsequent trials, and did not perform significantly different based on genotype.   
Figure 2.2 shows performance in the Y maze, with Panel A presenting the total 
number of arm entries and Panel B showing the percent of alterations between arms. 
The NOS2-/-/nTg mice displayed significantly greater percentages of alterations in the Y 
Maze than the other two genotypes, indicating that they had a better memory of which 
arms had already been visited.  These results are consistent with previous results by 
our laboratory, using this mouse line, even without the NOS2 gene deletion (Gordon et 
al., 2001).   
Figure 2.3 presents the results of RAWM and open pool tests.  Panel A shows 
RAWM results as a function of time.  Each Block represents the average of 3 trials, per 
block, conducted over two days.  This figure shows that all of the mice are able to learn 
the task and remember where the escape platform is located.  The total number of 
errors for the three groups (Panel B), was also compared, showing that there is 
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significant impairment in the NOS2-/-/APP/PS1 mice compared to the other two groups.  
Results are consistent with those previously reported from our laboratory for NOS2 
sufficient mice (Arendash et al., 2001).  Results in Panel C show that the mice were 
able to see the platform and were able to perform the tasks required to find it. 
 
Figure 2.4 demonstrates RAWM results, post injection.  A new platform was 
introduced, therefore initial errors were greater, initially.  All mice appeared to learn the 
new escape platform location, over time, with no statistically significant difffernece, 
although the Tau 5 treated mice appeared to perform slightly better. 
Figure 2.5 shows the results for all six groups (based on genotype and treatment 
differences) collectively, from pre- vs post-injection RAWM testing.  The NOS2-/-
/APP/PS1 mice, in both treatment conditions, demonstrated the most impaired 
performance, as was the case in the first, pre-injection RAWM test, while the NOS2-/-
/nTg mice learned the task most quickly and robustly.   
Figure 9 (Figure 2.8) divides the pre-injection RAWM testing into the resulting 6 
groups, and provides a comparison between pre- and post- injection RAWM testing for 
all six groups.  The most notable results are the increased number of errors at the onset 
of post-injection RAWM testing.  Also notable, for both rounds of testing (pre-, vs. post- 
injection), was a genotype difference.  Figure 2.8 demonstrates little difference due to 
treatment effects. 
After round 2 post-injection RAWM testing, the Tau 5 treated mice made fewer 
errors, across all genotypes.  However extra variability from comparing multiple 
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genotypes and attempting to evaluate treatment results across all three genotypes, 
introduced added variability, therefore a treatment-induced difference could not be 
identified statistically 
FC training results, shows that NOS2-/-/nTg mice increased freezing during the 
course of training Fig 2.6.  Tau 5 injected mice appeared to learn the task better than 
anti-GFP controls by freezing significantly less (Panel A).  NOS2-/-/APP mice froze 
similarly by treatment during the course of training (Panel B).  NOS2-/-/APP/PS1 mice 
showed a significant decrease in freezing behavior in response to Tau 5 injection (Panel 
C).  It is unlikely that the GFP antibody would have had an effect on freezing or learning 
abilities.   
Testing for contextual memory showed that in NOS2-/-/nTg mice, Tau 5 treatment 
appeared to improve memory of training, as the mice froze more quickly then 
maintained freezing for the course of the test, Figure 2.7 shows context results from FC 
in NOS2-/- mice. 
.  NOS2-/-/APP mice demonstrated a non-significant reduced time of freezing with 
Tau 5 treatment, and anti-GFP treatment may have led to an improvement in memory or 
ability to freeze, which was not an expected result.  Taken into consideration with 
performance during training, it would appear that the NOS2-/-/APP genotype is 
especially resistant to freezing behavior, and that antibody treatment probably made no 
difference.  Surprisingly, the NOS2-/-/APP/PS1 mice seemed to show retention of 
context, and performed somewhat similarly to the NOS2-/-/nTg mice. 
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Tau 5 treated mice appeared to minimally increase their associative memory 
freezing response (Panel A).  During training and contextual testing, NOS2-/-/APP mice 
showed little or no freezing, even in response to the tone.  This behavior continued into 
cued testing (Figure 2.8) which shows results from cued testing in NOS2-/- mice., and no 
treatment difference was noted.  NOS2-/-/APP/PS1 mice demonstrated very little 
freezing during cued testing.  Anti-GFP treated mice appeared to freeze a little more in 
association with the tone.  These responses were not significant, however. 
 
 
FC results here must be qualified, based on the low number of experimental 
subjects per group at the time of testing.  Three genotypes of mice were each divided in 
half for the different treatments, resulting in only 4 animals in each genotype-treatment 
group.  With that noted, there was consistency amongst the results.  The NOS2-/-/nTg 
mice performed all components of training and testing much like regular non-transgenic 
mice would be expected to perform, and the Tau 5 treatment seemed to improve 
learning and memory performance.  NOS2-/-/APP/PS1 mice generally showed impaired 
freezing responses, and surprisingly the NOS2-/-/APP mice were the most impaired in 
these tasks.  Unexpectedly, anti-GFP control treatment appeared to improve 
performance in some of the tasks compared to the Tau 5 treatment.  Anti-GFP is not 
known to have biological function, so it would not be prudent to assume it rescued 
performance.  In the end, there was limited statistical significance between any of the 
genotypes or the treatments, so any apparent improvement in anti-GFP treated mice is 
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likely an artifact due to the number of different factors being evaluated and to the low 
number of animals in each unique group.  The only statistically significant finding in all 
of these results was between the no-tone and tone phases of NOS2-/-/nTg cued testing 
(P < 0.05).  
Figure 2.9 shows the results of CD 45 IHC staining.  We focused our attention to 
the area of injection (essentially CA1) to best visualize relative microglial activation in 
response to intracranial injection of the 2 antibodies.  Specifically, we were trying to 
identify if the Tau 5 antibody resulted in more, less, or similar levels of inflammation 
compared to the control.  Most notably was greater CD 45 staining, reflective of 
inflammation, in the NOS2-/-/APP/PS1 mice compared to the other genotypes.  As for 
which antibody treatment produced greater indices of inflammation upon injection, slight 
differences between the genotypes demonstrated no significant difference between the 
treated vs. control groups.  
Aβ IHC was also examined, on the chance that the tau antibody treatment might 
show an impact on amyloid pathology in these primarily amyloid-producing mice.  As 
expected, there was no Aβ staining evident in the NOS2-/-/nTg mice, and the greatest 
staining was observed in the NOS2-/-/APP/PS1 mice.  Since we have not found tau 
pathology in any of these mice, and these mice are known to be primarily amyloid 
producers, we did not evaluate IHC pathology for tau.  Additionally, we weren’t 
anticipating any significant changes in Aβ IHC in the mice that were treated with Tau 5 
vs the anti-GFP controls, since the target is different.   
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Surprisingly, Figure 2.10 shows that an increase in Aβ staining was observed in 
the Tau 5 treated mice.  As with the behavior data (particularly the FC data), it must first 
be noted that the ending number of animals for each unique gr oup was only 4, 
thereby making the determination of satisfactory statistical significance difficult.  It is for 
this reason that the observed statistical significance was especially surprising.  
However, as with the behavioral results, the significance that we found is more likely to 
be genotype-dependent as opposed to being treatment-dependent.  
No significant differences in biochemistry were noted by Western blot, as a result 
of tau treatment.  Therefore results are not included here. 
Tau immunotherapy studies were expanded to evaluating treatment of rTg4510 
mice.  This series of studies evaluated different types of antibodies, targeted to different 
epitopes, and with different mechanisms of action. Our studies with total tau antibody 
were furthered to identify other variations of tau that might be as good, or better, at 
targeting pathological tau in disease states.   
Unilateral intracranial injections were administered into both the hippocampus 
(HPC) and the anterior cortex (ACx).  Whole brain sections were collected for IHC 
analysis, although the anterior pole was dissected and saved, for biochemical analysis 
by Western Blot.  Animals (8 per group) consisted of 11 – 13 month old rTg4510 mice; 
they received, either, antibodies for: PHF-1, MC-1, DA-9, or anti-GFP as an IgG1, 
control.  Tissue collection occurred 4 days after injection.  The anterior pole of each 
whole brain was dissected, and was snap frozen for biochemistry.  Sections of the 
remaining brain were collected into two horizontally aligned 24-well plates.  Four 
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adjacent sections were placed into each well, the next well was filled in the first plate, 
until the first plate was filled.  Section collection continued into the second plate.  
Sections from the center-most wells were used for IHC and other staining.  Positive 
staining was quantified; the values of the injected hemisphere were divided by values 
from the uninjected side, then statistics were computed to compare the results between 
treatment groups. 
  Three additional tau antibodies, which exhibit distinctly different mechanisms of 
action, were explored in hopes of identifying the best antibody treatment to evaluate 
further.  The additional antibodies examined here included two with demonstrated 
affinity for pathological tau but not normal tau, and one pan-tau antibody that has yet to 
demonstrate any specificity for pathological tau.  These antibodies included: 
• PHF-1, a phosphorylation-dependent antibody that recognizes phosphorylated 
Ser396 and Ser404.  This antibody is often used in IHC or Western Blotting to 
visually localize and quantify hyperphosphorylated tau, generally at sites 
considered to be “late stage” for AD.   This antibody can recognize either of the 
pSer epitopes alone, or both together which results in >10 fold sensitivity when 
both are present (Otvos et al., 1994). 
• MC-1, another important tau antibody which recognizes early-stage conformation 
changes of PHFs across all 6 isoforms of tau.  It has dual epitopes at the N-
terminal and between amino acids 312-342 in the third microtubule-binding 
domain (MBD) (Jicha et al., 1997, Oddo et al., 2004).  The tau protein needs to 
be conformationally modified such that MC-1 can simultaneously connect the N-
terminal epitope with the mid-domain epitope, otherwise MC-1 won’t bind.  Given 
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that conformational variations of proteins, especially the pathological 
conformations identified in AD and other neurodegenerative diseases, is an 
important factor in their overall function, it was prudent to evaluate a 
conformational-dependent antibody in these studies.  The ability to find and bind 
two linearly separated binding domains at the same time reflects the existence 
(and possible clearance, from treatment) of early NFT formation, an early toxic 
form of tau. 
• DA-9, a pan-tau antibody, has no known specificity for pathological tau and only 
binds normal tau.  This addition is important due to the necessity of normal tau 
for normal functioning.  Here, we addressed the question of whether reduction in 
normal tau is deleterious.  DA-9 is an anti-tau antibody with an epitope at amino 
acids 102 through 150 (Tremblay et al., 2010).  It is not known to interact with 
known toxic forms of tau, but rather binds normal tau.  DA-31, an additional pan 
tau antibody that binds amino acids 150 – 190, about which less is known, was 
considered to be an option should DA-9 prove an uninformative treatment 
alternative.  These 4 additional antibodies, PHF1, MC-1, DA-9, and DA-31 were 
all a gift from Peter Davies of the Albert Einstein College of Medicine in New 
York.  We received these antibodies, solubilized in PBS, at a concentration of 1 
mg/ml. 
Tau 5, PHF-1, MC-1, and DA-9, are all murine IgG1 antibodies.  Anti GFP was 
used as a control since it is the same isotype of IgG.  IgG1 antibodies do not activate 
complement in the mouse.  Any clearance observed from treatment antibodies 
	 64	
compared to the GFP IgG1, would be due to other mechanisms such as those 
described above for Aβ (Bacskai et al., 2002). 
Each antibody, and/or control, was injected intracranially, to ascertain acute 
benefit.   Antibodies were injected unilaterally, into the cortex and hippocampus, of 
rTg4510 mice that were 11 - 13 months of age.  Injection was conducted similarly to the 
Tau 5 antibody injections described in the Preliminary Results.  CED needles 
maximized dispersion of the injected antibodies, and injection was performed at a rate 
of 2.5 μl/min, for a total of 2 μl (2 μg) per injection site.  Once the injection was 
complete, one minute elapsed before the needle was retracted.  
Figures 2.11 and 2.12 present micrograph and statistical results for the microglial 
markers CD 45 and Iba1, respectively.  Figure 2.13 shows similar results for cell density 
using Nissl staining.  No significant differences were noted in any of these 
examinations, however the Nissl staining results did appear to reveal a greater, but non-
significant, number of cells in the treated animals compared to the control animals. 
Subsequent to antibody injection, behavioral analysis was conducted as 
described above.  Figure 2.14 provides results from Rotarod activity testing.  Figure 
2.15 presents results from Y Maze alternations. Both tests revealed no activity 
differences between the different treatment groups, for this genotype.  The open field 
test was also completed, but it similarly showed no difference between treatments, 
therefore the results are not included here. 
Post-treatment cognitive tests were also conducted to identify any treatment-
based effects.  Novel Object Recognition (NOR) testing results are reported in Figure 
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2.16.  RAWM results are reported in Figure 2.17. Novel Object Recognition testing 
showed that the MC-1 treatment restored rTg4510 mice to nTg performance levels.  
Tau 5 treated mice demonstrated slight improvement in recognition of a foreign object, 
suggesting that they remembered the original object and avoided the novel object.  The 
RAWM test revealed a high level of variability between the mice, but by the last block of 
testing, MC-1 treated mice performed significantly better than the IgG1 controls.  
Four days after behavioral testing, mice were anesthetized with Somnasol, 
followed by intracardiac perfusion using a 0.9% saline solution.  The left and right 
cortices (anterior poles of the brain, 3mm in length) were dissected, then snap frozen on 
dry ice for the purposes of conducting biochemistry such as Western blotting.  The 
posterior portion was immersion-fixed for 24 hours in 4 percent paraformaldehyde for 
IHC analysis.  After 24 hours, the posterior brain portion was cryoprotected using a 
series of sucrose immersions to remove residual water from the tissue, ending with 
immersion in 30% sucrose.  The brains were frozen for sectioning on a sliding 
microtome; 25 μm sections were collected and preserved in DPBS + Azide.  Sections 
used for staining were selected every 300 μm, at the approximate depth of antibody 
injection, for each staining procedure. 
Microglial activation was identified using CD45 antibody via IHC (Figure 2.18).  
NFTs were identified and quantified by Gallyas staining (Figure 2.19).  Positive staining 
was quantified; the values of the injected hemisphere were divided by values from the 
uninjected side, or were normalized to values from control animals, then statistics were 
computed to compare the results between treatment groups. 
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Analysis 
Histology data was digitized using a Mirax digital scanning microscope and was 
analyzed using Mirax software to identify percent staining, by antibody, for a given brain 
region.  Statistical analysis consisted of 1-way ANOVA, computed using Stat View, and 
the results are presented with means +/- SEM.  Positive staining was quantified; the 
values of the injected hemisphere were divided by values from the uninjected side, or 
were normalized to values from control animals, then statistics were computed to 
compare the results between treatment groups. 
We could attempt to dissect the observed differences, or lack thereof, by 
repeating these experiments using additional mice to increase the statistical power of 
the results.  However, this experiment was just a pilot study, so we chose not to pursue 
it further.  The main goal of this pilot study was to do a thorough behavioral investigation 
of the mice, both before and after surgery, and to note any substantial differences in 
microglial activation or amyloid pathology as a result of tau antibody administration 
(post-surgery).  The significance (or lack thereof) reported here could be substantiated, 
or contradicted, by adding additional animals, or by conducting follow-up studies.  
However the fundamental goals of the pilot study had been achieved and the decision 
was made to move forward by studying the effects of anti-tau antibodies on more 
relevant tau-producing mice. 
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2.8 Investigation of Additional Tau Antibodies, in Additional Brain Regions 
Preliminary data, above, reflected initial attempts to utilize an antibody directed to 
all forms of tau; its epitope is specific and conserved enough to represent binding to 
total tau and all forms of tau.  However, the tau molecule, itself, may not be the most 
toxic form in the context of AD and tauopathies.  Also, as noted above, tau can be 
hyperphosphorylated at many locations; it can undergo mutation and/or conformational 
changes, it can undergo other types of post-translational modification, and it eventually 
forms filaments, which can further aggregate and lead to the formation of NFTs.  There 
are many different “types” of antibodies directed for different forms of tau. 
 
2.9 Ventricular Injection Study 
Candidate antibodies were also investigated, via ventricular injection vs. 
parenchymal injection, to identify whether CSF administration might prove more 
effective than parenchymal injection.  Five or 6 rTg4510 mice were given 15 μl per 
animal at a flow rate of 2.5 μl /min into the right ventricle.  Tissue collection occurred 7 
days after injection.  Whole-brain sections were collected into two horizontally aligned 
24-well plates.  Sections from the center-most wells were used for IHC, for microglial 
markers.  Additionally, Gallyas and Nissl staining were completed to identify changes in 
NFTs or neuronal population.   No significant differences were noted as a result of 
ventricular injection, between any of the treatment groups.  This method of 
administration did not appear to be productive therefore results are not included. 
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2.10 Tau Aggregation Study 
An effort to further understand actions of the administered antibodies was 
conducted using an aggregation inhibition protocol that relies on the wavelength change 
of thioflavin T (ThioT), in order to identify the quantities of protein aggregation, with or 
without, antibody treatment.  Recombinant tau (P301L) was used, along with heparin (to 
induce aggregation), and varying concentrations of each of the antibodies were added 
to identify aggregation inhibition kinetics. 
These in vitro aggregation assays were conducted, using recombinant P301L tau 
protein (4R0N), to measure the kinetics of tau aggregation.  Equal amounts of antibody 
and tau were added to wells in a 96-well plate.  Dithiothreitol and heparin were added to 
initiate aggregation.  Varying antibodies (reported above) were added at different 
concentrations to identify their effects on aggregation of tau.  The resulting fluorescent 
shift was measured using ThioT.  Plates were heated in a 37° water bath (ensuring no 
water entered the plates), subsequently were read by a plate reader every 12 minutes 
for a total of 24 hours.  ThioT signals from the plate reader quantified protein 
aggregation. 
This study was conducted to identify if the antibodies are effective as aggregation 
inhibitors, for reducing pathological tau levels, given the questionable results from using 
them as treatments in vivo.  This study was also aimed to understand the 
dose/response, and time-course, of the potential actions of these antibodies.  The 
antibodies tested for aggregation included: PHF 1, MC-1, DA 9, DA 31 (all graciously 
received from Peter Davies, PhD.), Tau 5 (purchased), and 2 X TOMA, also known as 
H12, (a gracious gift from Rakez Kayed, PhD).  Proper IgG controls were paired with 
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each antibody: IgG1 was used as the comparison for all antibodies except for 
TOMA/H12, which required an IgG2b antibody control. 
Each antibody was tested in ½ of a 96-well plate, resulting in 2 antibodies per 
plate.  One antibody was the test antibody of interest, paired with the appropriate 
antibody control.  ThioT was added to all wells (in addition to the recombinant protein, 
heparin, and dithiothreitol) to visualize aggregation response(s), via the plate reader.   
Dose-response, and time course of action, was measured for each antibody.  The plate 
reader was programmed to read each plate at selected time intervals to identify 
aggregation over time.  Greater aggregation leads to a higher signal from ThioT binding. 
Recombinant P301L tau was the protein, with approximately 20 mM of cell 
content added, and was was prepared to about 5 – 8 mg/ml.   This protein content was 
dialyzed in 100 mM sodium acetate (pH = 7) the night before.  A BCA protein analysis 
was conducted the following day, to prepare the plate(s), as follows:   
 Dialyzed recombinant P301L tau – 20 mM 
 20 uM heparin (to induce aggregation) 
 Varying concentrations of antibody, per plate design  
Samples were run in triplicate.  The first row, for each antibody, was 10 ug, the 
second row was 1 ug, followed by the third row at b 0.1 ug, then 0, in terms of the 
amount of antibody added.  Plates were read using a plate reader with proper time 
points programmed in.  Electron microscopy (EM) was used to verify protein 
identification, using 1 ug/ul or less of the samples.  Results were provided after about 40 
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min per test (10 minutes to generate the picture, the rest involved equilibration, but no 
hydration). 
Experimental design included 4 columns per plate: antibody, IgG control, heat 
denatured antibody, and either heat denatured IgG control or tau alone (no Ab).  Heat 
denatured antibodies were boiled for 5 minutes; two identical aliquots for each antibody 
were included, one was heated, the other was used as is (no heat denaturation).  The 
antibody treatments did not appear to inhibit protein aggregation, therefore the results 
are not included, here. 
.  
 
Figure 2.1: Three genotypes of mice were tested for their general motor abilities by 
measuring the time they were able to remain on the balance beam (Panel A), then 
measuring the time they were able to remain on a rotating treadmill that gradually sped 
up over time (Panel B).  No siginificant difference was noted between the three groups.  
Error bars represent mean +/- SEM. 
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Figure 2.2:  Mice were placed in a Y maze for 5 minutes, while the arms entered, and 
the sequence of entry, was recorded.  No significant difference was noted in the 
sequence of arm entries (Panel A) however nTg/NOS2-/- mice made more alternations 
than the other two genotypes (Panel B).  
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Figure 2.3:  RAWM was conducted pre-Injection for all three genotypes of mice to 
establish a baseline (pre-treatment) level of behavior.  Panel A shows the number of 
errors per block.  Panel B shows the total number of errors on all blocks.  The NOS2-/-
/APP/PS1 mice made a significant greater number of errors compared to the NOS2-/-
/APP mice.  Open pool testing (Panel C) is a control test to verify that all mice are 
capable of completing the task.  
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Figure 2.4: RAWM testing, post injection, using a new platform location.  A greater 
numbers of errors were initially observed, since many animals returned to the original 
platform location. 
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Figure 2 5:  RAWM testing pre-injection (Panel A) vs post injection (Panel B).  More 
arm-entry errors are identified at the start of the second test, however by the end of 
testing, mice appeared to learn the new location, and Tau 5 treated mice performed 
better than anti-GFP treated mice. 
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Figure 2.6:  Fear conditioning was examined post-injection.  During training, mice were 
placed into a chamber where they received a mild foot shock, paired to a novel tone.  
Freezing is an expected response due to fear of foot shock.  Learning the association 
between the unconditioned tone and conditioned foot shock is indicated by time of 
freezing. 
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Figure 2.7:  Context testing was conducted 24 hours after FC training.  Mice were 
returned to the original chamber, with no shock or tone administration.  Freezing is 
measured as an indication that mice remembered the associative memory.  
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Figure 2.8: Cued response post FC training.  Mice were placed into novel surroundings, 
received the tone and freezing response was measured.  Freezing response reflects 
memory of the association between tone and foot shock.  NOS2-/-/nTg mice showed 
notable freezing in response to the tone, Tau 5 treatment appeared to increase their 
associative memory response.  NOS2-/-/APP mice showed little or no freezing in 
response to the tone.  NOS2-/-/APP/PS1 mice also demonstrated very little freezing and 
again the anti-GFP-treated mice appeared to freeze a little more in association with the 
tone. 
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Figure 2.9: Post injection staining results for CD 45 in region CA1 of the hippocampus of 
NOS2-/- background mice.  Tau 5 is compared to anti-GFP to identify differences in 
microglial activation due to injections.  Slight differences were noted, none with 
statistical significances between the antibodies or genotypes. 
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Figure 2.10: presents staining results for Aβ in the hippocampus post injection.  As 
expected, the APP/PS1 mice produced the most Aβ, followed by the APP mice, and the 
nTg mice produced essentially none.  The surprise finding here was an increase in Aβ 
noted in Tau 5 injected mice.  This is a likely artifact as the experimental n for this study 
was 4 animals per group.	
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Figure 2.11: CD 45 Staining.  Microglial activation in rTg4510 mice did not reveal a 
significant difference as a result of Tau 5 treatment compared to anti-GFP control.  
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Figure 2.12: IHC staining for microglial activation. Iba1 antibody was used to compare 
Tau 5 treatment to anti-GFP control.  No statistically significant difference as a result of 
Tau 5 treatment was noted. 
	 82	
 
Figure 2.13: Nissl staining to identify neuronal cells.   No significant difference as a 
result of Tau 5 treatment compared to anti-GFP treatment was noted in rTg4510 mice.
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Figure 2.14: Rotarod testing of general activity levels in post-treated rTg4510 mice. No 
significant differences in motor performance were observed between any of the 
treatment groups.  H12 is also called TOMA later.	
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Figure 2.15: Y-maze “alternations” provides another test of general activity.  It adds the 
component of being a simplistic test of working memory; no differences were observed 
due to any of the antibody treatments to NOS2-/- mice.  
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Figure 2.16: Novel Object Recognition testing.  MC-1 treatment restored rTg4510 mice 
to nTg performance levels.  Tau 5 treatment showed slight improvement. 	
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Figure 2.17: RAWM results for the last block of testing.  Variability between mice was 
high, but by the last block the MC-1 treated mice performed significantly better than the 
IgG1 controls.  
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Figure 2.18:  Gallyas silver staining for NFTs.  Bar graph results are normalized 
as treated animals vs nTgs.  ACX results are demonstrated, taken using MIRAX 
slide scanner.  Graphical Ratios are shown in bar graph.  H12 was the initial 
name for TOMA treatment.  Magnification = 20X, Scale bar = 200 μm. 
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Figure 2.19:  pSer199/202 staining:  Micrographs show injected (left) side compared to 
injected (right) side.  Graphical representation presents the ratio of treated/untreated 
(injected/uninjected) sides as a ratio, per different treatments.  Scale bar = 200 μm. 
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Figure 2.18: CD 45 staining did not reveal any significant microglial activation 
differences in pathology due to antibody treatment.  Other anti-tau antibodies tested 
(results not shown here) yielded similar results.  IHC for CD45, however, does show a 
positive trend to improvement in inflammation in rTg4510 mice, except for the Tau 5 
treated group.. Scale bar = 200 μm.	
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Figure 2.19: Gallyas Silver Staining did not reveal any significant differences in 
pathology in rTg4510 mice due to antibody treatment.  Other anti-tau antibodies tested 
(results not shown here) yielded similar results.  IHC for CD45, however, does show a 
positive trend to improvement in inflammation, except for the Tau 5 treated group.. 
Scale bar = 200 μm. 
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CHAPTER 3:  SYSTEMIC EVALUATION OF TAU ANTIBODY TREATMENT 
 
Our first published study regarding tau antibody treatment reported the results 
from 28 days of continuous antibody infusion into the right ventricle of rTg4510 mice.  
Following infusion, both behavior and pathology were examined.  Nine – 11 month old 
rTg4510 mice were implanted with mini-osmotic pumps to provide continuous delivery 
of the prospected antibody into rTg4510 mice.  Body weight and food intake were 
measured 3x/week to assess general physiological tolerance to this more aggressive 
treatment regiment.  On average, the mice were approximately 10 months of age at the 
time of pathology testing.  At that time, the groups consisted of 8 nTg mice (controls), 9 
rTg4510 mice infused with an IgG1 control treatment, 9 mice who received TOMA (H12) 
treatment, and 9 mice that were administered Tau 5 treatment.  These studies were 
conducted to provide a more direct comparison between these two antibodies, while 
changing the route of administration to better assess the effectiveness of antibody 
treatment.  Details, and results from this Infusion study can be found at: (Schroeder et 
al., 2016), and are included below: 
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Tau-directed Immunotherapy: A promising strategy for treating Alzheimer’s Disease and 
other Tauopathies 
Sulana K. Schroeder, Aurelie Joly-Amado, Marcia N. Gordon, Dave Morgan  
Republished with permission of Springer Science, from Neuroimmune Pharmacology, 
Schroeder, S, Joly-Amado, A. Gordon, M, Morgan, D, Volume 11:1, 2015; permission 
conveyed through Copyright Clearance Center, Inc. 
 
3.1 Abstract 
Immunotherapy directed against tau is a promising treatment strategy for 
Alzheimer’s Disease (AD) and tauopathies.  We review initial studies on tau-directed 
immunotherapy, and present data from our laboratory testing antibodies using the 
rTg4510 mouse model, which deposits tau in forebrain neurons.  Numerous antibodies 
have been tested for their efficacy in treating both pathology and cognitive function, in 
different mouse models, by different routes of administration, and at different ages or 
durations.  We report, here, that the conformation-specific antibody MC-1 produces 
some degree of improvement to both cognition and pathology in rTg4510.  Pathological 
improvements as measured by Gallyas staining for fully formed tangles and 
phosphorylated tau appeared four days after intracranial injection into the hippocampus. 
We also examined markers for microglial activation, which did not appear impacted from 
treatment. Behavioral effects were noted after continuous infusion of antibodies into the 
lateral ventricle for approximately 2 weeks.  We examined basic motor skills, which 
were not impacted by treatment, but did note cognitive improvements with both novel 
object and radial arm water maze testing. Our results support earlier reports in the initial 
review presented here, and collectively show promise for this strategy of treatment. The 
general absence of extracellular tau deposits may avoid the opsonization and 
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phagocytosis mechanisms activated by antibodies against amyloid, and make anti tau 
approaches a safer method of immunotherapy for Alzheimer’s disease.  
 
3.2 Introduction 
Dementias are a growing burdensome health condition, affecting an increasingly 
greater percentage of the world’s population.  People are living longer, and are surviving 
conditions such as heart disease and cancer, which are becoming relatively treatable 
and are declining as ‘cause(s) of death’.  Alzheimer’s Disease (AD) is the most common 
and most studied dementia associated with tau accumulation, however there are 
several other neurodegenerative disorders which are also classified as tauopathies.  
The term tauopathy suggests that there is some deposition of the protein tau 
metabolism and pathology occurs in association with this deposition. 
AD is the leading cause of dementia, accounting for 50 to 80 percent of dementia 
cases, and the prevalence of the disease is projected to increase significantly as the 
baby-boom generation retires and longevity continues to increase.  AD is characterized 
by severe cognitive decline with age, ultimately requiring continuous caregiving and 
eventually death.  The pathology of AD is characterized by the presence of extracellular 
amyloid plaques, intracellular neurofibrillary tangles (NFT) composed of 
hyperphosphorylated tau protein, neuron loss, and evidence of inflammation indicated 
by the presence of reactive microglia and astrocytes, as previously reviewed (Lee et al., 
2001, Medeiros et al., 2010).  Frontotemporal Lobe Dementia (FTLD) is a rare form of 
dementia that is somewhat related to AD, most notably in the pathology of 
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hyperphosphorylated tau and macroscopic brain shrinkage.  It has a more rapid onset 
than AD, with symptoms that reflect personality changes more than memory loss 
(Lashley et al., 2015).  Like AD, there are no known treatments or cures for FTLD.  
Other tauopathies, where tau becomes pathologic, include frontotemporal dementia with 
associated Parkinsonism linked to chromosome 17 (FTDP-17), Pick’s Disease, 
corticobasal degeneration, and argyrophilic grain disease.  These diseases have 
different origins and symptoms, but all share pathologic forms of tau as a major 
correlative factor underlying the disease (Braak et al., 1993, Utton et al., 2005).  
Tau exists as a normal protein within cells to assist in stability of the 
cytoarchitecture, especially in neurons.  It binds to microtubules to provide structural 
support for axons, and it also facilitates trafficking of important intracellular compounds 
and organelles, as reviewed by (Morris et al., 2011) and others.  It is considered to be a 
key protein for normal neural functioning; however there are numerous paths by which it 
can be rendered unstable, or pathological.  Post-translational modification is one way 
that tau can change from beneficial to detrimental; hyperphosphorylation, nitration, 
acetylation and truncation are examples of post-translational modifications that can 
significantly alter tau function (Wang et al., 2014).  In addition, while considered a 
natively unfolded protein, tau takes on multiple tertiary conformations, which hinder its 
ability to perform the intended function and ultimately render it as a toxic entity that 
leads to neurodegenerative disease (Yu et al., 2012).  Tau can become misfolded, 
leading to aggregation, which can lead to ubiquitination and breakdown by the ubiquitin-
proteasomal-system; larger aggregates require the autophagy system for breakdown 
and removal (Wang and Mandelkow, 2012, Castrillo and Oliver, 2016). 
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Initial efforts for treating tauopathies have focused on blocking 
hyperphosphorylation by using kinase inhibitors, which has been thought to be a 
primary initiating factor for aggregation (Sui et al., 2015).  Additional treatment 
approaches have included: aggregation inhibition using various types of small 
molecules (O'Leary et al., 2010); degradation of aggregates and clearance by 
enhancing metabolic processes such as those initiated by heat shock proteins (HSP), 
the UPS and/or autophagy (Fontaine et al., 2015); direct stabilization of microtubules 
using paclitaxel, EpoD, or other known microtubule stabilizing agents (Brunden et al., 
2010); proteolysis or use of proteases and other methods of aggregate degradation 
(Guerrero-Munoz et al., 2014) (Utton et al., 2005, Oddo et al., 2009, Gotz et al., 2012, 
Himmelstein et al., 2012, Mandelkow and Mandelkow, 2012a, Wolfe, 2012, Guerrero-
Munoz et al., 2014). 
While these potential treatment strategies continue to be explored, an emerging 
approach that has shown promise in mouse models of tau deposition is immunotherapy. 
Vaccination is the most common form of immunotherapy, which typically involves 
administration of antigen, often with adjuvant, to actively increase the body’s production 
of antibodies.  Additionally, immunotherapy can be accomplished by injecting antibodies 
or antisera against the unwanted substance, thereby eliminating the need for the 
recipient’s body to produce its own antibodies (passive immunization) (Lee et al., 2001, 
Wisniewski and Boutajangout, 2010). 
An adjuvant is frequently given with active vaccines to boost the immune 
system’s response to the foreign substance (the immunogen).  Adjuvants help improve 
immunogenicity of the administered compound by activating macrophages and other 
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innate immune system components, such as microglia in the central nervous system 
(CNS).  They increase the antigen-presentation of the immunogen to lymphocytes, 
thereby increasing endogenous production of antibodies by stimulating the immune 
system to produce more of a response than the antigen alone would (Wilcock and 
Colton, 2008, Agadjanyan et al., 2015, Halle et al., 2015).  Most well-tolerated adjuvants 
used in humans consist of aluminum-based compounds such as alum, which stimulates 
a Th2 (anti-inflammatory) cytokine response (Ghochikyan et al., 2006).  “Freund’s 
Adjuvant” (either Complete or Incomplete, CFA or IFA) is also commonly used 
experimentally, and stimulates a Th1 cytokine response (pro-inflammatory) (Billiau and 
Matthys, 2001).  Another common adjuvant, Quil A, is often used in veterinary practices, 
and the equivalent for human clinical studies is called QS-1 (discussed below) 
(Ghochikyan et al., 2006, Ragupathi et al., 2010).  
Tau has become a focus for immunotherapy studies, in part because of some of 
the issues and limitations of Aβ immunotherapy in clinical research trials, as previously 
reviewed (Lemere, 2013), and in part because tau pathology is more directly linked to 
the symptoms, progression, and severity of AD (Braak et al., 1993, Oddo et al., 2009).  
There is a much stronger correlation between cognitive decline and the development of 
tau aggregates than with Aβ deposition (Sigurdsson, 2008).  The best strategy for 
treating AD might prove to be one that targets both Aβ and tau in concert. 
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3.3 Active Immunization 
Aβ immunotherapy began with investigations of active immunization using 
various forms of Aβ formulated as a vaccine, first in mice and then in human clinical 
trials.  Passive immunization, which consists of injecting purified antibodies, followed 
preclinical research on active immunotherapy, as previously reviewed (Morgan, 2011a).  
A similar course has evolved in tau immunotherapy.  Active immunization was 
examined first (Table 1), using various mouse models and immunogens for tau, in 
addition to multiple adjuvants.  The next step was to consider passive immunization with 
various antibodies and multiple mouse models (see following section). Early studies 
showed that both active and passive forms of tau-directed immunization clear some of 
the pathological forms of tau. Even though tau has traditionally been considered an 
intracellular protein, recent studies have shown it to be released extracellularly and 
transmit pathology between cells (Lee et al., 2001, Kfoury et al., 2012). 
First attempts at tau immunotherapy were performed by a group in Israel 
(Rosenmann, 2006) who injected full-length recombinant human tau protein with CFA 
and pertussis toxin (PT) into wild type C57BL/6 mice to see if this might cause an 
autoimmune response such as encephalomyelitis, which was observed in clinical trials 
with Aβ vaccination (Orgogozo et al., 2003).  The CFA+PT adjuvant was chosen for its 
proinflammatory effect to identify immunotherapy safety issues.  Using this approach, 
they detected encephalomyelitis along with NFT formation 1.5 to 5 months post-
injection.  This study demonstrated that by giving tau to non-transgenic animals in the 
context of severe innate immune activation, tau pathology could be initiated.  In an 
attempt to target toxic forms of tau and avoid deleterious side effects, a follow-up study 
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involved injecting a combination of 3 phospho-tau peptides, along with CFA and PT, 
peripherally, into two NFT mouse models (E257T; P301S), hypothesizing a reduction of 
pathology (Boimel et al., 2010).  This peptide combination covered 5 pathogenic 
phospho- tau residues corresponding to the epitopes for antibodies AT 8, AT 100 and 
AT 180.  Encephalopathic symptoms were not seen up to 8 months post-injection, 
however significant reductions were seen in NFTs and phospho-tau by staining for 
Gallyas, AT 8 and AT 180.  Microglial population increased in response to the phospho-
tau peptide plus adjuvant injections. These effects were still seen 8 months after a 
single injection followed by one boost.   
This group further examined the exaggerated effects of proinflammatory 
adjuvants (Rozenstein-Tsalkovich et al., 2013) by administering 3 phospho-tau peptide 
antigens combined with CFA and PT.  This combination produces a pro-inflammatory 
(Th1) response, thereby creating an inflammation-based mechanism of treatment.  
However, given the initial results from Aβ-targeted immunotherapy in human trials, this 
type of Th1 biased immunization increased the risk of (apparently) autoimmune 
encephalitis-like responses.  The CFA adjuvant, with added PT, increases blood-brain 
barrier permeability of antigen, but consistent with the results from anti-Aβ vaccine 
clinical trials this pro-inflammatory condition can lead to encephalopathic conditions.  
They noted monocyte infiltration, however no added microglial activation, in response to 
the adjuvants alone.  Antibody production was observed resulting from the p-tau 
immunizations.  Nontransgenic (NTg) mice and double mutant E57T/P301S tau mice 
revealed significantly more inflammation in the NTg mice compared to the tau mice. 
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Ittner’s lab reported, in 2011, a study using different adjuvants over the course of 
administration (Bi et al., 2011).  This study examined active immunization using an 
antigen covering amino acids 395 – 406 (the PHF1 epitope) in pR5 mice 
overexpressing P301L mutation under the Thy1.2 promoter. Mice, aged 4, 8, and 18 
mos, were given three injections of the 12-amino acid antigen conjugated to keyhole 
limpet hemocyanin (KLH)  with CFA adjuvant, followed by injection of antigen with IFA.  
Four months after they received the initial immunization, the mice showed notable 
antibody titers. Six to nine months following the initial administration, they collected 
tissue for anatomical localization and quantification of tau pathology.   They identified 
reductions in Gallyas staining, immuno-staining for PHF1, and pSer422. In addition the 
oldest group of mice showed a marked significant increase in astrocytosis and there 
was a trend for increasing levels of GFAP in the middle-aged group of mice.        
Following this initial focus on pSer396, Troquier et al (Troquier et al., 2012) 
studied the pSer422 epitope as a potential therapeutic target.  They used THY-1 
promoter Tau22 mice, which demonstrate conformationally-based tau pathology at the 
pSer422 epitope, which is more easily accessible to immunotherapy than other 
phosphorylated tau epitopes, to investigate the effects of providing active 
immunotherapy that is specific to pSer422.  These mice display pathology starting at 3 
months of age.  They first tested two immunogens that specifically targeted the pSer422 
epitope (one included 7 amino acids, the other 11 amino acids) combined with CFA 
adjuvant.  The mice received immunization for 14 weeks.  They then chose the most 
immunogenic epitope to treat 3.5 mo old mice (15 weeks of age) for 18 weeks followed 
by analysis for performance in a 2-trial Y-maze test. Pathology was also assessed using 
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immunohistochemistry analysis (IHC) for AT100 and pSer422, along with Western 
Blotting for various phospho-tau markers.  The behavioral testing showed that 
vaccinated mice performed similar to NTg animals, based on time spent in the novel 
arm compared to unvaccinated transgenic controls.  The Sarkosyl insoluble tau fraction 
demonstrated significantly reduced pathology for AT100 and pSer422 by Western 
analysis.  IHC revealed a trend toward reduction of these pathological markers in CA1.  
They also noticed an apparent efflux of tau from brain parenchyma to the blood sera, 
suggesting an increase of clearance from brain to systemic mechanisms of clearance, 
referred to as a peripheral sink (Citron, 2010, Morgan, 2011a).  
 A very nicely designed series of studies on tau immunotherapy was conducted in 
the laboratory of Einar Sigurdsson at NYU.  Initial work by Sigurdsson’s group (Asuni et 
al., 2007) examined the effects of active immunization with 4E6G7, a computer-
designed immunogen peptide of tau covering amino acids 379-408, which includes the 
PHF-1 phosphorylation sites of Ser396 and Ser404 (a late-stage phosphoepitope in 
NFTs).  This immunogen, or the Alum adjuvant as a control, was injected 
subcutaneously between 2 and 5 months into JNPL3 P301L mice (Lewis et al, 2000), 
which express 4R/0N tau including a FTDP-17-associated tau mutation P301L (Denk 
and Wade-Martins, 2009) using the mouse prion promoter.  These mice develop 
pathology primarily in the motor cortex, brainstem, and spinal cord, typically resulting in 
hind limb paralysis after 9 months of age.  Alum was chosen as an adjuvant because it 
is well tolerated and leads to a Th2-type immune response.  The vaccinated mice were 
found to have reductions in insoluble tau and increases in soluble tau, and they 
exhibited improved performance on rotarod and balance beam tests.  Additionally, a 
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gender difference was noted, with females having more tau pathology before treatment, 
followed by similar levels to males post-treatment, suggesting that more pathological tau 
was prevented in the females (Bayer et al., 2005, Sigurdsson, 2008).  To address the 
question of the antibody distribution within the brain and whether or not they could enter 
neurons, Sigurdsson’s group collected and purified antibodies generated against the tau 
immunogen, then FITC-labeled them, and injected the antibodies into the carotid 
arteries of the JNPL3 P301L mice.  Later, histochemistry identified labeled antibodies in 
the brain, within neurons, and co-localized with markers for pathologic tau. Interestingly, 
the same labeled antibodies also were injected into NTg animals and no uptake into the 
brain was observed, suggesting that the blood-brain barrier is likely compromised in the 
transgenic animals, and probably also in humans with tauopathies, which would 
facilitate antibody passage into the brain (Sigurdsson, 2009).The mouse model used by 
Sigurdsson et al in their initial studies does not necessarily represent AD pathology; it is 
primarily a model of motor pathology that progresses so quickly that cognitive maze 
testing is not practical.  However, this was a pioneering study that indicated 
immunization against tau could be a successful therapeutic approach in tauopathies 
and perhaps AD.   
 They followed this with work using a different mouse model that mimics AD more 
closely, exhibiting development of forebrain tangles and cognitive deficits.  This model 
was created by crossing htau mice with M146L-mutation PS1 mice maintained on a 
mouse-tau knock-out background.  These mice displayed early (before 2 months of 
age), rapidly progressing tau pathology in cortical and hippocampal areas.  The same 
immunogen 4E6G7 was administered intraperitoneally (i.p.) with alum adjuvant, with 
	 102	
controls receiving adjuvant alone.  Antibody titers were measured by ELISA, and were 
notable, throughout the experiment.  Behavioral testing included the same motor tests 
as described above, and also the radial arm maze, the closed field symmetrical maze, 
and novel object recognition testing.  Immunization resulted in significant performance 
improvement in all three cognitive tests compared to controls.  IHC for PHF1 revealed 
significant decreases in the immunized mice vs. controls.  Soluble PHF1 tau was also 
reduced as measured by Western blotting.  Most notable is that the behavioral 
improvements correlated well with the levels of PHF1 pathology. (Boutajangout et al., 
2010).  
 Most recently reported work by our research group examined active 
immunization using different agents, to map relevant epitopes to target with vaccination 
(Selenica et al., 2014).  Specifically, human full-length wild-type tau or P301L tau was 
administered subcutaneously with Quil A adjuvant into rTg4510 mice for 6 weeks (three 
bi-weekly injections), rested for 10 weeks then administered 3 additional injections.  
High titer antibody production in sera was verified and the best antigenic sites on tau 
were estimated by epitope mapping.  The immune response resulted in greatest anti-tau 
antibody production of isotype IgG1, followed by IgG2b, IgG2a, then IgM.  Analysis of 
IFN-γ demonstrated a strong T-cell response in splenocytes from vaccinated mice.   
Two N-terminal epitopes, two in the proline-rich domain, and one C-terminal epitope 
were identified.  A 7-amino acid epitope at amino acids 21 – 27 proved to have the most 
robust binding to antisera, and this epitope corresponds to a caspase-cleavage site.  
The two epitopes in the proline-rich domain contain phosphorylation sites, perhaps 
leading to tau dissociation from microtubules and tangle initiation.  Microglial activation, 
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as assessed by CD45 and CD11b IHC revealed decreased inflammation in brains of the 
vaccinated mice.  H150 total-tau staining was reduced in response to the wild-type tau 
administration, GFAP was reduced in the P301L administration, and AT8 and CD45 
staining were reduced in response to both vaccines.  A summary of these active 
immunization studies against tau pathology is reported in Table 1.   
 
3.4 Passive Immunization 
Sigurdsson et al (2011) also pioneered passive tau-directed immunotherapy 
efforts (Table 2), by injecting the monoclonal antibody, PHF1, i.p., into JNPL3 mice.  
Two to 3-month old mice were given PHF1 weekly, or pooled mouse IgG as a control.  
At 5 to 6 months of age, behavioral testing (traverse or balance beam, rotarod, and 
open field) was conducted.  The dentate gyrus, motor cortex, and brainstem were 
evaluated for pathology using IHC for PHF1 to compare pathological forms of tau to 
total tau levels.  They found a significant reduction of PHF1 staining in the dentate gyrus 
along with a strong trend for reduction in the motor cortex, but no difference in the brain 
stem. Western blotting for PHF1 and CP13/B19 revealed significant decreases of 
insoluble pathological tau, but no differences in soluble or Sarkosyl soluble tau.  
Behavioral analysis resulted in fewer footslips on the traverse beam in the treated 
group, while the other motor testing did not appear to be affected.  Because this mouse 
model primarily exhibits motor deficits, cognitive performance was not evaluated.  The 
results do, however, show great promise for passive immunotherapy directed against 
tau, although the authors noted that this passive-immunotherapy approach seemed to 
be less efficacious than the prior active-immunization approach directed at essentially 
	 104	
the same region of phosphorylated tau.  This conclusion was based on the absence of 
an effect in the brainstem, despite effectiveness in the dentate gyrus.  They also noted, 
however, that passive immunization is likely to be safer, by avoiding a potentially 
adverse T cell response, such as that found in the AN1792 vaccine study against the 
amyloid peptide (Boutajangout et al., 2011a). 
In parallel work, Martin Citron, then at Eli Lilly was investigating passive 
immunotherapy directed at tau using two different tau-overexpressing mouse lines, the 
JNPL3 mouse and P301S mutant PS19 line.  The JNPL3 mice received 15 mg/kg of 
antibody three times per week, while the P301S mice (which demonstrate more rapid 
progression; pathology becoming evident at younger ages) received 15 mg/kg twice 
weekly. They tested two different types of anti-tau antibodies: first giving systemic i.p. 
PHF1 administration or MC-1, an antibody specific to conformational alterations of tau 
(Chai et al., 2011b).  The mice were given antibody or an IgG1 control hybridoma from 
non-immunized mice, starting at 2 months of age, continuing until 6 months.  Western 
blotting revealed reductions in phosphorylated tau (AT8) in the insoluble fraction, but no 
change in total tau levels. This was confirmed in an ELISA assay using the AT8 
antibody, which revealed a significant and substantial reduction of phosphorylated tau in 
response to both administered antibodies.  They then administered the same antibodies 
to P301S mice from age 2 to 5 months, tested motor performance and showed a 
significant improvement on the rotarod for both antibody groups compared to controls.  
The rate and progression of improvement in motor deficits was greater for the P301S 
mice, which exhibit a more rapid onset of pathology, than the JNPL3 mice.  Similarly, 
there appeared to be a delayed onset of pathology in the P301S mice.  ELISA analysis 
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revealed 45 percent reduction in pathology with PHF1 administration, and a 33 percent 
reduction in pathology after MC-1 administration.  IHC also revealed reduced tau 
pathology after administration of either antibody compared to control, and no significant 
difference in microglia or astrocyte activation. 
Work in Peter Davies’ lab has followed on these investigations using JNPL3 
mice.  PHF1, MC-1, or the pan-tau antibody DA31, were administerd to either 4 or 7 
month old mice for 4 months.  They showed that MC-1 treatment reduced CP-13 
staining in CA1 of the hippocampus as well as reducing RZ3 staining, in response to the 
antibodies directed against pathological tau isoforms.  Their study looked for IgG in 
neurons, but failed to identify any, leading to questions of mechanism of action 
(d'Abramo, 2013) 
Yanamandra et al examined the effects and actions of various extracellular tau-
targeting antibodies on P301S mice (Lee et al., 2001, Yanamandra et al., 2013).  
Ongoing collaborations between Marc Diamond and David Holtzman have resulted in 
the creation of a spectrum of antibodies with varying activities for binding extracellular 
tau, with a general emphasis on preventing extracellular aggregation and “seeding” 
(propagation) of tau pathology.  They have created a line of tau antibodies called the 
HJ8 series, which is raised against full-length human tau, as well as a HJ9 series that 
are directed against mouse tau (Espinoza et al., 2008).  These antibodies were 
developed in response to observations of extracellular tau appearance was followed by 
seeding of pathology into nearby cells. They hypothesized that tau can aggregate 
extracellularly, then become absorbed by adjacent cells, thereby transmitting the 
pathology.  They employed intracerebroventricular (ICV) administration using 3 of their 
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antibodies: HJ3.4 directed against Aβ, HJ8.5 an anti-human tau antibody, and HJ9.3 & 
HJ9.4, which are anti-mouse tau.  ICV provided continuous delivery of the antibodies, 
for 3 months, into 6-month old P301S mice.  Clearance of antibody from the CNS to the 
periphery was identified by temporary infusion of biotinylated HJ8.5 followed by analysis 
of CSF and plasma, during the course of the ICV treatment.   Behavioral analysis 
revealed no differences in motor function, but there was a significant improvement in 
contextual fear conditioning.  The HJ8.5 treated mice exhibited far greater freezing 
levels than control tau mice, and to a lesser degree the HJ9.4 treated mice also 
exhibited significantly more freezing. 
Pathological evaluation revealed that administration of HJ8.5, HJ9.3 and HJ9.4 
reduced immunostaining for AT8 (pSer202/pThr205), in the piriform cortex, amygdala, 
and entorhinal cortex, with HJ8.5 demonstrating the most robust improvement in 
pathology.  HJ9.4 did not show significant reductions in the piriform cortex, however.  
These results were consistent between male and female mice, however the males had 
greater overall pathology.  These results correlated with reductions in staining for PHF 1 
(pSer396/404) as well as reductions in the microglial marker CD68.   Additionally, a 
semi-quantitative ranking of ThioS staining revealed a reduction of tau deposition in the 
HJ8.5-treated mice compared to controls.    
Biochemical analysis of tau levels was determined using ELISA on 3 fractions 
from the anterior cortex: an aqueous fraction produced using RAB buffer, a detergent 
soluble fraction using RIPA buffer, and an insoluble fraction obtained by formic acid 
(FA) digestion of the resulting pellet.  The aqueous and RIPA-soluble fractions did not 
reveal significant changes in total tau levels as detected using their total-tau antibody 
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HJ8.7, however the detergent insoluble FA fractions demonstrated a significant 
decrease (> 50%) of total tau in the HJ8.5 and HJ9.3 treated animals.  Western blot 
analysis, using mouse polyclonal antibodies, revealed similar results to the staining for 
AT8 and CD68 in response to these two treatments.  The HJ9.4-treated animals did not 
demonstrate such reductions.  These results were specific to human, not mouse, tau as 
assessed by ELISA using species-specific tau markers.  AT8 levels followed a similar 
trend in the FA fractions based on treatment.  They further treated HEK293 cells with 
the RAB lysates from the treated mice; FRET analysis identified significantly lower 
seeding levels in response to the H8.5 and HJ9.3 (but not HJ9.4) treatments that 
correlated with the FA-fraction ELISA tau levels.  This study emphasized monomeric, 
extracellular tau in interstitial fluid (ISF), which was previously thought to be a very 
unlikely location for tau protein until recently.  Tau may aggregate extracellularly as well 
as intracellularly, thereby passing pathology on to nearby cells (Yamada et al., 2011).   
Alternatively, Rakez Kayed’s laboratory has been examining antibodies that are 
specific to oligomeric tau.  Oligomers of tau, as well as other proteins, have been 
identified as possibly being the most pathogenic form of these prion-like proteins 
(Mandelkow et al., 1996, Hoover et al., 2010, Medeiros et al., 2010, Lasagna-Reeves et 
al., 2011c).  Kayed’s laboratory developed and characterized, novel antibodies, T22 and 
TOMA, that specifically target tau oligomers, and not monomers or stable NFTs 
(Lasagna-Reeves et al., 2012a, Lasagna-Reeves et al., 2012b).  T22 is a rabbit 
antiserum that targets oligomers for analysis, whereas TOMA is a mouse monoclonal 
antibody that has been tested as an immunotherapy agent.  Initially, they administered 
recombinant tau aggregates to 2-month old BALB/c mice along with CFA. The 
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monoclonal antibodies derived from hybridomas from these mice were screened for 
specificity of tau oligomer targeting.  In vitro testing, by ELISA, Western and dot blot 
demonstrated that T22 selectively marked oligomeric tau, but not monomeric tau, when 
compared to Tau 5 which recognizes all forms of tau; T22 did not bind to monomeric 
tau, while Tau 5 recognized all tau forms, thus demonstrating that T22 is a specific 
marker for tau oligomers.  This original oligomer-specific polyclonal antiserum for tau 
enabled more specific identification of tau oligomers, so that characterization of tau 
pathology could be assessed in a new manner, then treatment approaches could be 
evaluated with a focus on oligomer-based pathology and improvements due to 
treatments. 
Kayed’s lab further created and validated a mouse monoclonal oligomer-specific 
antibody, TOMA (tau oligomer monoclonal antibody), which they administered to tau 
transgenic mice to examine its potential as a new immunotherapeutic approach for 
treating tauopathies (Castillo-Carranza et al., 2014a)  TOMA was administered by ICV 
or IV injection to 8 month-old male JNPL3 mice to examine the effects of oligomer-
targeted treatment of tau pathology in vivo. Their ICV protocol was to inject 1 μg TOMA 
into each lateral ventricle one time.  IV injection involved dilating the blood vessels in 
the tail, then injecting 30 μg of antibody.  An additional group of 8 month-old mice 
received a tail-vein injection of 30 μg of biotinylated TOMA.  Blood was collected before, 
and at several intervals after, injection to measure antibody concentration; brain tissue 
was collected to identify delivery of the antibody across the blood-brain barrier and into 
brain parenchyma.  In vivo imaging of these animals revealed that the biotinylated 
TOMA did cross into both the brain and spinal cord.  TOMA administration restored 
	 109	
behavioral performance to that of wild-type mice in the tests conducted.  The single ICV 
injection normalized rotarod performance to NTg levels. Additionally, the single IV 
administration yielded improvements in Y maze performance, which persisted through 
re-testing 2 months later.  Pathology was evaluated using Western Blot, and probing for 
oligomeric-only tau using the polyclonal T22, in comparison to total monomeric tau, 
using Tau 5.  ICV injection of TOMA led to a strong reduction in T22, but not Tau 5 
staining by immunoblot; results were confirmed by immunofluorescent IHC staining, and 
were further correlated to reductions in pThr231 detection of tau aggregates, which has 
been shown to be associated with oligomers in human tissue (Lasagna-Reeves et al., 
2011a).  HT7 results showed increased levels while various other phospho-tau markers 
were decreased, suggesting a possible transfer of oligomeric tau to monomers and 
early aggregates.  The single IV dose of TOMA, while showing improvements in Y-maze 
and rotarod performance, also revealed reductions in tau oligomers (assessed by 
Western blot, probed with rabbit-anti tau antibody), as well as reductions in ELISA levels 
of tau oligomers.  Further anatomical evaluation using immunofluorescence showed 
reduced levels of oligomers in cell bodies and axons of CA1 neurons compared to 
controls, and there were no reductions in AT8 or Gallyas staining, suggesting that 
changes in monomeric and NFT forms of tau were not involved in the improvements 
demonstrated here.  ELISA and Western blot analysis using numerous other phospho-
forms of tau did not show differences in either of the treatment protocols.  They 
concluded that oligomeric tau clearance leads to behavioral improvement, whereas 
earlier monomers, phospho-forms, and even fully formed NFTS did not need to be 
cleared for these functional improvements. 
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The next step in AD-related immunotherapy involved passive immunotherapy to 
3xTG animals to identify benefits to both tau and Aβ pathologies.  Frank LaFerla’s 
laboratory (Walls et al., 2014) has created a transgenic mouse line with the swAPP/PS1 
and tau P301L mutations (3xTg mouse line), with the intent to examine correlated 
effects and treatments for both Aβ and tau pathology (Walls et al., 2014).  Mice aged 15 
– 18 months old were administered the AT8 anti-tau antibody, which recognizes the 
pSer202 and pThr205 epitopes (Walls et al., 2014).   The mice were given AT8, 4G8 
(an anti-Aβ antibody) or IgG control, intracranially, into the CA1 region of the 
hippocampus.  A single injection was followed by tissue collection at weekly intervals (1 
to 4 weeks post-injection), then IHC to identify changes in pathology.  The AT8-injected 
animals showed a dramatic reduction in tau pathology one-week post-injection (HT7 
measurements).  This reduction continued through week 2, but starting at week 3 the 
levels of tau pathology started returning to levels seen in IgG-treated controls.  AT8 
staining was also reduced 1-week post-injection, as was Gallyas staining for fully-
formed NFTs. No changes in Aβ pathology were noted by staining for (6E10 
measurements) in response to AT8 injection. However injection of 4G8 resulted in Aβ 
reductions for 1-2 weeks followed by recovery back to baseline levels, analogous to the 
transient reductions in tau found with AT8.  A summary of these studies is reported in 
Table 2. 
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3.5 Mechanisms Of Action 
The results summarized above have demonstrated that varied methods of 
applying anti-tau antibodies are capable of clearing tau pathology, in parallel with 
improving behavior. The question that obviously arises is: what is the mechanism by 
which this clearance is occurring? 
The earlier work conducted by Sigurdsson’s group has suggested that the tau-
antibodies are taken up by neuronal cells.  Then autophagy and induction of lysosomal 
activity degrades and clears the protein. This is the preferred pathway for degradation of 
misfolded proteins, oligomers and aggregates.  These ‘bad’ proteins become 
sequestered into autophagosomes and then are enzymatically degraded (Ding and Yin, 
2008).  The autophagy pathway can be overwhelmed in pathologic conditions, leading 
to accumulation of aggregates in the cytosol, which leads to formation of fibrils, paired 
helical filaments, and other β-pleated sheet formations such as those seen in AD 
(Sigurdsson, 2009, Morris et al., 2011).  
Yanamandra’s group suggested an extracellular method of tau clearance.  Their 
antibodies were able to impede uptake of extracellular tau aggregates and inhibit prion-
like propagation of tau between cells.  They demonstrated that, by binding extracellular 
tau aggregates, intracellular tau pathology could be delayed or prevented from passing 
on to a neighboring cell (Yanamandra et al., 2013).   
Kayed’s group (Castillo-Carranza et al., 2014b) demonstrated that TOMA did not 
need to be internalized to reduce tau burden.  Their results argued for a distinct 
clearance of tau pathology extracellularly.  This extracellular clearance could also result 
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in a peripheral sink type of mechanism by drawing tau oligomers from the brain and into 
the circulation, not unlike what has been observed for some anti-Aβ antibodies (Morgan, 
2011a). 
Another potential mechanism of clearance that has largely been considered for 
both Aβ and tau immunotherapy involves microglial phagocytosis and removal, quite 
possibly in conjunction with inflammatory mechanisms.  Sigurdsson’s group addressed 
the role of inflammation and the immune system in tau pathology’s clearance by 
microglial phagocytosis. They concluded indications did not favor this route of 
elimination (Sigurdsson, 2008).  
Kayed’s group (Castillo-Carranza et al., 2014b) analyzed brain sections from 
treated and control groups using ELISA and immunofluorescence, for IL-6, IL-1β and 
Iba1, and found no differences between any of the antibody treatment groups, thereby 
suggesting that microglial activation and inflammation were not major factors in their 
model.  Their analysis of serum and CSF suggest that oligomeric tau clearance occurs 
extracellularly and leads to elevated breakdown products in systems designed for full-
body elimination, vs simply eliminating these polymers from neuronal cells. 
 Roche Pharmaceuticals has also examined tau immunotherapy using a triple 
transgenic model, and has followed on the earlier lines of targeting pSer422 with 
passive immunotherapy (Collin et al., 2014).  Their 3x mouse-line is TauPS2APP; 
swAPP mice crossed with PS2, then P301L tau mutant mice. These mice received 
either an acute treatment, or a chronic treatment of their cultured MAb86 antibody 
(phosphor tau 416 – 430, produced in rabbit) that was either mouse IgG1 (for chronic 
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administration) or human IgG1 (for shorter administrations).  Acute treatment consisted 
of two i.p. doses of the “human” MAb86, 3 days apart, in 16 month-old mice, with tissue 
collection 2 days  after the last injection.  Chronic administration began with 10-month 
old mice, which received weekly i.p. doses of antibody for 16 weeks, followed by tissue 
collection a week later.  The pSer422 monoclonal antibody, MAb86, specifically binds to 
tau phosphorylated at Ser422, but not unphosphorylated tau at that location.  MAb86 
specific binding was located to the CA1 region of the hippocampus of TauPS2APP 
mice, as shown by immunofluorescence, and it was further shown to be intracellular 
(somatic or dendritic) binding, suggesting that the antibody is taken into neuronal cells.  
Double staining with MAb86 and flotillin 1 (marker for lipid rafts) indicated localization in 
lipid rafts within the plasma membrane.  Further localization with lysosomes 
corroborated the prior studies that suggested anti-tau antibodies are internalized, 
leading pathologic forms of tau to lysosomes for degradation and removal.  They further 
demonstrated that chronic administration of MAb86 delayed tau pathology, while 
favoring lysosomal clearance using ELISA and immunofluorescence. 
In summary, there are multiple mechanisms anti-tau antibodies might engage 
when used for the clearance of pathological forms of tau. These include stimulation of 
intracellular degradation, possibly following internalization of complexes, neutralization 
of intracellular aggregates, or neutralization of extracellular aggregates, preventing 
internalization and/or spreading of pathologic tau. Moreover, the peripheral sink 
mechanism, which reveals increased blood levels of tau aggregates, has been reported 
and might aid in tau clearance from the brain. At this stage, there is not much evidence 
favoring an opsonization and enhanced phagocytosis as a mechanism for tau 
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clearance, as supported by work with anti-Aβ antibodies, but this cannot yet be ruled 
out. Just as it is likely that different anti-Aβ antibodies employ different or multiple 
methods of clearing amyloid (Morgan, 2011a), it is equally plausible that different anti-
tau antibodies employ different or multiple mechanisms to stem the propagation of, or 
clearance of tau.  Hence, there is not a right or a wrong mechanism of immunotherapy 
in opposing tau action in tau depositing mice. The apparent mechanistic differences 
observed by different research teams need not be viewed as conflicts. In fact they might 
be collectively integrated in attempts to identify the most efficacious monoclonal 
antibodies (possessing more than one mechanism of action).    
 
3.6 Recent Work In Our Laboratory  
Previous work in our laboratory has shown that peripheral administration of anti-
Aβ antibody was successful in reducing diffuse amyloid and compact plaques in the 
brain, and this was accompanied by improved performance in the radial arm water 
maze (Wilcock et al., 2004b).  Multiple microglial markers were modified by 
immunotherapy suggesting that one likely mechanism of clearance involved 
opsonization and Fcγ receptor-mediated phagocytosis.  Our work in tau immunotherapy 
has been less conclusive, to date.  So far, our results have suggested some positive 
impacts from tau passive immunotherapy, however the most effective tau antibody 
remains elusive. 
We’ve treated several ages of rTg4510 mice, which demonstrate rapid tau 
deposition resembling that of advanced AD or FTLD patients (Santacruz et al., 2005a).  
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This mouse line expresses the 4R0N tau isoform with a P301L mutation under control of 
a tetracycline (tet) promoter.  Crossing tau mice with a CamK++ Tet-transactivator-
protein mouse drives high-level forebrain tau expression. These mice develop robust, 
progressive, age-dependent, pre-tangle and NFT pathology starting at 3 months of age.  
In addition to robust tau pathology, this model develops readily observable brain 
shrinkage, visible as early as 6 months of age.  Concurrent with the tau pathology is 
neuronal loss and atrophy.  Behaviorally these mice exhibit extreme hyperactivity and 
impairment in a large number of cognitive function tests (Brownlow et al., 2014) 
Initial studies examined rTg4510 mice, at an age when robust tau pathology is 
well established (between 11 and 13 months of age), by intracranial injection of several 
tau antibodies into the frontal cortex and hippocampus.   Injections were performed 
unilaterally using convection-enhanced delivery (CED), as described in (Carty et al., 
2010), at a rate of 2.5 μl/min, resulting in a total of 2 μg IgG per injection site.  The 
contralateral hemisphere was untreated and used to normalize for differences in starting 
amounts of deposition. Four days post-injection, tissue was collected for IHC and 
histological staining to compare tau-pathology markers between the groups.  NFTs were 
identified using Gallyas silver staining (Brownlow et al 2014).  We also examined total 
tau using the rabbit polyclonal antibody H150 (Santa Cruz), rabbit-anti pSer199/202 
(AnaSpec), and rabbit-anti pSer396 (AnaSpec).   CD45 and Iba-1, markers for 
microglial activation, were also examined, as well as total neuron population via Nissl 
staining.  Sections were imaged with a digital scanning microscope (Mirax) and 
fractional area stained measured by image analysis of entire regions from 4-6 sections 
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per region. Results are expressed as a fraction of the uninjected contralateral 
hemisphere.   
Significant reductions in Gallyas staining were observed (Figure 1) as well as 
Ser199/202 (Figure 2) and H150 (Figure 3) staining in the hippocampus of mice treated 
with the antibody MC-1 when compared to mice treated with the antibody directed 
against the non-mammalian protein green fluorescent protein (GFP), which was not 
expected to remove tau deposits.  We also examined staining for pSer396 and relative 
microglial activation, because microglial activation is one of the common pathological 
features of AD (Table 3).  No notable increase in microglial activation, as examined by 
CD45, was identified which is an encouraging finding because over-activation of the 
innate immune system has proven to be a challenge in clinical studies of Aβ 
immunotherapy. Nonetheless, all tau-depositing mice have much more CD45 than their 
non-transgenic littermates.  Similarly, we did not observe notable difference in neuronal 
population between the different treatments when using Nissl staining. 
We conducted a subsequent study using 10 – 12 month-old mice, infused with 
either MC-1, Tau 5 or TOMA, or IgG1 (as a control) antibodies . The mice where 
implanted with mini-osmotic pumps (Alzet) filled with 20 μg of either MC-1, Tau 5, or 
TOMA, or IgG control, (all of which were 1 mg/ml) into the right lateral ventricle for 
continuous delivery of 0.5 µg a day over 28 days, using mini-osmotic pumps (Alzet) as 
described  previously (Selenica et al., 2013, Brownlow et al., 2014).  This route of 
administration allowed for behavioral testing as well as pathology evaluation.  Activity 
testing for open field, revealed a genotype effect but no treatment effect; no differences 
were noted between the treated mice and controls when comparing tau-depositing 
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transgenic mice to non-transgenic littermates (Table 4).  Cognitive assessment (as in 
Brownlow et al, 2014) did reveal performance improvements in both novel object 
recognition testing (Figure 4) and radial arm water maze (RAWM – Figure 5) in 
response to MC-1 treatment when compared to IgG1 treated mice. 
Overall these data suggest that MC-1, a conformation specific antibody 
developed by Peter Davies, has greater efficacy than several other antibodies when 
administered ICV. These data encourage consideration of a humanized form of this 
antibody or related human antibodies for testing in early stage cases of AD.  
 
3.7 Future Directions 
Tau provides many different strategies for treatment given its different isoforms, 
post-translational modifications, conformations, and more.  Presently, it appears that 
targeting oligomers of tau is likely to be the focus for many of these studies.  Multiple 
groups have been investigating oligomeric forms of amyloid and tau and consider these 
to be the most toxic forms of the proteins.  As the groundwork continues to be laid in tau 
immunotherapy studies, it is likely that the next generation of immunotherapies will be 
directed at oligomers, as Kayed’s lab has been doing.  Additionally, many have 
suggested a future immunotherapeutic approach targeting Aβ and tau in concert, as 
noted by recent work in LaFerla’s laboratory (Medeiros et al., 2011). Interestingly, the 
general success obtained with anti-tau approaches might favor tau immunotherapy over 
anti-amyloid immunotherapy. The low levels of extracellular tau coupled with the 
absence of general microglial activation may avoid the edema and hemorrhage 
	 118	
observed with anti-amyloid immunotherapy in mice and humans (Wilcock et al., 2007b, 
Sperling et al., 2012). 
On the clinical front, a tau active vaccine entered into a Phase 1 human clinical 
trial; an agent named AADvac1.  Axon Neuroscience SE began a clinical study in mid 
2013, recruiting subjects for a Phase I clinical study on the safety and tolerance, of this 
active immunotherapy agent: a synthetic tau peptide conjugated to KLH, also using 
aluminum hydroxide as an adjuvant to further stimulate the immune response.  The 
reported protocol consists of treating patients with mild to moderate AD three times, 
over a course of three months, then assessing response by measuring neuropsychiatric 
measures, cognitive testing, MRI, and blood biomarkers.  Additional measures of 
immune response to the treatment will be obtained to verify the responses as immune-
mediated. 
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Table 3.1: Active Immunization Using Tau Antigens 
Authors 
Antigen, 
Dose & 
Adjuvant 
Mouse 
Model, 
incl. 
mutation, 
if present 
Age 
at 
first 
inj Duration 
Techniques 
and markers 
examined Details/Results 
Asuni et 
al, J 
Neurosci 
2007 
100 μl 
Tau379-
408 @ 1 
mg/ml with 
Adju-Phos 
adjuvant, 
sc bi-
weekly for 
first 
month, 
then 
monthly 
JNPL3 
(P301L) 
2 mo 3 - 5 mo IHC and 
Western Blot 
for MC-1 & 
PHF1, 
Rotarod, 
NOR 
↓ MC-1 and 
PHF 1 by IHC; ↑ 
PHF 1 in soluble 
fraction by 
Western, ↑ time 
on rotarod; No 
cognitive 
change in NOR; 
noted antibody 
uptake into 
neurons  
Boutajan
gout, et 
al, J 
Neurosci 
2010 
100 μg 
Tau379-
408 + 100 
μl Alum, 
i.p.; 3 
injections 
bi-weekly, 
then 
monthly 
hTau/PS
1 
3-4 
mo 
5 - 6 mo IHC for PHF1 
& AT8, PHF1 
by Western, 
Rotarod, 
Traverse 
Beam RAM, 
NOR, CFSM 
↓ PHF1 and 
AT8, ↓ soluble 
PHF1, no 
change in 
rotarod 
performance, 
improved 
performance in 
RAM and NOR 
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Table 3.1: Active Immunization Using Tau Antigens (continued)	
Boimel et 
al, Exp 
Neurol 
2010 
sc 
injection of 
100 μg 
each of 3 
KLH-
linked 
phos-tau-
peptides 
(aa’s ~ 
195 - 238) 
with i.p. 
CFA + PT.  
Adjuvant 
booster @ 
48 hrs, 
then sc 
antigen 
booster 1 
wk later 
E257T/P
301S 
4 to 
12 
mo 
2 wks Clinical 
evaluation of 
paralysis; 
Gallyas 
staining 
(NFT); IHC 
for AT8, 
AT180, and 
glial markers 
GFAP, 
MAC3, 
CD45R and 
CD4; 
Bielschowsky
-Hematoxylin 
and 
lectin 
staining; 
double 
immunofluore
scence for 
CD11b, 
F4/80 and 
MAC3; & 
lysosomal 
staining for 
Cathepsin D 
No ↑ in 
paralysis; no 
difference in 
monocyte 
infiltration 
(Bielschowsky 
Hemotoxylin 
staining), 
CD45R & CD4 
staining showed 
limited B or T 
cell infiltration, 
no 
macrophages 
detected by 
MAC3 & no 
axonal damage 
noted by these 
stains, so 
encephalogic 
risk is minimal; 
injected tau 
present in sera 
& blood, not 
parenchyma; ↓ 
NFTs, ↓ AT8, ↓ 
AT180, ↑ 
microglia by 
lectin staining, ↓ 
Cathepsin D 
Bi et al, 
PLOS1 
2011 
100 μg 
KLH-
linked 
peptide 
(aa's 395-
406) with 
CFA (first) 
then with 
IFA 2 & 4 
wks after 
pR5 
(P301L) 
4, 8, 
or 18 
mo 
1 mo Gallyas 
staining for 
tangles, IHC 
for PHF1 & 
pSer422, 
GFAP 
staining 
↓ NFTs, PHF1 
and pSer422; 
↑GFAP in old 
mice, trend ↑ in 
mid-aged mice, 
no difference in 
GFAP in young 
after vaccine 
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Table 3.1 Active Immunization Using Tau Antigens (continued)	
Troquier 
et al, 
Curr Alz 
Res 
2012 
100 μg 
Y14T or 
Y10A 
(pSer422 
epitope) 
i.p. + CFA; 
2nd 
injection 2 
wks later 
with IFA, 
then 
monthly  
THY-
Tau22 
(4R @ 
g272v & 
p301S 
with Thy 
1.2 
promoter
) 
2 or 
3.5 
mos 
14 wks 
or 18 
wks 
IHC, Modified 
Y-maze, 
ELISA, 
Western 
No changes in 
AT8, ↓ in AT100 
& pSer422, 
vaccines ↑ 
performance to 
wt levels, ↑ tau 
in sera in 
correlation with 
duration of 
treatment & 
memory 
performance, ↓ 
AT100  & 
pSer422 in 
SDS-insoluble 
fraction  
Rozenst
ein-
Tsalkovic
h et al, 
Exp 
Neurol 
2013 
Sc 
injection of 
3 phos-
tau-
peptides 
@ 100 μg, 
in IFA and 
PT, given 
twice bi-
weekly, 
then 50 μl 
peptide 
monthly 
E257T/P
301S 
6 or 
12 
mos  
8 - 14 
wks 
Experimental 
autoimmune 
encephalomy
elitis test, 
IHC, 
behavioral 
observation 
↑ monocyte 
infiltration with 
memory 
improvement, 
no microglial 
change, treated 
mice developed 
paralysis 
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Table 3.1: Active Immunization Using Tau Antigens (continued)	
Selenica 
et al, J 
Neuroinfl
am 2014 
Sc 
administra
tion of 100 
μg tau 
(human wt 
or P301L 
tau) with 
20 μg 
Quil-A 
adjuvant.  
3 bi-
weekly 
injections 
followed 
with a 10 - 
week 
resting 
period 
then 
boosters 
every 3 
weeks for 
3 
additional 
times 
rTg4510 5 
mos 
19 wks, 
including 
a 10-day 
resting 
period 
[3-thymidine] 
assay to 
identify T-cell 
proliferation; 
epitope 
mapping via 
microarray; 
IHC for tau 
species, and 
glial markers 
CD45, 
CD11b and 
GFAP 
↑ antibody 
production, ↑ 
cellular 
response: ↓ 
CD45, CD11b 
and GFAP; ↓ 
H150 & AT8;  
5 new 
immunogenic 
epitopes 
identified by 
microarray: 2 N-
terminal (aa's 9-
15 and 21-27), 
two in the 
proline-rich 
domain (aa's 
168-174 and 
220-228) and 1 
in the C-terminal 
(aa's 427-438); 
5 new 
immunogenic 
epitopes were 
identified: 2 N-
terminal (aa's9-
15 and 21-27), 
two in the 
proline-rich 
domain (aa's 
168-174 and 
220-228) and 1 
in the C-terminal 
(aa's 427-438) 
 
Table 3.1: Active immunization using tau antigens, notes:  
sc = subcutaneous 
i.p. = intraperitoneal 
IHC = immunohistochemistry 
NOR = Novel Object Recognition 
RAM = Radial Arm Maze 
CFSM = Closed Field Symmetrical Maze 
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KLH = keyhole limpet hemocyanin 
aa’s = amino acids 
CFT = complete Freund’s adjuvant 
PT = pertussis toxin 
IFA = incomplete Freund’s adjuvant 
NFT = neurofibrillary tangles 
GFAP = glial fibrillary acidic protein 
wt = wild-type 
  
	 125	
Table 3.2: Passive Immunization Using Tau Antibodies 
Authors Antibody, 
Dose & 
Administra
tion 
Mouse 
Models, 
incl. 
mutation 
if present 
Age at 
first 
injection 
Duration Details/Results 
Chai, et al, 
JBC 2011 
PHF1 or 
MC-1, 15 
mg/kg, 
peripheral 
injection 
(not 
specified) 
JNPL3 
(P301L) 
and/or 
P301S 
2 mos 2 - 3 mos ↓ insol AT8, no change 
HT 7 by Western, ↑ Time 
on rotarod, ↓AT8 & PG5 
by IHC; Correlation of 
AT8 signals in P1 fraction 
with Sarkosyl-insoluble 
fractions to show that the 
preparations were valid 
Boutajang
out,et al, 
J. 
Neuroche
m 2011 
i.p. 
injection of 
PHF1 
Female 
JNPL3 
9 - 12 
wks 
2 - 3 mos ↑ Time on balance beam 
at 5 - 6 mos, but no 
difference on rotarod 
performance; ↓ PHF1/B19 
ratio, ↓ PHF1 (alone), ↓ 
CP13/B19 ratio, ↓ CP13 
(alone) in Sarkosyl 
fraction for Western; ↓ 
PHF1 in right Dentate 
Gyrus by IHC 
d'Abramo, 
et al, 
PLOS1 
2013 
i.p. 
injection of 
PHF1, 
MC-1, or 
DA31: 250 
μg/125 μl, 
for a total 
of 10 
mg/kg 
weekly 
Female 
JNPL3 
3 or 7 
mos 
3 - 4 mos ↓ CP13 in CA1 with MC-1 
treatment by ELISA, ↓ 
RZ3 in CA1 with DA31 
treatment and ↓ CP13 
from MC-1 in older mice 
by IHC; ↓ RZ3 in CA1 of 
older DA31 treated mice 
(total tau Western Blot), ↓ 
in total tau with MC-1, No 
change with DA3 
(Western Blot of insoluble 
fraction), no changes in 
survival 
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Table 3.2: Passive Immunization Using Tau Antibodies (continued) 
Yanaman
dro, et al, 
Cell/Neuro
n 2013  
icv 
injection of 
their own 
tau 
antibodies
: 
Continuou
s icv 
infusion of 
7.2 μg/d,  
for 6 
weeks of: 
HJ8 series 
(anti 
human 
tau); 
HJ8.5 = 
AA’s 25 – 
30; HJ9 
series 
(anti 
mouse 
tau);  
HJ9.3 = 
AA’s 306 
– 320 
(repeat 
domain); 
HJ9.4 = 
AA’s 7 – 
13 (N-
terminal); 
Or HJ3 
series 
(anti Aβ, 
mouse)  
P301S 6 mos 3 mos HJ8.5 ↓ AT8 in piriform & 
entorhinal Cx, hippocampus 
& amygdala (by IHC), 
HJ9.3 ↓ AT8 to lesser 
degrees in similar regions, 
HJ9.4 had less ↓, & no 
change in piriform Cx; 
ThioS and PHF1 staining 
yielded similar results.  
Staining for activated 
microglia strongly 
correlated with AT8 
staining; HJ8.5 & HJ9.3 ↓ 
activated microglia in 
piriform & entorhinal Cx and 
amygdala.  HJ9.4 showed 
lower effect on microglia; 
ThioS and PHF1 had 
similar results.  Staining for 
activated microglia strongly 
correlated with AT8 
staining; HJ8.5 & HJ9.3 ↓ 
activated microglia in 
piriform & entohinal Cx and 
amygdala.  HJ9.4 had 
lesser effect on microglia.  
Significant (>50%) ↓ of 
detergent-insoluble tau 
(Western) from HJ8.5 and 
HJ9.3 treatment; > human 
tau than mouse tau in the 
FA “insoluble” fractions, ↓ 
by treatment; “seeding” ↓ by 
HJ8.5 and HJ9.3, not 
HJ9.4, in correlation with 
insoluble tau.  No 
differences in motor testing, 
Contextual Fear 
Conditioning ↑ from all 
treatments with HJ8.5 = 
most robust freezing, Cued 
Fear Conditioning not 
affected by treatments 
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Table 3.2: Passive Immunization Using Tau Antibodies (continued) 
Castillo-
Carranza,
et al, J. 
Neurosci 
2014 
icv (1 μl @ 
1 mg/ml) 
or iv (30 
μg/animal) 
injection of 
TOMA 
(tau 
oligomeric 
monoclon
al 
antibody): 
single 
injection; 
either icv 
or iv, then 
4 days 
until tissue 
analysis  
JNPL3 4 or 8 
mos 
single 
injection 
icv ↑ time on rotarod, to 
near-wild type levels, 
correlating w/ reductions of 
oligos; icv treatment ↓ 
immunofluorescence of 
Thr231 and T22 as co-
localized with DAPI; Single 
iv injection↑ time on rotarod 
and ↑ alternations in Y 
maze 4 days post-injection; 
Single icv injection ↓ 
oligomeric tau (T22); Single 
iv injection ↑ oligo and HT7 
ELISA levels in serum, 
correlating to ↓ levels in the 
brain; Single iv injection 
had no effect on AT8 or 
Gallyas staining; only T22 
staining for oligos was 
reduced; Single iv injection 
did not change Western 
blot analysis for AT8 and/or 
PHF-13;  Western analyses 
showed ↓ oligo levels, while 
Tau 5 showed ↑ monomeric 
tau, by both 
administrations. 
Walls, et 
al, 
Neurosci 
Letters 
2014 
i.c. 
injection of 
either 
AT8, 4G8 
or IgG; 2 
μg/animal 
3xTg 
(swAPP/
PS1/P30
1L) 
15 - 18 
mos 
1 - 4 
wks 
HT7, AT8 and Gallyas 
staining ↓ 1 - 2 weeks post-
injection of AT8; From 3 
weeks on, levels of tau 
(phospho, and normal) 
returned to IgG-treated 
(control) levels; 6E10 levels 
reduced due to 4G8 
administration, following a 
similar pattern; AT8 
administration did not effect 
Aβ levels, and 4G8 did not 
affect tau 
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Table 3.2: Passive Immunization Using Tau Antibodies (continued) 
Collin, et 
al, Brain 
2014 
i.p. 
injection of 
MAb86 a 
pSer422-
specific 
antibody, 
60 mg/kg 
with 3 day 
intervals 
TauPS2
APP 
(P301L 
tau) 
Acute: 
16-mo; 
chronic: 
10-mo 
Acute = 
48 H, 
chronic 
= 1 wk 
MAb86 specifically binds to 
tau phosphorylated at 
Ser422, shown in Western 
(Sarkosyl fraction); 
Immunofluorescence in 
CA1 verified binding; 
double staining with flotillin 
showed binding and 
internalization via lipid rafts; 
Chronic treatment delayed 
tau pathology and favored 
lysosomal clearance as 
shown by ELISA. 
 
Table 3.2: Passive Immunization Using Tau Antibodies, notes  
IHC = immunohistochemistry 
i.p. = intraperitoneal 
icv = intracranial ventricular 
FA = formic acid extract 
iv = intravenous 
i.c. = intracranial 
 
  
	 129	
Table 3.3 – Additional Staining Results Following Intracranial Injection Of Antibodies  
STAIN 
Anti-GFP 
Treatment    Mean 
+/- SEM 
MC-1 Treatment 
Mean +/- SEM 
PHF1 Treatment 
Mean +/- SEM 
DA9 Treatment 
Mean +/- SEM 
pSer396 1.03 +/- 0.21 0.90 +/- 0.156 0.75 +/- 0.14 1.36 +/- 0.22 
CD45 1.06 +/- 0.13 0.96 +/- 0.12 1.13 +/- 0.11 1.06 +/- 0.10 
 
Table 3.3:  Sub-populations of mice were stained with other phospho-epitopes of tau; 
here we show an example using pSer396, which did not demonstrate significant 
reduction in pathology, similar to others tested.  Additionally, we examined the microglial 
marker CD45 to note if antibody treatment had any impact on pro-inflammatory 
response, which was not reflected here. 
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Table 3.4 – Activity Test Results 
Activity 
Test 
Non 
Transgenic 
mean +/- SEM 
rTg4510 + 
IgG1  mean 
+/- SEM 
rTg4510 + MC-1 
Mean +/- SEM 
rTg4510 + Tau 5 
Mean +/- SEM 
Open Field 
Distance 
Traveled 
50.6 +/- 5.9 126 +/- 28 149 +/- 26 143 +/- 26 
Rotarod – 
Total time 40.5 +/- 5.1 57.3 +/- 6.7 44.4 +/- 6.7 48.2 +/- 6.0 
Y-Maze – 
Number of 
Entries 
38.9 +/- 3.6 51.8 +/- 10.1 44.4 +/- 8.9 46.4 +/- 4.8 
Y-Maze - 
Alternations 55.2 +/- 3.7 58.3 +/- 6.4 64.0 +/- 5.8 61.4 +/- 4.2 
 
Table 3.4:  Our laboratory has observed that rTg4510 mice typically display much 
greater activity levels than NonTg mice, as mentioned above.  Such activity is 
demonstrated here, by comparing distance traveled in the Open Field test, the time on 
the Rotarod and the number of entries in the Y-Maze.  Slight increases are also shown 
in the number of alternations in the Y-Maze.  Treatment of the rTg4510 mice with either 
MC-1 or Tau 5 did not significantly impact performance compared to IgG1 treatment. 
 
	 131	
Fig 3.1: Gallyas silver staining of hippocampal sections, four days after intracranial 
infusion of anti-tau antibodies into rTg4510 mice,.  One-year old rTg4510 mice (n = 6 – 
8 animals per group) received intracranial injection (by convection enhanced delivery, 
CED) of potential tau-treatment antibodies into the right hemisphere.  The left 
hemisphere remained untreated.  Three different types of antibodies were tested, in 
comparison to an anti-GFP control injection.  PHF-1 is a phosphorylated form of tau, 
MC-1 is a conformation-dependent antibody, and DA-9 is a pan-tau antibody.  MC-1 
treatment demonstrated a reduction in NFTs (p < 0.05 by ANOVA), while the other 
antibodies did not.   Scale bar = 100 µm.  
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Fig 3.2:  Analysis of hyperphosphorylated tau (pSer199/202) in the hippocampus, four 
days post intracranial infusion of antibodies into one-year old rTg4510 mice.  The right 
hemisphere pathology, normalized by the uninjected left hemisphere, showed a marked 
response to two of the three different antibodies, compared to the anti-GFP control 
injection.  DA 9 treatment yielded a moderate reduction in pSer199/202 staining (p < 
0.05), while MC-1 treatment led to an even more dramatic reduction of pSer199/202 (p< 
0.01; n = 6 – 8 animals per group)).  Statistics were computed using StatView software 
and ANOVA analysis.  Scale bar = 100 µm.
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Fig 3.3:  H150 immunostaining after hippocampal antibody treatment to rTg4510 mice.  
One-year old rTg4510 mice (n = 6 – 7 per group) received intracranial injections of 
treatment antibodies into the right hippocampus.  Four days later, tissue was collected 
and the treated (right) hippocampus was compared to the untreated (left) hippocampus 
to identify differences in pathology by IHC.  Results were compared between antibody 
treatments and anti-GFP control injections.  Both MC-1 and DA 9 treatments led to 
significant reductions in H150 pathology (p < 0.05) compared to the anti-GFP control 
treatments.  Results were analyzed using StatView software, for the non-parametric 
Mann Whitney U Test.  Scale bar = 100 µm. 
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Fig 3.4:  Spatial memory testing, using the radial arm water maze (RAWM) was used to 
identify cognitive differences between treated and untreated rTg4510 mice.  Mice 
received two weeks of antibody infusion were subjected to a battery of behavioral 
testing, with emphasis on cognitive performance. Radial Arm Water Maze testing 
revealed that the IgG1 control antibody (n = 9) did not lead to performance improvement 
compared to Non Tg mice (n = 8).  In contrast, MC-1 treated mice (n = 8) showed 
cognitive performance levels that were nearly indistinguishable from the Non Tg mice.  
ANOVA statistical analysis was performed using StatView software. 
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Fig 3.5:  Cognitive-behavioral results from novel object recognition testing of rTg4510 
mice after receiving 2 weeks of continuous infusion of anti-tau antibodies into the right 
ventricle.  Mice that had received two weeks of antibody infusion were subjected to a 
battery of behavioral testing, with emphasis on cognitive performance. Novel object 
recognition testing revealed that the IgG1 control antibody (n = 9) did not lead to 
performance improvement compared to Non Tg mice (n = 8).  In contrast, MC-1 treated 
mice (n = 8) showed cognitive performance levels that were nearly indistinguishable 
from the Non Tg mice.  ANOVA statistical analysis was performed using StatView 
software 
  
	 136	
3.9 References  
Alzheimer’s Association, Alzheimer’s Disease Facts and Figures. 2011, Alzheimer’s 
Association: Chicago, IL. 
ClinicalTrials.gov identifier: NCT01850238 , Axon Neuroscience SE (2013).. 
Agadjanyan MG, Petrovsky N, Ghochikyan A (2015) A fresh perspective from 
immunologists and vaccine researchers: Active vaccination strategies to prevent and 
reverse Alzheimer's disease. Alzheimer's & dementia : the journal of the Alzheimer's 
Association. 
Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM (2007) Immunotherapy 
targeting pathological tau conformers in a tangle mouse model reduces brain pathology 
with associated functional improvements. J Neurosci 27:9115-9129. 
Bayer AJ, Bullock R, Jones RW, Wilkinson D, Paterson KR, Jenkins L, Millais SB, 
Donoghue S (2005) Evaluation of the safety and immunogenicity of synthetic Abeta42 
(AN1792) in patients with AD. Neurology 64:94-101. 
Bi M, Ittner A, Ke YD, Gotz J, Ittner LM (2011) Tau-targeted immunization impedes 
progression of neurofibrillary histopathology in aged P301L tau transgenic mice. PLoS 
One 6:e26860. 
Billiau A, Matthys P (2001) Modes of action of Freund's adjuvants in experimental 
models of autoimmune diseases. Journal of leukocyte biology 70:849-860. 
	 137	
Boimel M, Grigoriadis N, Lourbopoulos A, Haber E, Abramsky O, Rosenmann H (2010) 
Efficacy and safety of immunization with phosphorylated tau against neurofibrillary 
tangles in mice. Exp Neurol 224:472-485. 
Boutajangout A, Ingadottir J, Davies P, Sigurdsson EM (2011) Passive immunization 
targeting pathological phospho-tau protein in a mouse model reduces functional decline 
and clears tau aggregates from the brain. J Neurochem. 
Boutajangout A, Quartermain D, Sigurdsson EM (2010) Immunotherapy targeting 
pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci 
30:16559-16566. 
Braak H, Braak E, Bohl J (1993) Staging of Alzheimer-related cortical destruction. Eur 
Neurol 33:403-408. 
Brownlow ML, Joly-Amado A, Azam S, Elza M, Selenica ML, Pappas C, Small B, 
Engelman R, Gordon MN, Morgan D (2014) Partial rescue of memory deficits induced 
by calorie restriction in a mouse model of tau deposition. Behavioural brain research 
271:79-88. 
Brunden KR, Zhang B, Carroll J, Yao Y, Potuzak JS, Hogan AM, Iba M, James MJ, Xie 
SX, Ballatore C, Smith AB, 3rd, Lee VM, Trojanowski JQ (2010) Epothilone D improves 
microtubule density, axonal integrity, and cognition in a transgenic mouse model of 
tauopathy. J Neurosci 30:13861-13866. 
Carty N, Lee D, Dickey C, Ceballos-Diaz C, Jansen-West K, Golde TE, Gordon MN, 
Morgan D, Nash K (2010) Convection-enhanced delivery and systemic mannitol 
	 138	
increase gene product distribution of AAV vectors 5, 8, and 9 and increase gene 
product in the adult mouse brain. Journal of neuroscience methods 194:144-153. 
Castillo-Carranza DL, Gerson JE, Sengupta U, Guerrero-Munoz MJ, Lasagna-Reeves 
CA, Kayed R (2014a) Specific targeting of tau oligomers in Htau mice prevents 
cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric 
seeds. J Alzheimers Dis 40 Suppl 1:S97-S111. 
Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Lasagna-Reeves CA, Gerson 
JE, Singh G, Estes DM, Barrett AD, Dineley KT, Jackson GR, Kayed R (2014b) Passive 
immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes 
without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci 34:4260-4272. 
Castrillo JI, Oliver SG (2016) Alzheimer's as a Systems-Level Disease Involving the 
Interplay of Multiple Cellular Networks. Methods in molecular biology (Clifton, NJ) 
1303:3-48. 
Chai X, Wu S, Murray TK, Kinley R, Cella CV, Sims H, Buckner N, Hanmer J, Davies P, 
O'Neill MJ, Hutton ML, Citron M (2011) Passive immunization with anti-Tau antibodies 
in two transgenic models: reduction of Tau pathology and delay of disease progression. 
The Journal of biological chemistry 286:34457-34467. 
Citron M (2010) Alzheimer's disease: strategies for disease modification. Nat Rev Drug 
Discov 9:387-398. 
	 139	
Collin L, Bohrmann B, Gopfert U, Oroszlan-Szovik K, Ozmen L, Gruninger F (2014) 
Neuronal uptake of tau/pS422 antibody and reduced progression of tau pathology in a 
mouse model of Alzheimer's disease. Brain : a journal of neurology. 
d'Abramo C, Acker, C., Jimenez, H., Davies, P. (2013) Tau Passive Immunotherapy in 
Mutant P301L Mice: Antibody Affinity versus Specificity. PLOS ONE Volume 8:10. 
Denk F, Wade-Martins R (2009) Knock-out and transgenic mouse models of 
tauopathies. Neurobiol Aging 30:1-13. 
Ding WX, Yin XM (2008) Sorting, recognition and activation of the misfolded protein 
degradation pathways through macroautophagy and the proteasome. Autophagy 4:141-
150. 
Espinoza M, de Silva R, Dickson DW, Davies P (2008) Differential incorporation of tau 
isoforms in Alzheimer's disease. J Alzheimers Dis 14:1-16. 
Fontaine SN, Rauch JN, Nordhues BA, Assimon VA, Stothert AR, Jinwal UK, Sabbagh 
JJ, Chang L, Stevens SM, Jr., Zuiderweg ER, Gestwicki JE, Dickey CA (2015) Isoform-
selective Genetic Inhibition of Constitutive Cytosolic Hsp70 Activity Promotes Client Tau 
Degradation Using an Altered Co-chaperone Complement. The Journal of biological 
chemistry 290:13115-13127. 
Ghochikyan A, Mkrtichyan M, Petrushina I, Movsesyan N, Karapetyan A, Cribbs DH, 
Agadjanyan MG (2006) Prototype Alzheimer's disease epitope vaccine induced strong 
Th2-type anti-Abeta antibody response with Alum to Quil A adjuvant switch. Vaccine 
24:2275-2282. 
	 140	
Gotz J, Ittner A, Ittner LM (2012) Tau-targeted treatment strategies in Alzheimer's 
disease. British journal of pharmacology 165:1246-1259. 
Guerrero-Munoz MJ, Castillo-Carranza DL, Kayed R (2014) Therapeutic approaches 
against common structural features of toxic oligomers shared by multiple amyloidogenic 
proteins. Biochemical pharmacology 88:468-478. 
Halle M, Tribout-Jover P, Lanteigne AM, Boulais J, St-Jean JR, Jodoin R, Girouard MP, 
Constantin F, Migneault A, Renaud F, Didierlaurent AM, Mallett CP, Burkhart D, Pilorget 
A, Palmantier R, Larocque D (2015) Methods to monitor monocytes-mediated amyloid-
beta uptake and phagocytosis in the context of adjuvanted immunotherapies. Journal of 
immunological methods. 
Himmelstein DS, Ward SM, Lancia JK, Patterson KR, Binder LI (2012) Tau as a 
therapeutic target in neurodegenerative disease. Pharmacology & therapeutics 136:8-
22. 
Hoover BR, Reed MN, Su J, Penrod RD, Kotilinek LA, Grant MK, Pitstick R, Carlson 
GA, Lanier LM, Yuan LL, Ashe KH, Liao D (2010) Tau mislocalization to dendritic spines 
mediates synaptic dysfunction independently of neurodegeneration. Neuron 68:1067-
1081. 
Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI (2012) Trans-cellular 
propagation of Tau aggregation by fibrillar species. The Journal of biological chemistry 
287:19440-19451. 
	 141	
Lasagna-Reeves CA, Castillo-Carranza DL, Jackson GR, Kayed R (2011a) Tau 
Oligomers as Potential Target for Immunotherapy for Alzheimer Disease and 
Tauopathies. Curr Alzheimer Res. 
Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clos AL, Jackson GR, Kayed 
R (2011b) Tau oligomers impair memory and induce synaptic and mitochondrial 
dysfunction in wild-type mice. Molecular neurodegeneration 6:39. 
Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Guerrero-Munoz MJ, Kiritoshi 
T, Neugebauer V, Jackson GR, Kayed R (2012a) Alzheimer brain-derived tau oligomers 
propagate pathology from endogenous tau. Scientific reports 2:700. 
Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Sarmiento J, Troncoso J, 
Jackson GR, Kayed R (2012b) Identification of oligomers at early stages of tau 
aggregation in Alzheimer's disease. FASEB journal : official publication of the 
Federation of American Societies for Experimental Biology 26:1946-1959. 
Lashley T, Rohrer JD, Mead S, Revesz T (2015) Review: An update on clinical, genetic 
and pathological aspects of frontotemporal lobar degenerations. Neuropathology and 
applied neurobiology. 
Lee VM, Goedert M, Trojanowski JQ (2001) Neurodegenerative tauopathies. Annu Rev 
Neurosci 24:1121-1159. 
Lemere CA (2013) Immunotherapy for Alzheimer's disease: hoops and hurdles. 
Molecular neurodegeneration 8:36. 
	 142	
Mandelkow EM, Mandelkow E (2012) Biochemistry and cell biology of tau protein in 
neurofibrillary degeneration. Cold Spring Harbor perspectives in medicine 2:a006247. 
Mandelkow EM, Schweers O, Drewes G, Biernat J, Gustke N, Trinczek B, Mandelkow E 
(1996) Structure, microtubule interactions, and phosphorylation of tau protein. Ann N Y 
Acad Sci 777:96-106. 
Medeiros R, Baglietto-Vargas D, Laferla FM (2010) The Role of Tau in Alzheimer's 
Disease and Related Disorders. CNS Neurosci Ther. 
Medeiros R, Baglietto-Vargas D, LaFerla FM (2011) The role of tau in Alzheimer's 
disease and related disorders. CNS Neurosci Ther 17:514-524. 
Morgan D (2011) Immunotherapy for Alzheimer's disease. J Intern Med 269:54-63. 
Morris M, Maeda S, Vossel K, Mucke L (2011) The many faces of tau. Neuron 70:410-
426. 
O'Leary JC, 3rd, Li Q, Marinec P, Blair LJ, Congdon EE, Johnson AG, Jinwal UK, Koren 
J, 3rd, Jones JR, Kraft C, Peters M, Abisambra JF, Duff KE, Weeber EJ, Gestwicki JE, 
Dickey CA (2010) Phenothiazine-mediated rescue of cognition in tau transgenic mice 
requires neuroprotection and reduced soluble tau burden. Molecular neurodegeneration 
5:45. 
Oddo S, Caccamo A, Cheng D, LaFerla FM (2009) Genetically altering Abeta 
distribution from the brain to the vasculature ameliorates tau pathology. Brain Pathol 
19:421-430. 
	 143	
Orgogozo JM, Gilman S, Dartigues JF, Laurent B, Puel M, Kirby LC, Jouanny P, Dubois 
B, Eisner L, Flitman S, Michel BF, Boada M, Frank A, Hock C (2003) Subacute 
meningoencephalitis in a subset of patients with AD after Abeta42 immunization. 
Neurology 61:46-54. 
Ragupathi G, Damani P, Deng K, Adams MM, Hang J, George C, Livingston PO, Gin 
DY (2010) Preclinical evaluation of the synthetic adjuvant SQS-21 and its constituent 
isomeric saponins. Vaccine 28:4260-4267. 
Rosenmann H, Grigoriadis, N., Karussis, D., Boimel, M., Touloumi, O., Ovadia, H., 
Abramsky, O. (2006) Tauopathy-like Abnormalities and Neurologic Deficits in Mice 
Immunized With Neuronal Tau Protein. Arch Neurol 63:1459 - 1467. 
Rozenstein-Tsalkovich L, Grigoriadis N, Lourbopoulos A, Nousiopoulou E, Kassis I, 
Abramsky O, Karussis D, Rosenmann H (2013) Repeated immunization of mice with 
phosphorylated-tau peptides causes neuroinflammation. Exp Neurol 248:451-456. 
Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, Guimaraes A, 
DeTure M, Ramsden M, McGowan E, Forster C, Yue M, Orne J, Janus C, Mariash A, 
Kuskowski M, Hyman B, Hutton M, Ashe KH (2005) Tau suppression in a 
neurodegenerative mouse model improves memory function. Science 309:476-481. 
Selenica ML, Brownlow M, Jimenez JP, Lee DC, Pena G, Dickey CA, Gordon MN, 
Morgan D (2013) Amyloid oligomers exacerbate tau pathology in a mouse model of 
tauopathy. Neuro-degenerative diseases 11:165-181. 
	 144	
Selenica ML, Davtyan H, Housley SB, Blair LJ, Gillies A, Nordhues BA, Zhang B, Liu J, 
Gestwicki JE, Lee DC, Gordon MN, Morgan D, Dickey CA (2014) Epitope analysis 
following active immunization with tau proteins reveals immunogens implicated in tau 
pathogenesis. Journal of neuroinflammation 11:152. 
Sigurdsson EM (2008) Immunotherapy targeting pathological tau protein in Alzheimer's 
disease and related tauopathies. J Alzheimers Dis 15:157-168. 
Sigurdsson EM (2009) Tau-focused immunotherapy for Alzheimer's disease and related 
tauopathies. Curr Alzheimer Res 6:446-450. 
Sperling R, Salloway S, Brooks DJ, Tampieri D, Barakos J, Fox NC, Raskind M, 
Sabbagh M, Honig LS, Porsteinsson AP, Lieberburg I, Arrighi HM, Morris KA, Lu Y, Liu 
E, Gregg KM, Brashear HR, Kinney GG, Black R, Grundman M (2012) Amyloid-related 
imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: 
a retrospective analysis. The Lancet Neurology 11:241-249. 
Sui D, Liu M, Kuo MH (2015) In vitro aggregation assays using hyperphosphorylated tau 
protein. Journal of visualized experiments : JoVE e51537. 
Troquier L, Caillierez R, Burnouf S, Fernandez-Gomez FJ, Grosjean ME, Zommer N, 
Sergeant N, Schraen-Maschke S, Blum D, Buee L (2012) Targeting phospho-Ser422 by 
active Tau Immunotherapy in the THYTau22 mouse model: a suitable therapeutic 
approach. Curr Alzheimer Res 9:397-405. 
Utton MA, Noble WJ, Hill JE, Anderton BH, Hanger DP (2005) Molecular motors 
implicated in the axonal transport of tau and alpha-synuclein. J Cell Sci 118:4645-4654. 
	 145	
Walls KC, Ager RR, Vasilevko V, Cheng D, Medeiros R, LaFerla FM (2014) p-Tau 
immunotherapy reduces soluble and insoluble tau in aged 3xTg-AD mice. Neuroscience 
letters 575:96-100. 
Wang JZ, Gao X, Wang ZH (2014) The physiology and pathology of microtubule-
associated protein tau. Essays in biochemistry 56:111-123. 
Wang Y, Mandelkow E (2012) Degradation of tau protein by autophagy and 
proteasomal pathways. Biochem Soc Trans 40:644-652. 
Wilcock DM, Colton CA (2008) Anti-amyloid-beta immunotherapy in Alzheimer's 
disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis 
15:555-569. 
Wilcock DM, Jantzen PT, Li Q, Morgan D, Gordon MN (2007) Amyloid-beta vaccination, 
but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid 
and microhemorrhage while both reduce parenchymal amyloid. Neuroscience 144:950-
960. 
Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S, Alamed J, Wilson D, 
Wilson N, Freeman MJ, Gordon MN, Morgan D (2004) Passive amyloid immunotherapy 
clears amyloid and transiently activates microglia in a transgenic mouse model of 
amyloid deposition. J Neurosci 24:6144-6151. 
Wisniewski T, Boutajangout A (2010) Immunotherapeutic approaches for Alzheimer's 
disease in transgenic mouse models. Brain Struct Funct 214:201-218. 
	 146	
Wolfe MS (2012) The role of tau in neurodegenerative diseases and its potential as a 
therapeutic target. Scientifica 2012:796024. 
Yamada K, Cirrito JR, Stewart FR, Jiang H, Finn MB, Holmes BB, Binder LI, Mandelkow 
EM, Diamond MI, Lee VM, Holtzman DM (2011) In vivo microdialysis reveals age-
dependent decrease of brain interstitial fluid tau levels in P301S human tau transgenic 
mice. J Neurosci 31:13110-13117. 
Yanamandra K, Kfoury N, Jiang H, Mahan TE, Ma S, Maloney SE, Wozniak DF, 
Diamond MI, Holtzman DM (2013) Anti-tau antibodies that block tau aggregate seeding 
in vitro markedly decrease pathology and improve cognition in vivo. Neuron 80:402-414. 
Yu X, Luo Y, Dinkel P, Zheng J, Wei G, Margittai M, Nussinov R, Ma B (2012) Cross-
seeding and conformational selection between three- and four-repeat human Tau 
proteins. The Journal of biological chemistry 287:14950-14959. 
 
 
  
	 147	
	
	
	
CHAPTER 4: OLIGOMERIC TAU TARGETED IMMUNOTHERAPY 
 For these experiments, routine injection of tau antibodies into the peritoneal 
cavity of rTg4510 mice was performed.  Three month-old mice received regular 
systemic injections at 2-week intervals, for 10 injections.  Mice were given i.p. injections 
of either saline (control), IgG1 (also a control), or TOMA.  Additionally, there was a Tet-
only control group, which received saline injections.  All mice were subjected to a 
battery of behavioral tests, just prior to tissue collection.  Mice were approximately 7 
months old after treatment when plasma and CSF and tissue were collected at 
euthanisasia.  This chapter has been submitted for publication in Alzheimer’s Research 
and Therapy, 2017.  
 
Oligomeric Tau-Targeted Immunotherapy in rTg4510 mice 
Schroeder, S1*., Joly-Amado, A.1*, Soliman A.1, Sengupta, U.2, Kayed, R.2, Gordon, 
MN.1, Morgan, D.1, 3 
 
4.1 Abstract 
Finding ways to reverse or prevent the consequences of pathogenic tau in the brain is 
of considerable importance for treatment of Alzheimer’s disease and other tauopathies. 
Immunotherapy against tau has shown promise in several mouse models. In particular, 
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an antibody with selectivity for oligomeric forms of tau, tau oligomer monoclonal 
antibody (TOMA), has shown rescue of the behavioral phenotype in several murine 
models of tau deposition. In this study, we examined the capacity of TOMA to rescue 
the behavioral, histological and neurochemical consequences of tau deposition in the 
aggressive rTg4510 model. We treated mice with 60 µg TOMA I.P. from 3.5 to 8 mo of 
age. Near the end of the treatment, we found that oligomeric tau was elevated in both 
the CSF and plasma. Further we could detect mouse IgG in rTg4510 mouse brain after 
TOMA, but not after injection with mouse IgG1 as control. However, we did not find 
significant reductions in behavioral deficits or tau deposits by either histological or 
biochemical measurements. These data suggest that there is some exposure of the 
rTg4510 mouse brain to TOMA, but it was inadequate to affect the phenotype in these 
mice at the doses used. These data are consistent with other observations that the 
rTg4510 mouse is very aggressive and therefore more challenging to demonstrate 
efficacy of tau-lowering treatments than some other preclinical models of tau 
deposition/overexpression.  
 
4.2 Introduction 
 Tau is a microtubule binding protein (MBP), which assists in maintaining the 
physical structure of neurons, primarily the axons. It also facilitates trafficking of 
organelles and intracellular compounds within the cell in its normal state (Mandelkow 
and Mandelkow, 2012b). It is an important protein for normal cell functioning, but can 
become pathological. This pathology is associated with various post-translational 
modifications, most notably hyperphosphorylation. As tau becomes 
	 149	
hyperphosphorylated, it mis-folds and aggregates into oligomers, and ultimately fibrils. 
These aggregated forms of tau are associated with a class of neurodegenerative 
disorders called tauopathies, which include fronto-temporal lobe dementia, Pick's 
Disease, corticobasal degeneration, argyrophilic grain disease, and Alzheimer’s 
Disease (AD). These diseases have different origins and symptoms, but all have 
accumulation of aggregated forms of tau as a common feature. 
 Tau is an attractive target to treat because the progressive pathology of the 
protein highly correlates with AD symptoms (Braak and Braak, 1995, Nelson et al., 
2012).  Amyloid Beta (Aβ) was initially investigated, due to the linkage of amyloid 
metabolism to genetic forms of Alzheimer’s disease (Hardy and Selkoe, 2002).  One of 
the first approaches to  reducing brain Aβ was the use of immunotherapy (Schenk et al., 
1999a, Morgan et al., 2000b) and this approach has advanced to phase 3 clinical 
testing (Doody et al., 2014, Salloway et al., 2014). The success of immunotherapy in 
preclinical models of amyloid deposition led to later attempts to pursue 
immunotherapeutic approaches to tau deposition as well as reviewed in Chapter 3 
(Schroeder et al., 2016).   
 Traditionally, tau has been considered to be a presynaptic protein, as it stabilizes 
microtubules and assists in transport through the axon.  However, there have been 
recent studies that have identified mechanisms for tau to be transmitted across 
synapses to nearby post-synaptic cells, which serves as a means for understanding 
progressive tau pathology and spread (de Calignon et al., 2012, Liu et al., 2012).  
Dendritic tau has been associated with synaptic disruption (Ittner et al., 2010, Roberson 
et al., 2011). 
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 Immunotherapy has become a focus to attempt to treat tauopathies and other 
protein-based neural diseases (Sigurdsson, 2009), especially given the successes in 
using this strategy for treating the Aβ component of AD (Morgan, 2011b).  
Immunotherapy can either be “active,” where an antigen is delivered to the body which 
then produces its own antibodies to effect healing, or “passive,” in which actual 
antibodies are administered like a drug.  The former is more likely to produce side 
effects, whereas the latter requires more frequent administration to maintain effective 
titers of the treatment antibody.  Both strategies have been extensively investigated in 
the past several years. 
 Our laboratory has examined several antibodies directed against tau (focusing on 
passive immunization), in effort to find the most successful candidate to ameliorate 
pathology and behavioral deficits in rTg4510 mice. In this study, we utilized passive 
immunization of a tau oligomeric monoclonal antibody (TOMA), which was provided by 
Rakez Kayed's laboratory (Lasagna-Reeves et al., 2011b, Castillo-Carranza et al., 
2014b). This antibody had shown positive effects in JNPL3 mice and hTau mice, but 
had not been tested in rTg4510 mice. JNPL3 mice slowly develop tau aggregation and 
deposition in spinal cord and brainstem with small amounts of forebrain pathology. The 
rTg4510 mice rapidly accumulate tau deposits in forebrain regions overlapping CaM 
kinase II distribution. There is also considerable atrophy and neuron loss in the rTg4510 
forebrain with aging, while there is less such pathology in the JNPL3 model. hTau mice 
develop pathology even later than the JNPL3 mice (Andorfer et al., 2003) 
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4.3 Materials and Methods  
Animals:  
 The rTg4510 mouse line (0N4R P301L) was chosen for these studies because 
they are known to have tau pathology (expression of the P301L mutation) directed to 
the forebrain, which more closely resembles an AD type of tauopathy (Santacruz et al., 
2005b). Of note, the mutant human tau expression can be suppressed by application of 
doxycycline.  rTg4510 mice, and their littermates, were bred locally by crossing mice 
transgenic for a tetracycline-operon-responsive element (tTA), controlled by a 
calmodulin kinase II (CAMK II) promoter, with a separate mouse line transgenic for 
human P301L tau driven by the Tet operon, as previously described (Santacruz et al., 
2005b).  The resulting cross yields approximately 25% non-transgenic (nTg) mice, 25%  
P301L only (tau only) mice, 25% tTA only (Tet) mice, and 25% rTg4510 (tau-tet) mice.  
For this study, while the rTg4510 mice were the primary interest, we also used nTg and 
Tet-only littermates as controls.  The mice were approximately 3.5 mo old at first 
injection and 8 months old at the end of treatment.  Groups were as follows: nTg + 
saline n = 10, Tet + saline n = 10, rTg4510 + IgG1 n = 9, rTg4510 + TOMA n = 9. 
 
Antibody Treatment:  
 One antibody, tau oligomer monoclonal antibody (TOMA) (Lasagna-Reeves et 
al., 2011b) was the subject of focus. Efects of systemic administration to rTg4510 mice 
were examined, to evaluate if the antibody could prevent behavioral and pathological 
components of the Tg4510 phenotype. Mice were injected I.P with 60 µg TOMA or IgG 
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control, every two weeks for a total of 10 injections. Tet-only and nTg littermates were 
also injected at these times with saline to control for effects of biweekly injections on 
behavioral measures. The experimenter performing the injections was blind with respect 
to treatment condition. Body weight and food intake were measured at each injection 
time, to identify if the treatments were altering either of these metabolic measures. We 
noted that the rTg4510 mice consumed significantly more food, but also exhibited a 
significant reduction in body weight likely due to their excessive activity as previously 
described in (Brownlow et al., 2014, Joly-Amado et al., 2016). However, neither body 
weight nor food intake were modified by the antibody treatment. 
 
Behavioral	Testing:		
  Animals were tested for general activity levels after receiving 8 injections, by 
open-field testing, followed by rotarod and Y-maze. Y-maze testing indicates overall 
activity, or hyperactivity, based on the number of arm entries. It can also give a general 
indication of working memory when one analyzes the arm alternations. They were also 
tested for cognitive function using:  novel object recognition (NOR), spatial navigation 
memory using the 2 day radial arm water maze (RAWM;(Alamed et al., 2006)) followed 
by 1 day of reversal training (Brownlow et al., 2013), and associative learning using fear 
conditioning. Mice were also tested for novel mouse recognition (described in 
(Brownlow et al., 2014)), a modified version of a social interaction task. Open field and 
novel object recognition results were quantified using Anymaze software (Stoelting, 
Wood Dale, IL, USA). 
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Tissue Collection and Staining:  
 One day following the last antibody injection, the animals were euthanized using 
Somnasol (pentobarbital, phenytoin, EtOH, propylene glycol, rhodamine and benzyl 
alcohol). Anesthetized mice had CSF removed by penetrating the cisterna magna with a  
glass capillary tube (Sutter  Instruments, USA) following the method described in (Liu 
and Duff, 2008). Blood was collected by intracardiac puncture using EDTA and then 
centrifuged at 1,000 g for 15 min at 4°C for plasma collection. Mice were then perfused 
with buffered normal saline on a heated pad to prevent reductions in body temperature 
and artifactual tau phosphorylation. The brain was exposed and the right hemisphere 
was collected, preserved in freshly prepared 4% paraformaldehyde in Dulbecco’s 
phosphate buffered saline. Twenty-four hours later the brains were cryoprotected by 
successive incubations of 10%, 20% and 30% sucrose solutions for 24 h each. . The left 
hemisphere was dissected into the following regions: anterior cortex, posterior cortex, 
hippocampus, striatum, thalamus, cerebellum, and midbrain/hindbrain. All dissected 
tissue samples were snap-frozen on dry ice, stored at -80 degrees until ready for use.   
 Horizontal sections (25 μm thick) of the left hemisphere were collected into 24-
well plates. For each staining performed, 8 sections spaced roughly 600 µm apart were 
used. Gallyas silver staining for neurofibrillary tangles was conducted as per (Brownlow 
et al., 2014). Free-floating immunohistochemistry (IHC) was completed for H150 
(Santacruz Biotechnology, Dallas, TX, USA), tau phosphorylated at Ser199/202 
(pSer199/202, Anaspec, Fremont, CA, USA), pSer396 (Anaspec, Fremont, CA, USA), 
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and  the microglial marker CD45 (Invitrogen, Carlsbad, CA, USA) (Gordon et al., 1997). 
Additionally, we examined the staining for mouse IgG with biotinylated horse anti-mouse 
IgG specific secondary antibody (Vector Laboratories, Burlingame, CA, USA) to detect if 
the systemically injected antibodies may have bound to brain tissue.  
 Stained anatomical sections were digitally scanned using a Zeiss slide scanner 
followed by quantification of stained area in user defined regions of interest using 
custom designed software. Values from all sections from the same mouse were 
averaged to represent a single value for that region in subsequent statistical analysis.  
 
Biochemistry/Western Blotting:  
Dissected brain regions were homogenized then sonicated in RIPA buffer, containing 
protease inhibitor cocktail and phosphatase inhibitor cocktails I and II (Sigma Aldrich) as 
per the manufacturer and centrifuged at 40, 000 x g for 30min at 4°C. The supernatant 
was collected and protein concentrations were determined by BCA protein assay 
(Pierce, Rockford, IL). The resulting pellet was digested with 70% formic acid according 
to the wet tissue weight, and then neutralized with NaOH to analyze RIPA-insoluble 
proteins.  Equal amounts of proteins (5μg/well for soluble fraction, 2μg/well for insoluble 
fraction) were loaded in each well of a 4–12%  bis-tris gels, transferred to a 0.2 μm pore 
size nitrocellulose membrane and immunoblotted with H150 (Santacruz biotechnology, 
Dallas, TX), pSer199/202 (Anaspec, Fremont, CA), pSer396 and pser262 (Anaspec, 
Fremont, CA) at 1:1000-fold dilution. Fluorescently- tagged secondary antibodies (LI-
COR Biosciences) were used at a dilution of 1:10,000.Western Blot results were 
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quantified by scanning with a LI-COR Odyssey fluorescent scanner.  AlphaEase FC 
software was used to normalize the tau bands to actin for the soluble fraction.  
Normalization of the insoluble fraction was conducted using REVERT reagent (LI-COR) 
to measure total protein.  Statistical analysis was then conducted using StatView. 
 CSF and plasma samples were analyzed for oligomeric tau using both direct and 
sandwich ELISA, with T22 antibody selective for oligomeric tau (Lasagna-Reeves et al., 
2012a) 
 
Statistical Analysis: 
 In general, results were analyzed by 1-way ANOVA with subsequent means 
comparisons made using Fisher’s test for multiple comparisons. In some cases where 
tau was measured, the absence of any signal in nTg mice led to using t-tests in Tg4510 
groups only. 
 
4.4 Results  
Detection of Antibody in Brain 
 Immunohistochemistry was conducted for mouse IgG by incubating sections in 
anti-mouse IgG specific secondary antibody.  Positive peroxidase reaction product 
staining was observed in the hippocampus and anterior cortex of rTg4510 mice injected 
with TOMA, but not in rTg4510 mice injected with mouse IgG1 (Fig 1A,B). There was 
also dark staining of the ependymal regions of the ventricles seen in both treatment 
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conditions. When the parenchymal staining in the hippocampus was viewed at higher 
magnification, there was staining of the neuropil only in rTg4510mice injected with 
TOMA (Fig 1 C,D).  We quantified immunostaining in the anterior cortex (ACX), 
posterior cortex (PCX) and hippocampus (HPC). The ratio of positively stained to total 
area calculated from digitized images is shown in Figure 1E.  The rTg4510 mice 
exhibited significantly higher levels of IgG in the ACX (p < 0.05) compared to all other 
groups, and in the HPC (p < 0.05 when compared to IgG1, p < 0.01 when compared to 
the other groups).  No significant differences were observed in the PCX. 
 
Detection of Oligomeric Aβ 
 Plasma and CSF were assayed with an ELISA specific for oligomeric tau. In the 
CSF, oligomeric tau was detected only in the mice injected with TOMA (P < 0.001; Fig 
2A). In the plasma, the TOMA-treated animals demonstrated significantly elevated 
levels of oligomeric tau compared to the other 3 groups (p < 0.001; Fig 2B). These 
results suggested that the TOMA was effectively acting as a sink in both CSF and 
plasma retaining the oligomeric tau, indicating antibody access to both compartments. 
 
Behavioral Testing  
There were no overall ANOVA differences in the open field, rotarod or Y maze 
tasks for any of the comparisons (data not shown). Mice were tested for spatial 
navigation performance in the radial arm water maze. This is a variant of the Morris 
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water maze with a submerged platform at the end of one of six swim alleys, permitting 
errors to be measured rather than time.  Over the first two days of training, there was a 
significant ANOVA effect with both groups of rTg4510 mice requiring more errors to find 
the platform than nTg or Tet mice (Fig 3A). On the third day of testing, the platform was 
placed in the arm opposite that used for learning on the first 2 days. Again, the ANOVA 
was significant with more errors on this reversal task for both groups of rTg4510 mice 
than the nTg or Tet mice (Fig 3B). In neither the learning nor reversal portions of the 
training were the TOMA- treated rTg4510 mice different from the IgG1- treated mice. 
 Mice were also examined for novel object recognition memory. In this task, mice 
exposed to a novel and a familiar object are expected to spend more time attending to 
the novel object.  Overall ANOVA and means testing determined the rTg4510 mice 
spent significantly less time attending to the novel object than nTg or Tet mice (Fig 4). 
Again there was no significant difference between the TOMA- treated and IgG1- treated 
rTg4510 mice. 
 
Histology 
 One half of the brain was sectioned for histochemical analysis. One hallmark of 
AD brain neurofibrillary tangles is their capacity to be stained by silver stains, such as 
the Gallyas stain. rTg4510 mice at 8 mo of age have numerous Gallyas positive 
neurons throughout hippocampus in both pyramidal and granule cell layers (Fig 5A, B). 
No Gallyas positive cells were found in tissues from nTg or Tet mice (not shown). When 
the amount of staining was quantified in anterior cortex, hippocampus and posterior 
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cortex, there were small regional differences, but no effect of TOMA treatment on the 
development of this pathology (Fig 5C). Immunostaining for total tau (antibody H150), or 
antibodies against phosphorylated forms of tau (pSER396, pSER 199/202) also failed to 
show an effect of TOMA treatment relative to mice treated with IgG1 antibodies (data 
not shown). 
 
Western Blotting 
 The detergent soluble fraction (S1) of homogenized tissue from the right ACX 
was analyzed by Western Blot (Table 1).  We separately quantified the bands at 55 
kDa, 64 kDa, and 120-200 kDa (likely representing oligomers) and found no differences 
between the IgG1 control and the TOMA treatment using detection antibodies for H150, 
pSer 262 and pSer 396.  S1 blots were normalized to actin, and were quantified using 
AlphaEase FC software.  
 The detergent insoluble tissue fraction was digested with formic acid then 
neutralized using NaOH, to permit analysis of tau components as insoluble tangles or 
other detergent insoluble intermediates.  Table 1 also shows the results from Western 
analysis of the insoluble fractions (FA) from ACX, which similarly show no significant 
differences between the treatments or controls for any of the forms of tau we examined, 
including the high molecular weight/oligomeric forms. 
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4.5 Discussion  
 Numerous studies have been conducted, to date, utilizing various 
immunotherapy strategies in an attempt to prevent the development of a tau phenotype 
in a variety of preclinical models.  We have recently reviewed this literature and included 
some of our own data in investigating intracranial delivery of immunotherapy agents in 
Chapter 3 (Schroeder et al., 2016).  Here, we focused on an oligomeric tau-targeted 
antibody as passive immunotherapy for rTg4510 mice. We evaluated the tau phenotype 
in these mice with respect to behavior, histology and biochemical markers of pathology 
in attempt to identify if TOMA would be a potential therapeutic candidate to pursue in 
human trials (Gerson and Kayed, 2016).  On the whole, our studies showed that in this 
mouse model, TOMA was not as effective as has been demonstrated in previous 
studies using different models of tauopathy (Castillo-Carranza et al., 2014a, Castillo-
Carranza et al., 2014b) (Castillo-Carranza et al., 2015).  
 One possible explanation for an absence of impact on the tau phenotype could 
be failure of the antibody delivery or altered pharmacokinetics. We were able to observe 
elevated Tau oligomers both in CSF and in plasma of mice treated with TOMA, but not 
in mice treated with mouse IgG1. The most probable explanation for these elevations is 
the binding of tau oligomers to the antibody in these compartments and the delay in its 
clearance due to being bound by antibody. Such a mechanism has been proposed to 
explain elevated circulating Aβ levels after treatment with some antibodies (DeMattos et 
al., 2001, Levites et al., 2006, Karlnoski et al., 2009). Other antibodies targeting 
monomeric tau have also been reported to elevate plasma tau (d'Abramo et al., 2016). 
However, a different study found antibodies specific for phospho-tau treated for 12 
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weeks decreased tau levels in CSF (associated with declines in tissue tau levels; 
(Sankaranarayanan et al., 2015)).  
 A second explanation may be the poor penetration of antibody into brain 
parenchyma. However, we detected mouse IgG decorating the neuropil of hippocampus 
and cerebral cortex, sites of tau expression in rTg4510 mice. This staining in general did 
not appear to be within neurons, but associated with the molecular layers in 
hippocampus. It is conceivable that the absence of an effect was due to the inability of 
this antibody to become internalized by neurons, as appears to be the case for some 
anti-tau antibodies (Congdon et al., 2013, Shamir et al., 2016). However, given the 
specificity of the antibody for oligomeric tau, it may represent the locations of this 
antigen extracellularly or on the cell surface. Again we did not observe this staining in 
mice injected with IgG1 control antibodies. These results suggest that at least some 
antibody reached the brains of the rTg4510 mice. 
 The results from behavioral tests indicated the expected genotype effect of the 
rTg4510 mice as having worse performance than the nTg or the Tet control mice. We 
included the Tet group because of prior work showing that the Tet transgene alone can 
result in a phenotype, including slightly reduced hippocampal volume (Han et al., 2012).  
When we compared the IgG1 and TOMA treated rTg4510 mice, there was no significant 
difference, indicating the TOMA was not able to prevent the cognitive deficits in the 
radial arm water maze, either in the initial learning phase or in the reversal phase.   
These results were unexpected based on the behavioral improvements in Y-maze 
performance in the initial publication of this treatment (Castillo-Carranza et al., 2014b). 
However those studies used the JNPL3 mouse model, not the rTG4510 mice. The novel 
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object recognition (NOR) results were consistent with the radial arm water maze results 
indicating a genotype effect, but no treatment effect. These results contrast with those 
reported by (Castillo-Carranza et al., 2014a), where they did identify that 
immunotherapy with TOMA led to an improvement in NOR using  htau mice seeded 
with preformed tau aggregates to induce pathology and behavioral deficits. 
 The results from Gallyas staining do not show any significant differences 
between the treatments for the three regions inspected, thereby suggesting that there 
was little to no effect on parenchymal levels of neurofibrillary tangles. Although not 
shown, we further found no effects on histological measures of total tau, nor several 
phospho-tau isoforms.  Other work with the TOMA antibody has failed to detect 
reductions in AT8 staining or Gallyas staining in JNPL3 (P301L) tau transgenic mice 
((Castillo-Carranza et al., 2014b), or in htau mice injected with tau seeds (Castillo-
Carranza et al., 2014a). It was argued that the behavioral deficits were due to tau-
oligomers and their removal was sufficient to rescue behavioral deficits. 
We examined four markers of tau pathology via Western blot to quantify changes in 
different tau fractions and molecular weight variants.  We examined both detergent 
soluble tau, and detergent insoluble tau (solubilized with formic acid) fractions.  We 
were unable to detect treatment effects in the two tau monomer bands we could discern 
(55 and 64kd), nor in the higher molecular weight forms of tau believed to represent 
oligomers.  This latter observation is in contrast to prior work in the JNPL3 and htau 
models (Castillo-Carranza et al., 2014a, Castillo-Carranza et al., 2014b). 
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 There were several methodological differences between the present results and 
those demonstrating successful rescue of cognitive changes with TOMA. One is the 
route of antibody administration. Prior work performed intravenous administration via 
the tail vein. All of our prior efforts using passive systemic immunotherapy in mouse 
models of Alzheimer’s pathology (largely anti-Aβ studies) successfully administered 
antibodies via intraperitoneal injections (Wilcock et al., 2004a, Morgan et al., 2005, 
Wilcock et al., 2007a, Karlnoski et al., 2009).  Other potential explanations for the 
discrepancies could be that the rTg4510 mouse is sufficiently aggressive that higher 
antibody doses would be required to effectively lower the tau oligomers to rescue the 
cognitive impairments. The rTg4510 mouse deposits tau earlier than most other tau 
transgenic mice and has greater neurodegeneration than most other models (Dujardin 
et al., 2015). However a third possibility is that the cause of the cognitive impairments in 
the rTg4510 mouse is different than in JNPL3 or htau models. By 6 mo, there is 
considerable loss of hippocampal neurons and cortical atrophy in rTg4510 
mice(Santacruz et al., 2005b, Nash et al., 2013). The data with TOMA obtained 
previously results in relatively rapid reversal of the cognitive impairment, implying the 
rescue is not due to protection from structural changes, but impairments of synaptic 
function that are reversible. However, it is feasible that the rTg4510 mouse has 
cognitive deficits that are secondary to neurodegeneration and brain atrophy. These 
would not be expected to be rapidly reversed, but may require protracted administration 
from before the age when pathology begins. Thus, treating from 3.5 to 8 mo may not be 
adequate to provide this protection. It is conceivable had we tested the mice at an 
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earlier age (e.g. 5 mo) the cognitive deficits might have been more susceptible to 
clearance of oligomeric tau. 
 Our overall experience has been that preventing pathology in the rTg4510 mouse 
is challenging. Some of our negative results have been published (Brownlow et al., 
2013, Brownlow et al., 2014, Joly-Amado et al., 2014) while others have not. In the few 
instances where we have obtained positive effects of treatment, they have required 
direct  and long term application to the brain of genes expressed at high levels resulting 
in reduced tau deposition (Nash et al., 2013, Hunt et al., 2015).  To our knowledge, the 
only study demonstrating a significant impact of passive immunotherapy in the rTg4510 
model was a study by Sankaranarayan et al (Sankaranarayanan et al., 2015). These 
authors treated rTg4510 mice weekly (as opposed to bieweekly here) with 25 mg/kg (10 
times more than used here) of two phospho-tau specific antibodies from 3-6 mo. They 
detected a 20% decline in soluble AT8. However, there was no decline in detergent 
insoluble total or AT8 tau isoforms. In parallel studies, they examined the PS19 (P301S) 
tau mouse and observed much larger reductions in tau pathology, on a percentage 
basis. 
 In conclusion, tau immunotherapy remains an attractive area of investigation for 
the treatment of AD and other tauopathies.  However, the wide range of preclinical 
tauopathy models, each having its own characteristics, and also the wide range of 
immunogens administered to date, confounds the field.    The goal of this avenue of 
research is to ultimately identify a treatment for tauopathies such as AD, but that bulls-
eye treatment has not been identified yet.  Synergy between tau and Aβ treatments 
would likely provide a most useful avenue for further investigation into AD treatments, 
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as recently TOMA was found to benefit an APP mouse model (Castillo-Carranza et al., 
2015) (but see also (Mably et al., 2015). Although the rTg4510 model rigorously 
replicates the extensive neuron loss and atrophy of Alzheimer’s disease, it may be 
prudent to reserve this model only for treatments already demonstrated effective in 
other preclinical tauopathy models and to initiate treatment at very early stages. An 
alternative is to suppress transgene expression with doxycycline until the mice reach an 
age when they can receive the treatment.  
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Table 4.1: Treatment with TOMA did not affect levels of soluble or insoluble tau in ACx 
Western blot quantification of tau markers in the soluble fraction (S1) and formic acid 
treated insoluble fraction (FA) in rTg4510 mice treated with TOMA or IgG1 for 5 months. 
Values were quantified using alphaEase FC software and normalized to actin for the 
soluble fraction and total protein using REVERT reagent (LI-COR) for insoluble fraction. 
Data are presented as mean ± S.E.M. 
 
  
 
55 kda 64 kda  Oligomers (120-200 kda) 
 
Tg510 IgG 
Tg4510 
TOMA  Tg510 IgG 
Tg4510 
TOMA  Tg510 IgG 
Tg4510 
TOMA  
 
avg sem avg sem avg sem avg sem avg sem avg sem 
S1 (ratio to 
actin)             
H150 1.60 0.13 1.60 0.09 0.61 0.09 0.77 0.13 0.67 0.07 0.75 0.05 
Pser262 1.95 0.12 1.98 0.16 1.74 0.26 2.20 0.23 1.57 0.28 1.67 0.19 
Pser396 3.62 0.24 3.63 0.21 3.25 0.32 3.31 0.15 10.89 1.92 12.15 1.07 
Pser199/202  2.32 0.37 2.32 0.57 0.16 0.05 0.31 0.09 0.25 0.04 0.25 0.04 
             FA (ratio to 
total protein) 
            H150 0.06 0.01 0.03 0.01 0.05 0.02 0.02 0.01 ND ND ND ND 
Pser262 0.04 0.02 0.02 0.01 0.05 0.02 0.03 0.01 0.04 0.01 0.02 0.01 
Pser396 0.07 0.01 0.05 0.02 0.07 0.01 0.04 0.02 0.08 0.02 0.06 0.03 
Pser199/202  0.09 0.01 0.11 0.04 0.07 0.02 0.10 0.05 0.05 0.01 0.07 0.03 
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Figure 4.1:  rTg4510 mice injected systemically with TOMA present elevated levels of 
mouse IgG in the brain. Micrographic representation of mouse IgG staining in 
hippocampus (HPC) of rTg4510 mice treated with TOMA (rTg4510 TOMA, A,C) or IgG1 
(rTg4510 IgG1, B,D) for 5 months (from 3.5 to 8 months of age). Panel C and D show 
magnification of square area in A and B, respectively. No staining was observed in non-
transgenic or Tet only littermates.  Immunostaining quantification (E) utilizing Mirax 
software (Zeiss Inc.) in anterior cortex (ACX), hippocampus (HPC) and posterior cortex 
(PCX) of non-transgenic littermates (nTg, white bars), tet only mice (Tet, grey bars ) and 
rTg4510 mice treated with IgG1 (rTg4510 IgG1, black bars) or TOMA (rTg4510 TOMA, 
shaded bars) for 5 months. One-way ANOVA showed a significant increase in positive 
area ratio stained for mouse IgG in the anterior cortex (ACX) and hippocampus (HPC) 
of rTg4510 treated with TOMA compared to Tg4510 treated with IgG1 and non-
transgenic and Tet only control mice. Data are presented as mean ± S.E.M., n = 9-
10/group. *p < 0.05, ** p<0.01.  Scale bar = 200μm (Panels A and B) or 50μm (Panels C 
and D)  . 
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Figure 4.2:  rTg4510 mice injected systemically with TOMA present elevated levels of 
oligomers in both CSF and plasma. Quantitative analysis of oligomeric tau in cerebro 
spinal fluid (CSF, Panel A) and plasma (Panel B) of non-transgenic (nTg, white bars). 
Tet only mice (grey bars) and rTg4510 mice treated with IgG1 (rTg4510 IgG1, black 
bars) or TOMA (rTg4510 TOMA, shaded bars) treated for 5 months. Analysis was 
performed using both direct and sandwich ELISA. T22 was the antibody used for 
identifying tau oligomers. One-way ANOVA showed a significant increase in levels of 
oligomers in CSF of rTg4510 treated with TOMA compared to rTg4510 treated with 
IgG1 and non-transgenic and tet only control mice. Data are presented as mean ± 
S.E.M., ***p < 0.001. 
  
	 168	
 
Figure 4.3:  rTg4510 mice demonstrated spatial memory deficits in the radial arm water 
maze (RAWM) and reversal trial that were not rescued by TOMA treatment.  Number of 
errors during 2-day RAWM (Panel A) and reversal (Panel B) in non-transgenic mice 
(nTg, white bars), Tet only mice (Tet, grey bars) and rTg4510 mice treated with IgG1 
(rTg4510 IgG1, black bars) or TOMA treated mice (rTg4510 TOMA, shaded bars) for 5 
months. rTg4510 mice made significantly more errors attempting to locate a hidden 
platform in the 2-day RAWM test, compared to nTg mice and Tet only mice, regardless 
of the treatment. rTg4510 mice were not able to learn a new platform location on the 
reversal trial. Data are presented as mean ± S.E.M., n = 10/group. *p = 0.05.
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Figure 4.4: rTg4510 mice presented memory deficits during novel object recognition test 
that were not rescued by TOMA treatment. Percentage of exploration (calculated as the 
time spent with the novel object divided by the sum of times spent with novel and 
familiar, multiplied by 100) of the novel object presented in the last trial of the Novel 
object recognition test in non-transgenic (nTtg, white bars) tet only mice (Tet, grey bars) 
and rTg4510 mice treated with IgG1 (rTg4510 IgG1, black bars) or TOMA (rTg4510 
TOMA, shaded bars) for 5 months. Tg4510 mice spent significantly less time exploring 
the novel object compared to non-transgenic littermates, regardless of the treatment. 
Data are presented as mean ± S.E.M., n = 10/group. *p = 0.05.
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Figure 4.5: Treatment with TOMA did not affect levels of tau deposits when assessed 
with Gallyas impregnation. Micrographic representation Gallyas silver staining in 
hippocampus (HPC) of rTg4510 mice treated with IgG1 (rTg4510 IgG1, A) or TOMA 
(rTg4510 TOMA, B) for 5 months. No signal was detected in non-transgenic or tet only 
littermates. Immunostaining quantification (E) utilizing Mirax software (Zeiss Inc.) in 
anterior cortex (ACX), hippocampus (HPC) and posterior cortex (PCX) of rTg4510 mice 
treated with IgG1 (rTg4510 IgG1, black bars) or TOMA (rTg4510 TOMA, shaded bars) 
for 5 months. Data are presented as mean ± S.E.M. 
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CHAPTER 5: DISCUSSION 
Initial investigations conducted by our laboratory examined various 
immunotherapeutic treatments, time course of administration, and routes of 
administration, for amyloid clearance (Aβ) in amyloid-producing mice (Tg2576). 
Additionally, microglial activation (inflammation) has been evaluated in response to 
intracranial administration of antibodies to Aβ.  These studies were conducted using the 
Tg2576 mouse model, which over-produces Aβ, and which provided a useful mouse 
model for investigating strategies for Aβ treatment by immunotherapy (Wilcock et al., 
2011).  The studies reported here were designed to target tau clearance by 
immunotherapy, in pathological tau-producing mice, using both APP/PS1/NOS-/- mice 
and rTg4510 mice. 
The previously reported studies demonstrated that Aβ antibody displayed a 
broad distribution of effect, after injection.  These effects were observed within one day, 
then diminished over the course of 7 days.  At 4 hours post-treatment, diffuse Aβ 
pathology was not reduced, but by 24 hours it was dramatically reduced, and this effect 
persisted 3 and 7 days later.  Compact plaques were not affected until 3 days post 
injection, when microglial activation was also identified.  At one week post-injection, 
microglial levels had returned to normal levels, but the reduction of Aβ and plaques 
persisted.  These results suggested that amyloid clearance occurs in two phases, the 
first occurring between 4 and 24 hours, resulting in clearance of diffuse Aβ that is not 
	 178	
microglial dependent, and the second occurring between 1 and 3 days where microglia 
are activated, leading to clearance of compact plaques (Wilcock et al., 2003).   
The current studies reported herein describe a series of studies directed against 
the tau protein (typically an intracellular protein, which subsequently has been found to 
exist extracellularly, as well).  The first step was to identify a most effective antibody 
treatment.  Once that was accomplished, it was important to examine various 
parameters relating to the mechanisms and duration, as well as identifying the most 
effective route of administration of treatment.  The goals herein were to examine 
numerous antibodies so as to identify a treatment regimen deemed “safe” for clinical 
administration and testing. 
Temporal effects after antibody treatment were important, and relevant, as 
observed in the Aβ immunotherapy studies (once a select antibody treatment was 
identified).  Routes and duration of administration were also considered to be to be 
important.  Therefore, a similar approach to tau immunotherapy was followed here. 
Oddo et al (2004), examined the temporal effect of immunizing 3xTg mice 
(complex Aβ-producers which have shown added tau pathology), using antibodies 
directed against Aβ.  This mouse model has the advantage of developing Aβ and tau 
pathology, versus focusing on singular-pathology mouse lines (Aβ producers which 
have also shown tau pathology).  Oddo’s laboratory reported clearance of Aβ by day 3 
post-injection, but reported no immediate effect on tau pathology.  By day 5, post-
injection, both Aβ and tau levels were reduced.  Pathological assessments were 
followed for 45 days post-injection to identify if either of the pathologies re-emerged.  At 
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day 30, Aβ pathology had returned but tau pathology had not.  By day 45, tau pathology 
also returned.  Gallyas staining for NFTs was not decreased in response to the antibody 
treatment, so it was concluded that aggregated tau was not affected due to treatment.  
In other words, the Aβ antibody was only effective in clearing early tau deposits, but not 
hyperphosphorylated tau or NFTs (Oddo et al., 2004). 
Preliminary tau-based studies reported herein were directed towards identifying 
an effect from numerous types of tau antibody administration, then to identify the most 
successful routes of administration.  Additionally, it was important to identify the 
necessary time frames for achieving pathological tau reduction to best establish a 
potential clinical treatment treatment approach for tauopathy using tau-based 
immunotherapy.  
The initial studies reported here were designed to select a candidate tau antibody 
for further evaluation and then identify an ultimate treatment regimen.  Numerous anti-
tau treatments were evaluated to identify which antibody to investigate further by 
infusion, then systemic administration.  The overall evaluations focused on several 
attempts to identify a preferred antibody treatment, then to determine how effectively 
and/or how quickly any candidate antibody might provide significant clearance of tau.  
Additionally, it was important to examine how long such treatment might remain 
effective.  
Throughout the studies reported herein, microglial activation was measured at 
different time points to assess if tau antibody treatment increases inflammation.  This 
approach was conducted in a similar manner as was reported in the previous Aβ series 
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of experiments published from this laboratory (Wilcock et al., 2011).  The intent was to 
use the most robustly successful antibody against tau pathology, as determined initially 
in these studies, for further investigation.  Given this approach, we expected to identify a 
specific antibody that was capable of producing significant clearance of tau pathology at 
some time point.  It was also expected that activation of microglia would be observed at 
some time point, and might correlate to tau clearance.  Further, it was expected that any 
such microglial activation would eventually subside.   
What wasn’t known initially was, at what times these changes would become: a) 
evident, b) maximized, and c) lasting.  Based on our earlier work with Aβ passive 
immunotherapy, it was predicted that microglial activation would occur between 2- and 
7-days post-injection, and that this index of immune response might be gone by the 14-
day time point.  Considering the studies noted above, tau clearance was expected to 
become evident around 7-days post-injection, then persist through 28 days or more, 
then perhaps diminish over time.  However, these expectations were based on the 
identified pathways involved in disease progression and immune system activation for 
Aβ clearance, which were expected to be different compared to tau clearance. 
Concerns existed as to whether the selected tau antibody might fail to 
demonstrate success in clearing pathologic forms of tau. However, if tau clearance 
could not be adequately observed, the first step was to re-examine our injection 
protocols, locations and concentrations of antibody administered, as well as the specific 
tau antibodies administered.  Numerous tau antibodies were investigated, and in two 
different tau-producing mouse models.  Another potential concern regarded whether the 
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mice could survive to their requisite time points.  The rTg4510 mice are quite impaired, 
so their ultimate survival is of some concern in any study. 
Several different antibodies were evaluated, using different mouse models, 
different routes of administration and time points for their impacts on tau pathology.  The 
post-injection time points for tissue collection were varied to ensure identification of 
critical time-points to achieve maximal effectiveness of antibody treatment.  Injection 
locations were modified to accomodate for brain shrinkage as pathology advanced 
(depending on mouse age).  Pathology and behavior were evaluated as a function of 
post-injection to identify amelioration of tau pathology given our various treatment 
regimens and experimental evaluations. Additionally, microglial activation (inflammation) 
was monitored to identify the ideal strategy for carefully progressing to more invasive 
attempts of treatment (infusion then repeated i.p. injection). 
Previous work in our laboratory has shown that peripheral administration of anti-
Aβ antibody was successful in reducing diffuse amyloid and compact plaques in the 
brain, and this was accompanied by improved cognitive performance in the radial arm 
water maze.  Different microglial markers were also examined, leading to a likely 
mechanism of clearance, suggesting that the Aβ becomes opsonized then subject to 
Fcγ receptor-mediated phagocytosis (Wilcock et al., 2004b).  Here, we examined if the 
selected tau antibody (TOMA) is also able to enter the brain then reduce or prevent 
intracellular tau pathology, and importantly, to improve cognitive behavior. 
Specifically, rTg4510 mice received i.p. injections of the tau antibody or the anti-
GFP control, starting at 2 months of age.  They received 10 mg/kg of antibody once per 
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week until 10 injections were administered.  A battery of behavioral tests was conducted 
to identify cognitive improvements or detriments resulting from antibody administration.  
The behavioral tests included: motor performance and activity level tests using the 
balance beam, rotarod, and Y maze.  Y maze was additionally useful for identification of 
working memory.  Spatial memory was examined using the RAWM test, then FC was 
conducted to test additional parameters of cognitive functioning.  Open pool testing was 
completed to assess vision and swimming ability (RAWM control).  FC examined 
training, then specific parameters of memory retention in terms of associative memory.  
Upon completion of the behavior regimen, the mice were euthanized as 
described above, then plasma, CSF and tissue were collected. The right hemisphere 
was dissected into the anterior cortex, posterior cortex, hippocampus, striatum, 
thalamus, cerebellum and midbrain/hindbrain which were snap-frozen on dry ice then 
stored at -80 degrees.  The left hemisphere was immersion fixed and cryoprotected as 
described above.  IHC was conducted on sections from the left hemisphere, and 
Western Blotting for tau was conducted on relevant brain sections from the right 
hemisphere. 
It was hoped that peripherally administered antibodies would cross the BBB, and 
remain functionally intact after doing so.  The previous Aβ studies suggested this 
general approach might prove fortuitous.  However, such results were not conclusively 
demonstrated, as a result of these studies. 
The background results presented above were used to assume that antibodies 
are capable of clearing intracellular proteins.  The initial tau studies were conducted in 
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an effort to establish that antibody treatment could clear tau pathology, via intracellular 
or extracellular means.  Our studies were not designed to evaluate specific 
mechanisms, but were based on a plethora of previously reported research that 
indicated that they should prove effective.  It remains to be examined if other tau 
antibodies might prove more effective in crossing the BBB, and/or in treating 
neurodegeneration.  Perhaps, peripheral antibody administration of different antibody 
treatments might prove effective, and perhaps different mouse models would be a better 
means for examining such effects.  The rTg4510 mouse model did not seem to be 
treatable, given our antibody studies. 
 The rTg4510 mouse model posed a concern of overall survival for the mice, as 
described above.  These mice tend to be very hyperactive, and also have a reduced life 
span.  Therefore, tau treatment regimens were started at a variety of ages, in hopes of 
achieving measurable effect before the inherent transgenes were too severe to 
experience treatment.   
Additional studies could have been conducted, by varying initial mouse ages, 
treatments, and testing methods.  However, it had appeared that an effective antibody 
had been identified, and we wanted to investigate more extended methods of treatment, 
by utilizing intracranial injection into multiple brain regions, then examining 
intraventricular administration, followed by 28-day continuous infusion, then finally by 
long-term systemic administration. 
Our studies demonstrate that administration of tau antibodies to rTg4510 mice 
does not ameliorate AD or tauopathy symptoms.  We have examined behavior, 
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biomarkers (CSF and blood), as well as key tissue samples, and have failed to strongly 
demonstrate improvements in tau pathology as a result of anti-tau administration.  Much 
as we would have liked to identify something curative in all of these studies, it would 
appear that the rTg4510 mice are resistant to treatment. 
The purpose of this research was to: a) identify an antibody that is most effective 
in clearing tau pathology in robust tau-producing mice, b) examine the most effective 
route of administration for neurological antibody treatment, c) establish the timeframe of 
antibody activity to identify preventative or therapeutic optimums for it, d) to characterize 
the role of the immune system in clearing pathologic tau, then e) determine if such an 
antibody can be administered peripherally, reach the brain, and clear intracellular tau 
pathology, which would provide a more feasible method for treating humans with 
tauopathies.   
Our laboratory has a well-established history of investigating immunotherapeutic 
approaches for the treatment of AD, leading to clinical studies targeting Aβ.  Tau-based 
immunotherapy has been demonstrated to be somewhat effective, using different 
antibodies, immunogens, other animal models, and in other contexts.  Once greater 
therapeutic benefit has been demonstrated, in a safe and effective manner, then it could 
ultimately be applied to humans in clinical trials.  The antibodies examined here do not 
lead to this future, however antibody treatment (immunotherapy) could become a 
manner for preventing or treating AD and other tauopathies in the future. 
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